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Rheumatoid arthritis (RA) is a systemic autoimmune disease that is predominantly 
characterized by symmetrical synovitis of the small joints of hands and feet. However, 
every joint with synovial lining can be affected.1 
In addition to synovitis, after prolonged inflammation extra articular manifestations can 
also arise such as several pulmonary diseases, ocular diseases, cutaneous manifestations 
like rheumatoid nodules and cardiovascular diseases. However some of these extra 
articular manifestations occur only rarely these days, thanks to better treatment 
outcomes.2  The prevalence of RA in European and North American countries is about 
0.5-1.0 percent with an incidence of 20-50 new cases per 100.000 persons each year.3  
Women are affected two to three times more often than men. Though RA can occur at 
any age in adults, the majority of patients are middle aged at disease onset. 
Synovitis on the inside of the joints expresses itself on the outside of the body 
by typical joint swelling (arthritis). RA patients may also experience tender joints, 
stiffness in and around joints particularly in the morning, limitations of movement 
and fatigue. 
To date, the pathogenesis of RA is still being unravelled. Genetic and environmental 
factors (e.g. smoking) both play a role in the onset and the course of RA.4 In the 
seventies and eighties of the twentieth century, the most important genetic risk factors 
for development of RA were identified, which are several HLA-DRB1 alleles.5,6 Later on, 
more susceptibility Single Nucleotide Polymorphisms (SNPs) in Caucasian RA-patients 
were identified via candidate gene approaches as well as genome-wide associations 
studies (GWAS).(4) Two of these susceptibility SNPs will be discussed in the current 
thesis, namely PTPN22 and TRAF1-C5.7,8
If RA is untreated, it can lead to considerable joint destruction, even resulting in disability 
in certain patients. However, the disease course may differ in patients individually from 
being mild and non-destructive to rapid and destructive.9 
Auto-Antibodies
Several antibodies in RA have been found, the best known are rheumatoid factor (RF) 
and anti-citrullinated peptide antibodies (ACPA). As RF has been the most ‘classic’ 
autoantibody in RA. RF is not only found in RA patients but also in patients with other auto-




1the specificity of RF for RA are about 69% and 85% respectively. This indicates that not all patients that are positive for RF will develop RA.10 In early RA patients the prevalence 
of RF is about 60 percent.11-13 
ACPA, on the other hand, is more specific for RA (sensitivity ~67% and specificity of 
~95%) and is thought to play an important role in the pathogenesis of the disease.(10) 
The prevalence of ACPA in early RA is about 50%].11-13  Interestingly, there is an overlap in 
the presence of antibodies in RA patients. This means that most patients that are tested 
positive on the presence of ACPA are also positive on the presence of RF.  
The presence of RF as well as ACPA can precede the clinical phase of RA. This was 
found by Nielen et al; they investigated patients with RA that had been blood donor 
prior to their disease and they matched them with controls.14 Interestingly, RF and ACPA 
was present in half of these RA patients with a median of 4.5 years before they even 
experienced symptoms. 
Classification of RA
The term ‘rheumatoid arthritis’ was first presented by Alfred Garrod in 1859.15 The 
diagnosis RA is made by a physician based on a combination of certain characteristics 
(e.g. presence of auto-antibodies) and symptoms (e.g. morning stiffness, symmetrical 
joint swelling, tenderness of joints) a patient has. However, this may result in a 
heterogeneous group of patients. For research purposes, the goal is to apply the findings 
on a group-level. To achieve that, a more homogenous group of patients is required. 
Therefore, classification criteria were established. Most frequently used are the revised 
1958 ARA-criteria, the revised 1987 ACR criteria and lastly the 2010 ACR-EULAR criteria 
for RA.16-18 The approach in formulating the criteria have changed over time: for the 1958 
ARA-criteria, data was used from 332 North American cases, for the 1987-ACR criteria 
262 patients with RA and 262 control subjects with rheumatic diseases other than RA 
(non-RA) were used, whilst for the 2010 ACR-EULAR criteria data was used from 2000 
European and North American cases with early arthritis (UA+RA). In 1958 criteria for 
diagnostic classification (developed in 1956 consisting of 11 criteria) were revised since 
more strict criteria,  specificity and simplicity were demanded. Thus a group of ‘classical 
RA’ was added in addition to ‘definite RA’, ‘probable RA’ and ‘possible RA’. Whereas 
in 1987, the aims were to develop a new set of criteria with fewer criteria (in total 7 
criteria), again to be more specific than the old ones and a stricter definition for RA 
instead of the broad spectrum of diseases identified by the revised 1958-ARA criteria
Moreover, the aim of the latest criteria was to identify patients earlier in the disease 
course, thereby allowing the inclusion of patients at an earlier stage in clinical trials, 
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preferably before the development of any structural damage. In clinical practice these 
classification criteria can be used as guidelines to establish the diagnosis of RA but these 
criteria are not mandatory. In this thesis patients are classified by the 1987 ACR or the 
2010 ACR-EULAR criteria for RA.
Table 1. Different classification criteria for RA
Revised ARA 1958 
criteria




2. Swelling of a joint
3. Swelling of 
another joint
4. Pain on movement 















*Criteria 1-5 continues 
for at least 6 weeks
Possible RA: 2/11 
*joint symptoms at least 
3 weeks
1. Morning  stiffness 
(at least one hour)
2. Arthritis in three 
or more joints
3. Arthritis of the 
hand joints (1 










Four of seven criteria 
must be present. The 
first four criteria must 
have been present for 
at least 6 weeks.
1.  Joint involvement (0-5)
• One medium to large joint (0)
• Two to ten medium-to-large joints (1)
• One to three small joints (large joints not 
counted) (2)
• Four to ten small joints (large joints not 
counted)
• More than ten joints (at least one small 
joint) (5)
2.  Negative RF and negative ACPA (0)
• Low positive RF or low positive ACPA (2)
• High positive RF or high positive ACPA (3)
3. Acute phase reactants (0-1)
Normal CRP and normal ESR (0)
Abnormal CRP or abnormal ESR (1)
4. Duration of symptoms (0-1)
• less than 6 weeks (0)
•  6 weeks or more (1)
Points are shown in parentheses. The cut 
point for RA is six or more points. Patients can 
also be classified as having RA if they have: 
(a) typical erosions, (b) longstanding disease 
previously satisfying the classification criteria
Treatment and treatment strategy
Over the last fifty years the treatment options as well as the approach has changed 
dramatically. In the 1970s it was common to start with non-steroidal anti-inflammatory 
drugs (NSAIDs). Strikingly, disease-modifying anti-rheumatic drug (DMARD) therapy 
was at the time only initiated after radiographic damage had been demonstrated. 
Interestingly, during the nineties DMARD-therapy was also called SAARD-therapy, which 




1conventional DMARDs were available, such as anti-malarias (hydroxychloroquine), sulphasalazine, oral gold, intramuscular gold, azathioprine and methotrexate. After 
NSAIDs had failed, DMARD-therapy was started and preferably one that was least toxic. 
At the time a so-called pyramid approach was applied, this means that when the disease 
activity was not sufficiently suppressed another DMARD was added. 
However, at the end of the twentieth century treatment strategies changed. DMARD-
therapy was started much earlier in the disease course and combination therapy was 
often started. Several clinical trials such as the COBRA and BeSt-trial showed that 
initiation of combination therapy including corticosteroids in an early phase of RA led to 
less joint destruction.20,21
Besides conventional DMARDs another type of DMARD was added to the market, 
namely ‘biologics’. These are drugs that are genetically engineered, by using human 
genes in non-human cell cultures to produce a biologic agent. Patients who use biologics 
are more prone to infections (such as tuberculosis) and use the use of biologics involves 
high costs. Therefore, the use of biologics is preferably restricted to patients who failed 
on two or more conventional DMARDS. However, exceptions can be made.22 
In the current thesis we made use of a large inception cohort (the Leiden Early Arthritis 
Clinic), which included early RA patients.11 In this EAC-cohort the change in treatment 
and the change in strategy is reflected. RA patients that were included between 1993-
1995 were initially treated with NSAIDs and if there was persistent disease a DMARD was 
added, in most cases after a median of 5 months and generally within 2 years’ time.23 
Between 1996-1998 RA patients were initially treated with hydroxychloroquine and 
sulphasalazine and patients included after 1999 and onwards were promptly treated 
with methotrexate or sulphasalazine as monotherapy.
Early recognition and the window of opportunity
It has become apparent that initiating aggressive treatment early in RA is associated with 
less joint damage. Therefore, the aim is to start the treatment of RA patients as soon 
as possible. To achieve early initiation of DMARD-therapy it is necessary that patients 
become under the care of rheumatologists shortly after symptoms arise.  
The speed with which patients see a rheumatologist will differ between countries due 
to access to the organisation of medical and rheumatologic care (e.g. distance) and the 
way in which healthcare is organised.24 For example, in the Netherlands healthcare is 
organised in such a manner that general practitioners (GP) control access to medical 
specialists like rheumatologists. 
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First of all, a patient must feel the urge to seek medical attention due to his symptoms. 
Secondly, in case of our Dutch system, a GP must recognize the compilation of 
symptoms and physical examination as a potential rheumatologic disorder and refer 
to a rheumatologic clinic as quickly as possible. In 2011 in the Netherlands, a total of 
295 per 1000 male persons and 325 per 1000 female persons visited their GP because 
of musculoskeletal symptoms. Of these visits 5 per 1000 male persons and 6 per 1000 
female persons were registered under the diagnosis ‘Rheumatoid arthritis’. It needs to 
be mentioned, however, that this includes patients that were newly diagnosed as well as 
patients already diagnosed with RA.25 
Aside from the fact that treatment should be initiated early, it has been suggested 
that treatment should even be initiated in the so-called therapeutic ‘window of 
opportunity’.26,27Although this concept is not yet fully understood, this window is said 
to represent a very early phase of the disease in which therapeutic modification is more 
successful, presumably because of not fully matured disease processes. This window has 
been suggested to encompass the first 12 weeks after symptom onset. 
In a recent research in the Netherlands it was observed that the total delay in RA 
patients [time between symptom onset and first visit to a rheumatologist] was 18.4 
weeks (median) and the GP-delay was the main contributor with two-thirds of the total 
delay. It is worth noting that only 31% of the RA patients were seen within 12 weeks’ 
time after symptom onset.28
Disease severity:  joint damage and disease persistence
There are several ways to study the severity of RA. One could question what is meant by 
the term ‘severity’, because physicians and patients are likely to interpret this differently. 
For a patient it may be important that his or her daily activities aren’t impaired, that he 
or she experiences less pain, fatigue and stiffness and that he or she prefers to use less 
medication. However, the latter can also be the other way around: some patients may 
feel anxious to taper medications because they fear for a relapse. 
On the other hand, rheumatologists typically prefer to use ‘objective’ methods to 
characterize the disease, for example by monitoring inflammatory markers such as the 
erythrocyte sedimentation rate, the C-reactive protein and presence of erosive joint 
visualized on X-rays. Rheumatologists will, during a physical examination, also take into 
account the number of swollen and tender joints. Newer techniques are nowadays 
applied in assessing disease severity – either in clinical practice or for research purposes 
– such as ultrasound and magnetic resonance imaging (MRI) of hands and feet. 
In the current thesis, though, the main focus is on joint damage on X-rays and the 





29 In this method 44 joints of the hands and feet are evaluated on 
their joint space width and presence of erosions. The maximum attainable score is 448, 
with a range of 0-4 for joint space narrowing and 0-5 for erosions in the hands and 0-10 
for erosions in the feet. In this thesis damage on X-rays was evaluated cross-sectional on 
a single time point as well as longitudinal to study joint damage progression over time.
The main aim of treatment in RA is to achieve remission: this has not only become an 
attainable goal in clinical studies and trials, but in clinical practice as well. Remission as 
outcome has been studied extensively over the years. However, there is heterogeneity 
in the definition of remission. For example a disease activity score (DAS)-28 <2.6 or DAS-
28>1.6  and the ACR remission introduced by Pinals et al. have been used.30 In 2011 new 
remission criteria were proposed by the ACR/EULAR for clinical trials namely a Boolean-
based definition and an Index-based definition.31 It can be argued that these forms 
of ‘remission’ are merely a ‘state’ which is achieved in the disease course since these 
definitions of remission can be achieved while under treatment and also allow presence 
of minor (subclinical) inflammation (e.g, 1 swollen joint, increased ESR). 
Therefore, in my view, the ultimate treatment goal is to achieve DMARD-free sustained 
remission. DMARD-free sustained remission in the current thesis was defined as the 
sustained absence of arthritis after discontinuation of DMARD-therapy, including 
biologics and corticosteroids for the entire follow-up and during at least one year.32 
DMARD-free sustained remission can be seen as the opposite of disease persistency and 
is the closest proxy to a ‘cure’ in RA. 
Mortality in RA
Mortality is the most undesirable outcome in any disease and has been studied 
extensively over the years. Even though this outcome is definite, predictors of mortality 
give clues for therapeutic interventions since these predictors are often predictors for 
other long-term outcomes.33
Previously, RA has been associated with increased death rates compared to the general 
population (1.2-1.3 in inception cohorts and 1.6-1.7 in non-inception cohorts).33 In 
addition, it has been observed that the incidence mortality rates (IMR) in RA decrease 
over time, with an estimated pooled IMR from 4.7/100 persons-years for studies before 
1970 to 2.0/100 person-years for studies started after 1985. This resulted in a relative 
decrease of 2.6% per year between 1955 and 1995.34 These observations are based on 
early RA cohorts that were initiated between 1955-1995, thus before more stringent, 
early and aggressive treatments were introduced. 
Significant predictors for early death that have been found in many RA cohorts are 
increasing age, male sex, comorbidities, patients and physician global estimates and a 
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poor functional status (assessed by physical measures and patient questionnaires).33 
Poor functional status can be reflected among others by  various radiographic scores, 
ESR, CRP or rheumatoid factor. 
The major causes of death in RA are cardiovascular diseases (CVD), cancer and infections 
with percentages similar to the general population. The proportions of cardiovascular 
deaths may not be higher than their peers, but RA patients die at an earlier age of CVD.33 
RA is associated with CVD, the risk of developing CVD is approximately 2-3 times higher 
than the general population.35. Especially accelerated atherosclerosis has been observed 
in RA patients, which may precede major cardiovascular events. This accelerated 
atherosclerosis can not only be explained by traditional CVD-risk factors being more 
present in RA patients such as hypertension, hyperlipidemia, diabetes and smoking36,37 
but also by ongoing inflammation. 
Aim and outline of this thesis
There were four main aims of this thesis:
1. To improve early recognition of arthritis.
2. To investigate if  a so-called ‘therapeutic window of opportunity’-  is present in RA.
3. To investigate diagnostic and prognostic markers in arthralgia, early arthritis and RA 
patients.
4. To identify predictors for mortality and compare survival of RA patients with the 
general Dutch population.
This thesis is divided into four parts.
In Part I the efficacy of two early arthritis recognition clinics was evaluated as well as the 
reasons for arthralgia patients to seek medical  help. As described above, the median 
delay of RA patients with which they are seen by a rheumatologists after symptom onset 
in the Netherlands was 18.4 weeks.28 Two-third of this delay was contributed by the 
GP. This underlines, in combination with previous data on the wait-and-see approach, 
that GPs may have difficulties recognising arthritis of the small joints of the hands and 
feet.38 To diminish the GP-delay a new initiative was set up at two academic hospitals in 
Leiden and Groningen (The Netherlands): The early arthritis recognition clinic (EARC). 
Instead of applying the wait-and-see approach, GPs could send their patients to an EARC 
in case they were unsure about the presence of arthritis. This clinic was held twice a 
week and patients did not need to make an appointment. At the EARC, after the patient 
filled out a small questionnaire on symptoms and reasons to seek medical advice,  an 




1examination. In case arthritis was present the patients returned to the outpatient clinic within approximately 1 week for a full examination including additional laboratory test, 
X-rays and initiation of appropriate treatment.  
In chapter 2 the efficacy of the clinic after 1 year was evaluated. The GP-delay was the 
main outcome followed by the total delay. Early arthritis patients from early arthritis 
clinics (EACs) were used as control group. In chapter 3 the reasons for arthralgia patients 
to seek medical help were studied. Among others, patients were divided into two groups; 
patients who sought medical help shortly after symptom onset and patients who sought 
medical help rather late. Finally, a partial least square regression analysis was performed 
to assess whether certain variables (symptom characteristics, motivations/variables 
regarding the ability to work) frequently clustered together in the same arthralgia 
patients.  
In part II the aim was to investigate whether a therapeutic window of opportunity is 
present in RA indeed. Many previous studies on RA demonstrated that early treatment 
initiation leads to a more beneficial outcome.39,40 It needs to be taken into consideration 
that  an ‘early’ start can be interpreted differently over the years, for example within 
2 years after diagnosis of RA until initiation within a couple of weeks after diagnosis. 
Thus the following question was whether RA patients in which treatment was initiated 
shortly after symptom onset also had a more beneficial outcome than RA patients with 
a prolonged symptom duration. Since many studies included symptom duration as 
covariate in their analysis in chapter 4 a systematic literature review on all such studies 
was performed to assess whether a short symptom duration at treatment initiation was 
associated with a favourable disease outcome. Subsequently, it was demonstrated that 
a prolonged symptom duration was associated with severe radiographic progression 
and a lower chance on DMARD-free sustained remission, the latter by performing a 
meta-analysis. These results led to the following question: is this association a linear 
one according to ‘the-earlier-the-better principle’ or does a specific time-frame exists 
in which the disease is more susceptible to treatment referring to a ‘window of 
opportunity’. This question was addressed in chapter 5 by investigating the shape of 
the association of symptom duration with DMARD-free sustained remission (opposite of 
disease persistence) in two large early RA cohorts. 
In part III several disease symptoms, characteristics and classification criteria are 
investigated for their diagnostic or prognostic value in arthralgia, early arthritis and RA 
patients.  In chapter 6 a well-known disease characteristic (morning stiffness) that is 
frequently assessed in clinical practice was evaluated for its diagnostic abilities in three 
arthralgia cohorts and two early arthritis cohorts and its prognostic abilities in two early 
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RA cohorts. Current research on morning stiffness showed associations with impaired 
functional ability in the morning, effects on quality of life and work loss.41,42 In addition, 
it has been mentioned that morning stiffness is a poor discriminator between RA and 
other rheumatologic disorders.43,44 However, these observations are based on studies 
with a small sample size. In chapter 7 it was investigated whether an SNP located in the 
region of the protein tyrosine phosphatase non-receptor 22 (PTPN22) was associated 
with radiological damage in RA patients as well as in a subset of ACPA positive RA 
patients derived from two cohorts. This region encodes a negative regulator of T-cell 
activation and is an important risk factor for RA susceptibility in ACPA-positive patients.45 
In chapter 8 another frequently assessed disease characteristic (baseline erosions) 
was studied more in-depth. Baseline erosions, visualized by X-rays, have been used 
for decades in classification criteria for RA and have been associated as a predictor for 
further radiographic damage.16,17,46 However, mechanisms leading to baseline erosions 
as a predictor for further joint damage have not been thoroughly explored. Therefore, 
this question was addressed by performing mediation analyses in early RA patients with 
radiological data over 7-years of follow-up and subsequently regression analyses in 
early RA patients with baseline radiographs and MRI-data. As mentioned above, various 
classification criteria for RA have been developed. The most recent classification criteria 
for RA, the 2010 ACR-EULAR criteria, are considered to be more sensitive but less specific 
for RA.47 It has become apparent that the phenotype of ‘2010 RA’ patients is milder than 
the phenotype of patients classified according to the 1987 criteria for RA. Long-term 
outcomes between these two classification criteria were lacking. Therefore, in chapter 
9 joint damage progression over 7-years and DMARD-free sustained remission over 
10-years of follow-up was compared between patients classified according to the 1987 
and 2010 criteria for RA.
In part IV, risk factors and predictors for mortality in RA are described and comparisons 
are made between RA patients and the general Dutch population. TRAF1-C5 is another 
susceptibility allele for RA but also has been associated with other autoimmune diseases, 
a variant rs3761847 has been studied in relation to mortality in RA. An increased 
mortality risk for the susceptible genotype GG was observed compared to the non-
susceptible AA genotype (hazard ratio 3.96 95% confidence interval 1.24-12.6).48 Also, 
RA patients carrying GG homozygotes had increased rates for the causes of death cancer 
and infections but not for CVD. Since these patients had a median disease duration of 
10 years, CVD related deaths earlier in the disease may have been missed. Therefore, 
in chapter 10,  the association between TRAF1/C5 locus and mortality including causes 
of death was further explored in a cohort of early RA patients. Since an association 





1Rheumatoid factor and ACPA have been associated with less favourable outcomes in RA such as joint damage. In the newly developed criteria for RA both ACPA and rheumatoid 
factor play an important role, not only by their presence but also their titre.18 Regarding 
mortality in early arthritis as well as RA, very few studies are available investigating 
solely the role of antibodies. Therefore, in chapter 11, the presence of antibodies 
as well as their titre was studied in two large cohorts of early arthritis patients. As is 
described above, treatment strategies changed dramatically over time. In chapter 12, 
we investigated whether these changes in treatment strategies were also reflected by 
changes in mortality rates in RA patients. Analyses were performed within three groups 
of RA patients according to different treatment strategies that were applied and also 
mortality rates were compared with the general Dutch population. Chapter 13 provides 
a summary and discussion of the results which are provided in this thesis. 
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Only 31% of Dutch rheumatoid arthritis (RA)-patients visit a rheumatologist within 
12 weeks after symptom onset; this is mainly due to delay at the level of the general 
practitioner (GP). In order to reduce delay of GPs in identifying early arthritis, we initiated 
an Early Arthritis Recognition Clinic (EARC).
Methods 
EARCs were initiated at the Leiden and Groningen University Medical Centers. At this 
EARC, patients filled in a questionnaire about their symptoms, followed by a short visit 
with only a full joint examination by an experienced rheumatologist. If arthritis was 
present the patient got an appointment the same week at the regular outpatient clinic. 
The main outcome parameter was the GP-delay; the secondary outcome parameter was 
the total delay. In both centers, patients included in early arthritis clinics that had arrived 
via regular referrals served as control group.
Results 
Four hundred patients visited the Leiden EARC and 212 patients the Groningen EARC. 
Arthritis was detected in 42% and 49% respectively. The median GP-delay for these 
arthritis patients was 2.0 (0.4-7.3) and 2.0 (0.4-10.0) weeks and the median total delay 
8.6 (3.6-22.3) and 10.6 (3.1-30.8) weeks respectively. At these two clinics 59% and 51% of 
all arthritis patients and 65% and 53% of the patients that were subsequently diagnosed 
with undifferentiated arthritis  or RA were seen within 12 weeks after symptom onset. In 
the Leiden and Groningen control groups that arrived via regular referrals, only 32% and 
38% were seen within 12 weeks time.
Conclusions 
The EARC increased the early identification of arthritis and RA.
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Data of multiple observational cohorts and clinical trials indicate that early initiation of 
aggressive treatment in rheumatoid arthritis (RA) patients results in a better outcome.1,2 
RA-patients that were treated very early in the disease course more often developed 
remission and had less joint damage.3,4 This so-called ‘window of opportunity’ for 
treatment is estimated to encompass about the first 12 weeks after symptom onset.5,6 
Therefore, recognizing arthritis within the first 12 weeks after symptom onset is essential.7
We recently observed that only 31% of Dutch RA-patients visit a rheumatologist within 
12 weeks after symptom onset.8 In the Dutch system, general practitioners (GPs) control 
the access to specialists such as rheumatologists. We also observed that delay at the 
level of the GP was the main contributor to the total delay, as it encompassed about 
two-third of the total delay of 18.4 weeks (median).8 This observation is in line with 
Dutch data revealing that GPs have difficulties in recognizing arthritis of small joints and 
that in case of doubt they apply a ‘wait-and-see’ approach.9 The distribution between 
patient delay and GP-delay may be different between countries or settings. Nonetheless, 
a recent study in 10 centres across Europe showed that there is a substantial delay 
between symptom onset and the first visit to the rheumatologic outpatient clinic, with 
the median total delay ranging between 16 and 38 weeks.10 Also, in a recently initiated 
immediate access clinic in Vienna the median symptom duration at first visit of RA-
patients was  9 months.11 
 We aimed to increase the proportion of arthritis and RA-patients that is identified within 
the first 12 weeks after symptom onset. Given the local situation, we particularly aimed 
at decreasing the GP-delay. To this end we initiated Early Arthritis Recognition Clinics 
(EARC) at two university medical centres in the Netherlands. GPs were advised to send 
any patient for which they were doubtful about the presence of arthritis to the EARC, 
instead of applying a ‘wait-and-see’ approach. At the EARC patients were, during a short 
visit, screened on the presence of arthritis by physical examination by experienced 
rheumatologists. This study investigated the efficacy of the EARC to decrease the GP-
delay and consequently reduce the total delay in identifying arthritis.  
PATIENTS AND METHODS
Early Arthritis Recognition Clinic (EARC)
This clinic started in September 2010 in Leiden and in October 2010 in Groningen, the 
Netherlands.  Before we started, there was an educational campaign among regional 
GPs in Leiden and Groningen, focusing on the importance and the methods of identifying 
arthritis and the purpose of the EARC. The campaign included articles in GP-oriented 
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journals, lectures and discussions at periodic trainings of GPs and correspondence to 
GPs. No campaign was held at the level of the general public. GPs were advised to send 
any patients for which  they had a clinical suspicion of arthritis but were doubtful of 
the presence of arthritis to the EARC, instead of applying a ‘wait-and-see’ approach. 
There were no formal inclusion or exclusion criteria. All patients that visited the EARC 
during the first 15 months were included in this study. The EARC is held 2 times a week. 
Patients, referred by their GPs, can visit the EARC without making an appointment. A 
referral letter is not required, though was generally provided by the GPs. This screening 
clinic has no waiting list. The EARC, a screening clinic aiming to improve early detection 
of arthritis, is different from the Leiden Early Arthritis Clinics (EAC) that includes and 
follows patients with  , by a rheumatologist confirmed, early arthritis. Thus the subgroup 
of arthritis patients identified at the EARC can subsequently be included in the EAC. The 
Leiden University Medical Center is the only referral center in a health care region of 
~400 000 inhabitants in the western part of the Netherlands. The University Medical 
Center of Groningen is situated in the northern part of the Netherlands and is one of two 
referral centers in a health care region of ~700 000 inhabitants. The University Medical 
Center of Groningen also has an EAC that includes patients suspected of having arthritis. 
In both areas patients had equal access to a GP. In the area of Leiden there was one full-
time equivalent GP available per 2400 inhabitants and in the area of Groningen this was 
one per 2383 inhabitants.12 
At the EARC patients complete a questionnaire about their joint symptoms, their reasons 
for seeking medical help and a HAQ (for further details see 13). Hereafter, they are seen 
by an experienced rheumatologist who performs a full joint examination. In case arthritis 
is present, patients visit the general outpatient clinic, within 1 week time for further 
examinations, inclusion in the EAC after informed consent and appropriate treatment.14 
Outcome 
The main outcome that is relevant for determining the efficacy of the EARC was the GP-
delay. Secondary outcomes were the total delay and the proportion of patients that had 
a total delay of less than 12 weeks. The total delay was defined as the period between the 
by patient reported symptom onset and the first visit to the rheumatologic outpatient 
clinic. It is composed of the patient delay and GP-delay. The GP-delay was defined as the 
time between the first visit to the GP and the first visit to a rheumatologist. As the EARC 
has no waiting list, it mainly represents the time the GP takes to refer a patient to the 
rheumatologist.
In order to evaluate the efficacy of the EARC two comparisons were made. The first was 
between EARC patients and patients that were included in the Leiden and Groningen 
Early Arthritis Clinics and had arrived by regular referrals at the same time period as the 
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EARC was present. This comparison may be relevant since an educational campaign was 
held and a reduction in delay may be attributable to both education and the EARC itself. 
If, hypothetically speaking, the GP-delay would mainly be affected by the educational 
campaign – and not by the EARC – the GP-delay of patients that came via regular referrals 
might also decrease. Alternatively, if the EARC would be the most effective strategy, it was 
hypothesized that the GP-delay of the patients that visited the EARC would be shorter 
than the GP-delay of patients that came via regular referrals. The second comparison 
was a historical comparison and could only be applied to the Leiden dataset. The GP-
delay and total delay in early arthritis and early RA-patients included between 1993 and 
2006 in the Leiden EAC and thus before the institution of the EARC8 were compared to 
the EARC data. For a full overview of patients studied please see figure 1.
The outcomes were assessed for all early arthritis patients and for patients that were 
diagnosed as undifferentiated arthritis (UA) or RA at the subsequent regular outpatient 
clinic visit. RA was classified using the 2010 ACR/EULAR classification criteria.15 
Figure 1. Flowchart of patients with joint symptoms who were screened at the Leiden and 
Groningen Early Arthritis Recognition Clinics (EARCs) during the first 15 months. 
Legend Figure 1. With regard to the control group, presented are the number of patients that 
were included in the Early Arthritis Clinics of both centers and that arrived via regular referrals. 
The total numbers of patients who visited the outpatient clinic of the LUMC or UMCG have not 
been counted. LUMC, Leiden University Medical Center, UMCG,  University Medical Center of 
Groningen. Rheumatoid arthritis  (RA) is classified according to the 2010 criteria at the first regular 
outpatient clinic visit. Since it is in this very early disease phase often challenging to definitely 
discern between undifferentiated arthritis (UA) and RA, these two patient-sets were analysed 
together.
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Statistical analysis
Comparisons were made using the χ2 test, Student t-test or Mann-Whitney U-test as 




During the first 15 months, 400 patients visited the Leiden EARC and 212 patients the 
Groningen EARC. Arthritis was observed via physical examination in 168 (42%) patients 
screened in Leiden and in 104 patients (49%) screened in Groningen. The baseline 
characteristics are presented in table 1. The diagnoses made during the first regular 
outpatient clinic visit were: RA (Leiden 14.3%, Groningen 9.6%), UA (Leiden 35.1%, 
Groningen 32.7%), inflammatory osteoarthritis (Leiden 18.5%, Groningen 26.9%), 
crystal-induced arthritis (Leiden 7.8%, Groningen 5.8%), psoriatic arthritis (PsA) or 
spondyloarthritis (SpA) (Leiden 4.2%, Groningen 6.7%) and other diagnoses (Leiden 20.1 
%, Groningen 18.3 %). 
In order to make comparisons, patients included in the Early Arthritis Clinics, that had 
arrived via regular referrals were studied (n=116 and n=147 respectively, table 1). These 
patients had the following diagnoses: RA (Leiden 33.6%, Groningen 17.0%), UA (Leiden 
33.6%, Groningen 11.6%), PsA or SpA (Leiden 15.5%, Groningen 5.4%), inflammatory 
osteoarthritis (Leiden 8.6%, Groningen 18.4%) and crystal arthritis (Leiden 2.6%, 
Groningen 10.9%), other diagnoses (Leiden 6.8%, Groningen 36.4%).
Dates on symptom onset were missing for 5 and 14 arthritis patients in Leiden and 
Groningen EARCs respectively and dates on the first visit to the GP were not available 
for 18 and 9 patients respectively. For the control groups, dates on symptom onset were 
missing for 1 and 34 patients in Leiden and Groningen and dates on the first GP visit were 
not available in 27 and 55 patients respectively.
The Groningen control group was used for comparisons on all early arthritis patients 
but considered too small for sub-analyses on UA-patients and RA-patients (only 19 UA-
patients and RA-patients  had complete data). 
GP-delay of early arthritis patients
When evaluating all patients screened at the EARCs, the median GP-delay was 2.0 (0.4-
8.4) weeks in Leiden and 2.3 (0.6-9.1) weeks in Groningen. Since the aim was to more 
frequently identify arthritis at an early stage, the delay of patients with arthritis was 
studied more extensively (figure 2A). In the Leiden EARC arthritis patients, the median 
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GP-delay was 2.0 (0.4-7.3) weeks in contrast to 9.4 (5.9-23.2) weeks in the Leiden arthritis 
patients who arrived at our clinic via regular referrals. Thus indicating a difference of 
about 7.4 weeks, p<0.001. The median GP-delay of early arthritis patients identified via 
the EARC was also considerably lower than the historical GP-delay which was 8.0 (2.7-
18.4) weeks.(8) The median GP-delay in the Groningen EARC arthritis patients was 2.0 
(0.4-10.0) weeks which was comparable to the Leiden EARC data, and lower than the 
GP-delay of the patients that arrived via regular referrals in Groningen which was 3.9 
(2.6-12.8) weeks (p<0.001). The GP-delay was  rather stable during the study period (see 
online supplementary figure S1).
Figure 2. General practitioner-delay (A) and total delay (B) of patients with arthritis and without 
arthritis screened at the Leiden and Groningen EARC.
Legend Figure 2. The delays of the patients that arrived via regular referrals were presented as 
well. Each data point represents a single patient; the black horizontal lines show the median.; In 
(A) 22 data points are out of range (arthritis n=8, no arthritis n=14). In (B) 93 data points are out of 
range (arthritis n=44, no arthritis n=49).
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GP-delay in UA and RA
The GP-delay of arthritis patients with different diagnoses is depicted in figure 3A. 
Evaluation of the Leiden EARC patients (n=83) that at baseline were diagnosed with UA 
or RA revealed a median GP-delay of 2.1 (0.7-8.1) weeks. The median GP-delay of the 
UA-patients or RA-patients (n=76) that were referred regularly during the same period 
as the EARC existed was 9.4 (6.0-15.8) weeks, which was significantly longer than that 
of UA-patients or RA-patients that arrived via the EARC (P<0.001). Our historical data on 
RA-patients also showed a longer median GP-delay (11.8 weeks).8 The median GP-delay 
in the UA-patients or RA-patients identified via the EARC in Groningen (n=44) was similar 
to that in the Leiden EARC, namely 2.9 (0.5-16.4) weeks. 
Total delay of early arthritis patients
In all patients screened at the EARC, the median total delay was 14.0 (4.6-76.6) and 16.5 
(4.8-60.9) weeks in Leiden and Groningen respectively. Evaluating all arthritis patients, 
the median total delay in Leiden was 8.6 (3.6-22.3) weeks which was considerably lower 
than arthritis patients that came via regular referral during the same period as the EARC 
was running, where the median total delay was 21.0 (9.6-52.1) weeks, p<0.001 (figure 
2B).  The total delay of 8.6 weeks was also lower than that of the historical data where 
the median total delay was 13.7 (5.7-28.5) weeks.8 The median total delay of arthritis 
patients identified in the Groningen EARC was quite similar (10.6 weeks, IQR 3.1-30.8 
weeks) to that of Leiden EARC early arthritis patients (figure 2B) and much lower than 
that of regular referral patients from Groningen (21.6 weeks IQR 8.1-104.3, p<0.001). 
Total delay in UA and RA 
The total delay per diagnosis is shown in figure 3B. When studying the Leiden EARC patients 
that were diagnosed with UA or RA at the first regular outpatient clinic visit, the total delay 
was 7.6 (3.5-23.8) weeks. This was considerably lower than the total delay of UA-patients 
and RA-patients that were referred by regular routes, which was 19.3 (9.4-40.3) weeks. 
Our historical data also showed a longer median total delay in RA-patients namely, 18.4 
(10.4-35.0) weeks.8  Together, these results are indicative of a substantial decrease in total 
delay of UA-patients and RA-patients that were identified via the EARC. UA-patients and 
RA-patients  from the Groningen EARC had a median total delay of 10.4 (3.5-20.4) weeks.
Proportion of patients seen < 12 weeks after symptom onset
The proportion of patients that visited the rheumatologist within 12 weeks after 
symptom onset was evaluated as well.  The percentages of all early arthritis patients 
that were identified via the EARC were 59 and 51 in Leiden and Groningen respectively. 
In contrast, 32% and 38% respectively of  early arthritis patients that came via regular 
referrals were seen within 12 weeks, and therefore showed lower percentages than the 
EARC groups (p<0.001 and p=0.074) (See figure 4A-D). 
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This analysis was repeated among the patients classified with UA or RA that came via 
the Leiden and Groningen EARC, 65% and 53% respectively arrived <12 weeks after 
symptom onset. Only Leiden, but not Groningen, UA and RA-patients that arrived via 
regular referrals were available for comparison,  showing a much lower percentage (36%) 
of patients that was identified <12 weeks’ time (see figure 4E,F). Historically, 31% of 
RA-patients visited rheumatologists within 12 weeks’ time.8 Altogether, the percentage 
of UA-patients and RA-patients  that was identified within the first three months after 
symptom onset has almost doubled when using the EARC. 
Figure 3. General practitioner-delay (A) and total delay (B) of the patients screened with arthritis at 
the Early Arthritis Recognition Clinic (EARC) according to the diagnosis made by the rheumatologists 
at the first regular outpatient clinic visit. 
Legend Figure 3. Patients from the Leiden and Groningen EARC were combined in one figure. 
Each data point represents a single patient; the black horizontal lines show the median. In (A) 
three data points are out of range. In (B) 15 data points are out of range. React, reactive arthritis 
viral and bacterial; Sarc, Sarcoidosis; Cryst, Crystal arthritis; SLE, systemic lupus erythematosus; 
UA, undifferentiated arthritis;  OA,osteoarthritis; RA, rheumatoid arthritis 2010 criteria; PsA/SpA, 
psoriatic arthritis/spondyloarthritis; Other, Other diagnosis. 
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Figure 4. Proportion of Leiden and Groningen early arthritis patients (A-D) and Leiden UA and 
rheumatoid arthritis-patients  (E, F) that at first presentation at the rheumatologists had symptoms 
for less than 12 weeks.
Legend figure 4. Black: proportion seen by a rheumatologist < 12 weeks after symptom onset. 
Grey: proportion seen by a rheumatologist > 12 weeks after symptom onset.  The proportion of 
patients seen within 12 weeks was A: 32%, B: 57%, C: 37%, D: 51%, E:36% and F: 62%.
DISCUSSION
Early initiation of treatment of RA is associated with a higher chance of achieving 
remission and less progressive joint destruction.3,4,8  Early start of treatment requires early 
identification of arthritis and of RA.7 A recent study across Europe in RA-patients revealed 
that the median period between first symptoms and first visit to the rheumatologist is 
considerable and that the proportion of patients seen within 12 weeks after symptom 
onset ranged between 8% and 42%.10 
In our setting, delay in referral by GPs was the main contributor to the total delay.8 To 
reduce this delay we initiated an EARC. The present study, which evaluated the efficacy 
of this screening clinic, revealed that the GP-delay decreased from about eight weeks to 
about two weeks in arthritis patients. Furthermore, the proportion of patients that was 
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identified with UA or RA within the first 3 months of the disease has doubled. Based on 
these results we conclude that the EARC strategy significantly decreases the delay in 
recognizing arthritis and RA.
Throughout Europe several other strategies were developed to recognize arthritis at an 
early stage or to increase awareness of arthritis symptoms. For example in Vienna the 
‘Rheuma-bus’-initiative was launched and, more recently, an Immediate Access Clinic 
was established. Elsewhere, triage systems and the effectiveness of education of GPs 
were evaluated.11,16-19  A difference with some of these initiatives is that the present EARC 
focuses particularly on decreasing the GP-delay in referring arthritis patients.
This new referral strategy was initiated at two different places that are situated 200 km 
apart in the Netherlands. Strength of the current study is that the GP-delay and total 
delay of arthritis patients at both places were comparable. 
In order to evaluate the efficacy of the EARC two comparisons were made. Both have 
drawbacks. The comparison with delay data obtained before the initiation of the EARC 
is informative. Nevertheless, although the delay durations were stable between 1993 
and 20068, differences in delay durations with those of the patients screened at the 
EARC in 2010 and 2011 may have other reasons than the EARC itself. A limitation of the 
comparison between EARC arthritis patients and arthritis patients that came via regular 
referrals is that the motivations of the GP to send to the EARC or to use the regular 
referral route were not evaluated. In this study referral strategies were not randomized 
and none of the control groups yielded perfect comparability. Nonetheless, in both 
control groups the delays observed were longer than those of the arthritis patients 
identified by the EARC. 
Another shortcoming is that we depended on patients’ memory for collecting the dates 
of symptom onset and of first visits to the GPs. A study in patients with acute heart 
disease showed a good agreement at the aggregate level between self-reported delay 
and delay data obtained by structured interviews, suggesting that this way of collecting 
data is acceptable.20 Nonetheless, patients with symptoms for a relatively short time 
period may be more precise in indicating the exact dates than patients that experience 
symptoms for years. 
When evaluating the length of the delay in relation to the diagnoses, it is evident that 
diseases characterized by an acute severe onset such as sarcoidosis and reactive arthritis 
had the lowest delay (figure 3), and patients diagnosed with RA, UA, PsA or SpA had the 
longest delay. This observation is in line with our previous findings.8 
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The EARC aims to decrease the GP-delay as this is the main contributor to the total delay 
in the Netherlands.8 Recent UK studies revealed that patient delay was most the most 
important factor here.21,22 The EARC did not address the level of delay that is caused by 
the patients themselves.  Hence the applicability of an EARC should be regarded in the 
context of the local setting.
We did not calculate whether the initiation of an EARC is cost-effective. Given that 
almost one out of two patients screened had arthritis and that the costs of screening 
by physical examination are low (5-10 minutes per rheumatologist per patient), it may 
well be cost effective. Most important is to determine prospectively whether the group 
of RA-patients identified via the EARC indeed has a better long-term outcome than the 
group of RA-patients that was identified at our clinic via regular referrals. Longer follow-
up of these two groups is therefore required.  
Altogether, EARCs were initiated at two different places and the first results of these EARCs 
consistently showed that this initiative importantly increased the early identification of 
arthritis and RA.
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CHAPTER 3
Reasons for medical help-seeking 
behaviour of patients with recent-
onset arthralgia 
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Patient delay in seeking medical help may cause suboptimal use of the therapeutic 
window in rheumatoid arthritis. We aimed to assess the motivations and the urgency 
with which patients with arthralgia seek medical help. 
Methods 
612 patients with arthralgia – visiting two Dutch Early Arthritis Recognition Clinics – were 
studied. Patients filled out a questionnaire with questions on their symptoms and their 
reasons for seeking medical help. Comparisons were made for patients with short or 
prolonged patient delay, patients with and without arthritis, age and gender. 
Results 
The median symptom duration was 4 weeks. A prolonged delay in seeking help was 
associated with a gradual onset of symptoms (78%) and the perception that symptoms 
would not be serious or would go away (16% and 48%, respectively). Arthralgia patients 
who promptly sought medical help more often had an acute onset of symptoms and 
more frequently reported impairments at work or in daily functioning than patients 
who postponed seeking help (all p<0.005). Patients with and without arthritis generally 
had similar reasons for seeking help. The proportion of patients who had a prolonged 
patient delay was comparable between male and female subjects and between age 
categories. Particularly younger patients postponed seeking help because they thought 
their symptoms would disappear spontaneously.  
Conclusion 
This large-scale study observed several reasons and symptom characteristics influencing 
the help-seeking behaviour of persons with arthralgia. These data can be helpful to 
define strategies aiming at early identification of arthritis.
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Data of multiple observational cohorts and clinical trials indicate that treatment initiation 
in the first 3 months of rheumatoid arthritis (RA) is particularly effective at controlling 
arthritis and results in a better outcome.1-6  To allow early treatment initiation, it is 
required that arthritis is recognized at a very early stage.7  The time between symptom 
onset and the first visit to the rheumatologist is composed of several components, 
such as delay on part of the patient in seeking medical help at symptom onset, delay 
in referral by the general practitioner (GP) and delay in getting access to rheumatologic 
care.8 This study evaluated reasons of patients with arthralgia for seeking medical help 
in the primary healthcare. Understanding the motivations leading to a delay in seeking 
medical help is required when considering targeted health interventions (directed at 
early recognition of arthritis) on the level of the general public. 
A recent study across Europe showed that the contribution of the patient delay to the 
total delay in RA varies from place to place. For instance, in Heraklion and Birmingham 
the median patient delay was 30 weeks and 12 weeks, respectively, whereas in Vienna, 
Berlin and Warsaw the patient delay was relatively short (median 2-6 weeks).9  In a recent 
Dutch study a median patient delay of 3.3 weeks was observed.10 Cultural differences or 
differences in design or the access to the healthcare system might contribute to the 
observed variations in patient delay.8,11 
The help-seeking behaviour of RA-patients has been studied before and was recently 
summarized.12 Former studies had relatively small sample sizes (on average 30 patients 
per study, minimum 3, maximum 120 patients) and studied patients classified with RA 
who had variable disease durations (1-15 years). None of the previous studies evaluated 
drivers or barriers for seeking help at the stage of arthralgia.12 The present large-scale 
study was conducted to assess the reasons why patients with arthralgia seek medical 
help and to determine the readiness with which they seek medical help. 
PATIENTS AND METHODS
Arthralgia patients
We studied patients with arthralgia who were referred to one of our two Early Arthritis 
Recognition Clinics (EARC). These clinics were initiated in September 2010 in Leiden and 
in October 2010 in Groningen, The Netherlands. These outpatient clinics aim to decrease 
the GP delay.13 Our observation that in the Netherlands, GP delay contributed for two-
thirds to the total delay and GPs frequently ‘wait-and-see’ in case they are unsure 
about the presence of arthritis, which prompted us to initiate the EARC.10 For further 
details on the design of the EARC, please see 13. At the EARC, patients were asked to 
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fill out a questionnaire with questions on their symptoms, their functioning, and their 
reasons for seeking medical help. Subsequently, they were screened for the presence 
of arthritis by physical examination by experienced rheumatologists. In case of arthritis 
observed by physical examination (this was found in 44.4 % of cases), patients visited the 
general outpatient clinic within 1 week for further examinations (such as laboratory and 
radiological evaluations) and appropriate treatment.14 All arthralgia patients who were 
seen in our EARCs during the first 15 months were included.
Questionnaire
The questionnaire consisted of questions about several items. First, there were 
questions about the characteristics of the symptoms (pain, swelling or stiffness of joints 
experienced by the patient), the acuteness of onset, the distribution of the symptoms and 
the presence of morning stiffness. The dates of symptom onset (reported by the patient) 
and of the first visit to the GP were determined. Second, there were questions related 
to work absenteeism, presenteeism (reduced functioning while being at work) and the 
presence of impairments in daily functioning. Patients filled out a Health Assessment 
Questionnaire (HAQ). Finally, motivations for seeking medical help or postponing seeking 
medical help were evaluated. Patients were asked to indicate whether one or more 
reasons (presented in a list) were applicable to them; multiple answers were allowed 
(for the questions see online supplementary table 1). The questionnaire was completed 
by the patients without interference from the rheumatologist. 
The patient delay was defined as the period between symptom onset and the first visit 
to the GP. This delay is a composite of delay on the part of the patient in seeking medical 
help by a GP and the time a patient has to wait to see his/her GP after an appointment 
is made. In the Dutch healthcare system patients have direct access to GPs, so the latter 
part of this delay is negligible. Of all 612 patients, 125 patients did not report the first 
visit to the GP, so the duration of the patient delay could not be determined. Patients 
without data on the first GP visit were older (55.8 vs 49.2 years), less often had arthritis 
(32% versus 48%), less often had acute onset of symptoms (16% vs 37%) and had a 
significantly longer total delay (median 167 vs 12 weeks) than patients who did report 
the date of their first GP visit. Out of all patients with arthritis (n=272), there were 40 
patients who did not report a date on the first GP visit. These patients were older (58 vs 
51 years) and had a longer total delay (144 vs 8 weeks) than arthritis patients who did 
report the date of the first GP visit.
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We started with an analysis of all arthralgia patients’ data. Subsequently, analyses were 
repeated for patients with short and prolonged patient delay, patients with and without 
arthritis and for gender and age categories (<40, 40-60 and >60 years). 
Comparisons were made using the χ2 test, Student t test or Mann-Whitney U test and 
Kruskal-Wallis test as applicable. 
Then we studied whether certain symptom characteristics and reasons for seeking 
medical help frequently occurred together. This was done at the variable level using 
the variable reduction technique Partial Least Squares regression (PLS). PLS combines 
variables that frequently occur together in the so-called latent factors. Age, gender, 
symptom characteristics, work-related questions and reasons for seeking help were 
included in the PLS as independent variables; the patient delay (short/prolonged) 
was entered as dependant variable. Identified latent factors were plotted to look for 
clustering. To perform PLS, the relevant SPSS extension packages were downloaded from 




In total, 612 patients with arthralgia were evaluated; arthritis was observed in 272 
patients (44.4%).  Baseline characteristics are presented in table 1. The median patient 
delay was 4.1 (0.9-17.14) weeks. Overall, 24% of the patients were absent from work 
due to their symptoms and 61.7% of the patients experienced impairments in daily 
functioning (table 2). Frequently mentioned motivations to seek medical help were 
worsening of symptoms (66%) and impairments in daily functioning (35%). A frequent 
reason to postpone seeking medical help was the thought that symptoms would go away 
by themselves (39%) (table 3). Only 14% of the patients with arthralgia were concerned 
about having joint inflammation  and knew that, in that case, they had to act quickly 
(table 3). The reasons for seeking medical help or postponing seeking medical help did 
not differ between the centres (data not shown). Therefore, we combined the datasets 
from both EARCs for this study.
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Table 1. Baseline characteristics of all arthralgia patients as well as separated for short and 
prolonged patient delay and for patients with and without arthritis.
All arthralgia 
patients
Patient delay Arthritis at examination
< 4 weeks > 4 weeks Present Absent
N=612 N=242 N=245 N=272 N= 340
Female (n (%)) 426 (69.6) 157 (64.9) 174 (71.0) 177 (65.1) 249 (73.2)*
Age, years, mean±SD 50.6 (16.3) 49.5 (17.0) 49.1 (15.5) 51.9 (17.1) 49.6 (15.5)
Gradual onset symptoms, n(%) 394 (64.4) 103 (42.6) 192 (78.4)* 165 (60.7) 229 (67.4) 
Morning stiffness, minutes 20 (10-60) 17.5 (10-60) 30 (10-60) 30 (12.5-60) 15 (10-60)*
Patient Reported TJC 8 (4-12) 6 (2-14.25) 9 (4.25-18)* 7 (3-15) 9 (5-19)*










Arthritis at examination, n(%) 272 (44.4) 137 (56.6) 95 (38.8)*
Unless otherwise stated values are median (IQR). 
Missing values for patients with PD<4weeks and patients with PD>4 weeks: onset complaints 
n=5 and n=5, duration mornings stiffness n=116 and n=84, self-reported TJC n=0 and n=1, and 
HAQ n=27 and n=19. Missing values for arthritis patients and patients without arthritis: onset 
complaints n=6 and n=10, duration mornings stiffness n=115 and n=134, self-reported TJC n=0 and 
n=1, and HAQ n=30 and n=24.
*p Value< 0.05
HAQ, Health Assessment Questionnaire; PD, patient delay; TJC, tender joint count 68.
Comparisons for short versus prolonged patient delay
Subsequently, patients with a short or prolonged patient delay were studied separately. 
Categorization into ‘short delay’ and ‘prolonged delay’ was done using the median 
symptom duration at evaluation (4 weeks) as cut-off. Patients with a short patient delay 
more often experienced a sudden onset of symptoms than patients with prolonged 
delay (p<0.05 table 1). They also had a higher Health Assessment Questionnaire score, 
were more frequently absent from work (36% vs 14.4%, p<0.001), had more often 
functional impairment at work (70% vs 56%, p=0.006) as well as impairments in daily 
functioning (71% vs 54%, p=0.001). Furthermore, arthralgia patients with a short delay 
more frequently mentioned suddenly occurring symptoms and functional impairments 
as important reasons for rapidly seeking medical help (48% vs 18% and 41% vs 29% 
respectively, p <0.05, table 3). Patients with a prolonged patient delay postponed 
seeking medical help because they thought the symptoms would go away by themselves 
or that the symptoms did not indicate anything serious. In all, 69% of the patients with a 
prolonged delay sought medical help because the symptoms were getting worse (table 
3). 
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Comparisons between patients with and without arthritis 
The median patient delay in the arthralgia patients who also had arthritis was 2.6 (0.7-
9.0) weeks and 5.9 (1.1-27.9) weeks in the patients without arthritis (p<0.001) (table 
2). Generally speaking, the reasons of patients with and without arthritis were not 
different, though patients with arthritis were more often motivated to seek medical help 
because they experienced symptoms that occurred suddenly (34% vs 23%, p<0.05) and, 
interestingly, also because they were more often advised to do so by family or friends 
(26% vs 19%, p<0.05, table 3).  
Comparisons between female and male subjects
Overall, 70% of the arthralgia patients were female subjects. The median patient delay 
was 3.1 (0.9-12.9) weeks in male subjects and 4.3 (1.0-19.6) weeks in female subjects 
(not statistically significant). More male than female subjects were absent from their 
work due to the symptoms (31% vs 21%, p=0.033, table 4). Female subjects more 
often reported occurrence of new symptoms (41% vs 29 %, p=0.005) and worsening of 
symptoms (69% vs 58%, p=0.015) as reasons for seeking medical help. Male subjects 
were more often concerned about the cause of the complaints (49% vs 39%, p=0.034, 
table 5). There were no differences in reasons for postponing seeking medical help. 
Comparisons between different age categories
Patients with arthralgia were divided into three age categories based on the distribution 
of the raw data (not shown) as follows: <40 years (26%), 40-60 years (44%) and > 60 
years (30%). The median duration between symptom onset and first visit to the GP 
was 4.0 (1.1-12.6), 4.3 (1.0-21.9) and 3.3 (0.4-15.1) weeks, respectively. Patients in the 
youngest age category more frequently sought medical help because they experienced 
suddenly occurring symptoms (table 5). They were also more encouraged by family and 
friends to seek medical help (32.9% vs 17.4% and 20.1%, p=0.001). Patients in the oldest 
age category more often mentioned the wish for asking a painkiller as reason for seeking 
medical help . With regard to reasons for postponing seeking medical help, arthralgia 
patients in the youngest age category more often thought that the symptoms would go 
away by themselves (51.3% vs 39.3% and 29.3%, p<0.001).
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We subsequently questioned whether some symptom characteristics, motivations or 
variables concerning the ability to work frequently occurred together, thus clustering 
in the same arthralgia patients. A data reduction method, PLS regression analysis, was 
applied to this end. Two latent factors were found that together accounted for 33% of 
the observed variation (see online supplementary table 2). In figure 1, the individual 
patient scores on these factors were plotted against each other. Two clusters were 
observed. A group of patients was found who were characterized by a short patient 
delay, a sudden onset of symptoms, functional impairments and absenteeism. The other 
group consisted mainly of patients with a prolonged patient delay, a gradual onset of 
symptoms and no absenteeism.
 
Figure 1. Clustering of variables in arthralgia patients related to help-seeking behaviour. 
Legend figure 1. In this plot each dot indicates a single person. Latent factor scores indicate how 
strongly each factor is represented in each patient. Patients with a patient delay <4 weeks are 
blue, whereas patients with a patient delay >4 weeks are green.  The first latent factor is plotted 
on the y-axis, and the second latent factor is plotted on the x-axis. A group of patients (below 
y=0) was found who mostly had a short patient delay, had more often a sudden symptom onset, 
more functional impairments and were more often absent of work. The other group (above y=0) 
consisted mainly of patients with a prolonged patient delay, a gradual onset of symptoms and less 
absent from work.
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This study aimed to assess reasons of persons with arthralgia for seeking medical help. 
For early recognition of arthritis, it is required that such patients seek timely medical 
help. Comprehension on the symptoms or reasons that motivate persons with arthralgia 
to seek or postpone seeking medical help is crucial. It may be helpful in developing 
intervention strategies for public health. In the present study, 612 patients with arthralgia 
for whom the GP was unsure of the presence of arthritis were evaluated. The median 
duration between symptom onset and seeking help with the GP was relatively short (4 
weeks) and was comparable with the patient delay that we observed recently in early RA 
patients who visited our early arthritis clinic.10 Despite the short patient delay on a group 
level, several symptom characteristics and reasons were associated with the readiness of 
seeking medical help. Most importantly, prolonged delay in seeking help was associated 
with a gradual onset of symptoms and the perception that symptoms were not serious 
and would go away by themselves. Arthralgia patients who rapidly sought medical help 
more often did so because symptoms suddenly occurred, because they had functional 
impairments and because they were absent from work due to their symptoms.  
Musculoskeletal problems are very common among the general population.15,16 A large 
population-based survey (3664 respondents) on musculoskeletal pain in the Netherlands 
showed that only about half of the persons consulted a health professional.16  This 
is consistent with a report on an Austria’s initiative, the ‘Rheuma-bus’; here they 
found that about 40% of persons with musculoskeletal complaints never contacted a 
physician.17 The present study focused on patients who did seek medical help, although 
with differences in the readiness to do so. The present study is the first to evaluate 
patients with arthralgia instead of patients who are identified with RA. However, our 
study was not designed to identify the motivations of patients with musculoskeletal pain 
that did not seek medical help. 
The present study has several strengths. The patients studied had symptoms for (on 
average) a relatively short period. This indicates that the arthritis patients included 
in the present study were studied at a very early disease stage, earlier than has been 
studied thus far. The short symptom duration may also have reduced possible recall bias. 
Another strength of this study is the sample size, which is considerably larger than other 
studies on this subject 9 and also allowed for performing subanalyses. 
Interestingly, the reasons for seeking medical help of patients with and without arthritis 
were not evidently different. It is noteworthy that in all subcategories studied, about 
two-thirds of the patients reported impairments in daily functioning as well as functional 
impairments at work. In about half of these patients (35%), these functional impairments 
were mentioned as a reason for seeking medical help. 
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This study also has limitations. A limitation is that we did not use a validated questionnaire 
since such a questionnaire on this topic does not yet exist. It is reassuring that some of 
the findings of the present study are in line with previous, smaller studies. For instance, 
the association between impairment in daily functioning and a short patient delay 
has been observed before. 11,18-20 At present, a questionnaire is being developed and 
validated that will assess reasons for delay in RA patients as well as in inflammatory 
arthritis patients.21  It would be very interesting to use this questionnaire in arthralgia 
patients as well. Arthralgia patients were not asked about their socio-economic status 
and educational level. This might also be considered a limitation. 
Importantly, only 14% of all arthralgia patients were aware that, in the presence of 
arthritis, it is relevant to act quickly. A lack of knowledge on arthritis and RA has also 
been observed previously in patients diagnosed with RA in the UK and Canada.11,19,20 
This might call the need for public health intervention strategies. When designing such 
strategies, the results of the present large-scale study may be helpful. A gradual onset 
of arthralgia and the perception that these symptoms were not serious and would go 
away by themselves were the main reasons for waiting for seeking medical help. Based 
on these results, in particular at places where patient delay is an important contributor 
to the total delay, it may be relevant to inform the general public about the type of 
symptoms of arthralgia for which medical help should be sought immediately.
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Supplementary Table 1. Overview of the EARC Questionnaire
In an accompanying letter with the questionnaire it was explained that the questions concerned 
joint pain or swelling. Subsequently patients were asked to fill out the following questions. Patients 
finally also filled in a HAQ, which is not presented here. The layout presented here is the different 
from the original questionnaire. 
Symptom-related questions Possible answers
When did the symptoms first occur? …-…-…. (date)
When did you first visit your GP regarding
 your joint symptoms?                                                                                
…-…-…. (date)
Did the symptoms appear suddenly or gradually? suddenly gradually




Please indicate in the manikin which joints are bothering you (by 
filling in the circles).
 
501866-L-sub01-bw-vanNies
Early identification of rheumatoid arthritis
62
Work-related questions Possible answers
Do you have a (paid) job? no yes
If so, have you missed work/have you been absent from work due to your 
symptoms?
no yes
If so, did you have functional impairment at work due to your symptoms? no yes
Have you been impaired in your daily functioning due to your symptoms? no yes
Why did you visit your family doctor/ general physician?
(Multiple answers are possible. There are no “right” or “wrong” answers.)
*patients could tick the box below
The symptoms suddenly occured  Г  
The symtoms were getting worse  Г  
More symptoms occured  Г  
I worried about what could be wrong  Г  
I worried I might have had a joint inflammation  Г  
I worried I might have had an inflammation in my joint and 
I heard/read that you have to act quickly
 Г  
Due to my symptoms, I was unable to do things  Г  
I wanted to ask for a painkiller  Г  
My family/friends thought I should go  Г  
If you did not immediately visit your family doctor/general physician, why did you wait?
(Multiple answers are possible. There are no “right” or “wrong” answers.)
*patients could tick the box below
I was unable to go sooner  Г  
I wanted to wait and see  Г  
The doctor could not see me sooner  Г  
It seemed like it was getting better  Г  
I thought it would go away by itself  Г  
I thought nothing could be done about it  Г  
I thought it I wouldn’t be taken seriously  Г  
It didn’t seem serious  Г  
I was afraid it might have been serious  Г  
I asked somebody else to look at it first  Г  
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Supplementary Table 2. Overview of major variables in the two latent factors of the Partial Least 




Onset of symptoms (Acute) 2.496 2.413
Questionnaires 
If so, are you absent of work due to your symptoms? 1.629 1.579
Do you have impairment in daily functioning? 1.241 1.198
Of sudden onset of symptoms 2.632 2.547
New symptoms kept coming 1.020
I thought the complaints would pass 1.327 1.282
It didn’t seem to be anything serious 1.123 1.084
I was afraid it would be something grave 1.111 1.078
Legend supplementary table 2. Two latent factors in the Partial Least Square regression analysis 
were found that together accounted for 33% of the observed variation. Presented are the most 
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What is the evidence for the 
presence of a therapeutic window of 
opportunity in rheumatoid arthritis? 
A systematic literature review
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Initiation of DMARD-therapy in the ‘window of opportunity’ is thought to result in a 
more effective modification of the processes underlying rheumatoid arthritis (RA). We 
questioned whether this effect is true or hyped and performed a systematic literature 
review. 
Methods 
Medical literature databases up to June 2012 were systematically reviewed for cohort 
studies and randomised controlled trials reporting outcome data of early RA in relation 
with symptom duration at treatment initiation. The quality of these studies was assessed 
by two independent reviewers using a criteria scoring system of 15 items. Studies were 
dichotomised with the median score (79%) as cut-off. Best-evidence synthesis was 
applied to determine the level of evidence per outcome category. A meta-analysis was 
performed on the studies reporting on achieving DMARD-free sustained remission (the 
reverse of disease persistency). 
Results 
Out of 836 screened articles, 18 fulfilled the selection criteria and were not duplicates. 
Ten were scored as high quality. remission (various definitions) and radiographic 
progression were frequently studied outcomes. There was strong evidence for an 
association between symptom duration and radiographic progression. A meta-analysis 
on datasets evaluating DMARD-free sustained remission showed that s symptom 
duration was independently associated with such remission; HR 0.989 (95% CI 0.983 
to 0.995) per week increase in symptom duration. A moderate level of evidence was 
observed for other remission outcomes. 
Conclusions 
Even when heterogeneity of patients is taken into account, prolonged symptom duration 
is associated with radiographic progression and a lower chance on DMARD-free sustained 
remission. These data may support the presence of a ‘window of opportunity’.
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Delay in initiating treatment after the diagnosis rheumatoid arthritis (RA) has been 
established is associated with progression of joint damage.1 Recently it has been suggested 
that it is important to initiate treatment even earlier, in the so-called therapeutic ‘window 
of opportunity’.2 Although not yet fully understood, this window is said to represent a very 
early phase in the disease in which therapeutic disease modification is more successful, 
presumably because of not fully matured underlying disease processes. The thought 
is that intervention in this period may hamper disease progression in such a way that 
chronicity is reduced. In case such a period is present, this has  important consequences 
for the care of RA, as using this period will reduce the burden of the disease and may, 
for instance, reduce the number of patients who ultimately require biologics. If a period 
in which the disease is more susceptible to disease modifying drugs truly exists, efforts 
resulting in identification of a very early stage of RA may also be cost effective. However, 
the question arises; does it really exist? One reason for advocating an absence of this 
particular window is citation bias, assuming that positive studies are preferentially cited 
and those with negative results neglected. Since many studies have included symptom 
duration as covariate in their analysis, it is relevant to systematically review all such studies 
in order to assess whether short symptom duration at treatment initiation is associated 
with less progression of the disease. It has also been suggested that the window of 
opportunity encompasses the first 12 weeks after symptom onset.3, 4 A difficulty here is 
that the definition of symptom onset is highly variable between studies5; it can relate to 
the start  of symptoms or the start of swelling, and be self-reported by patients or recorded 
by physicians. Such differences yield incompatibility between studies with regard to the 
timeframe that was assessed, and preclude performing an extensive meta-analysis. We 
therefore aimed to perform a qualitative systematic literature review, focusing on two 




To identify studies investigating the relationship between symptom duration and the 
outcome of RA, we searched with the assistance of a medical librarian (JS) in medical 
literature databases (MEDLINE (OVID-version), PubMed, Embase (OVID_version), Web 
of Science, CochraneLibrary, CINAHL, Academic Search Premier and ScienceDirect) up to 
June 2012. Central terms in our analysis were ‘RA’ and ‘symptom duration’, for a detailed 
overview of the search per database, please see online supplementary file 2. Additional 
articles were searched in the reference lists of identified articles or via expert opinion.
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Inclusion and exclusion criteria
Selection of titles, abstract and articles was performed independently by two reviewers 
( JABvN and AHMvdH-vM). In case of disagreement, consensus was reached after 
discussion. First, all retrieved titles were screened, subsequently, abstracts were 
retrieved for detailed review and, finally, full text articles were read and screened on our 
inclusion/exclusion criteria. Included studies fulfilled the following criteria: (1) patients 
with RA were studied, (2) patients were prescribed DMARDs, allowing to evaluate the 
time period before treatment initiation, (3) patients had early disease; symptom duration 
(period between symptom onset and start of treatment) was recorded and <2 years, 
(4) patients were followed prospectively and follow-up was ≥1 year and (5) symptom 
duration was part of the analyses on disease outcome. Animal studies, studies with 
patients <18 years, reviews, conference) abstracts, letters to the editor, case reports, 
case series and studies in languages other than English were excluded.
Data extraction
A standardised form was used to extract information about the following data: (1) study 
population (population size, setting and time period of the study, symptom duration, age 
and gender), (2) follow-up period, (3) outcomes ( joint damage progression, remission or 
other outcomes), (4) effect estimates.
Methodological quality assessment
The quality of each included paper was reviewed by two reviewers independently (JABvN 
and AHMvdHvM) using a maximum of 15 criteria (see online supplementary table 
S1), which were based on previous systematic reviews in the field of musculoskeletal 
disorders.6, 7 The criteria were adapted for our research question of symptom duration. 
When a criterion was met in the article, a ‘1’ was given, otherwise a ‘0’. A‘0’ was also 
given when no information was given about the specific criterion mentioned in the 
article. In case of differences in ranking, a consensus was agreed after discussion. The 
maximum score (100%) for each study was based only on the items that were applicable 
for that study design (randomised controlled trial with radiographic outcome 15, and 
14 without, observational cohort with radiographic outcome 14, and 13 without). Total 
scores per study were calculated as the percentage of maximum obtainable scores.
Rating level of evidence
Because the studies obtained were heterogeneous with regard to the reported effect 
estimates, a pooled-effect estimate could not be calculated (except for a meta-analysis 
on the outcome achieving DMARD-free sustained remission). Therefore, we performed 
a best-evidence synthesis based on the guidelines on systematic review of the Cochrane 
Collaboration Back Review Group.8 This is a method to summarise evidence in 
observational studies if the population, outcomes and data analyses are heterogenic. It 
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consists of five levels of evidence (table 1).A study was considered to be of high quality 
(HQ) if the total quality score was ≥79% (which is the median of the quality scores 
obtained in this study).
Table 1. Best evidence synthesis used in this article
Strong Generally consistent findings (≥75%) in multiple high quality longitudinal 
studies. 
Moderate Generally consistent findings (≥75%) in multiple low quality longitudinal 
studies and/or positive findings in one high quality longitudinal study.
Limited Findings in one or more low quality longitudinal studies
Conflicting Inconsistent findings among multiple longitudinal studies. 
No evidence No longitudinal studies, either observational cohorts or RCTs, could be found.
RCT, randomised controlled trial.
Data analysis
Three studies reported on the same outcome (achieving a DMARD-free sustained 
remission) and were homogeneous in the definition of symptom onset (by the patient 
reported start of symptoms).9–11 The data of these three datasets were evaluated with 
univariable and multivariable Cox regression analyses. An inverse weighted meta-
analysis on these datasets was performed; the effect estimate was the HR. A fixed-effect 
model was used. The follow-up durations of these datasets, as reported in the articles, 
were 10 years9, 10 and 5 years.11 STATA V.12 was used.
RESULTS
Selection and inclusion of articles
In total, 1625 titles were identified; after removing duplicate references, 836 unique 
references were left for screening (see figure 1). After detailed review, 22 articles 
satisfied the inclusion and exclusion criteria.9–30 Four of these were excluded, since they 
concerned duplicate patient populations (two were based on the Leiden Early Arthritis 
Clinic,20, 29 one publication on the BeSt trial19 and one publication on the FINRACo trial26). 
Consequently, in total, 18 articles were used for further analyses (see table 2).
Figure 1. Overview of literature research.
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Methodological quality assessment
The two reviewers scored 249 items in total and agreed on 234 items (94%, table 2), the 
16 disagreements were resolved in consensus (see online supplementary table S1). The 
median quality score was 79% (mean 72.7%, range 43–100%). Consequently, articles 
with scores ≥79% were ranked as HQ. Low-quality (LQ) studies frequently missed points 
on the following items: description of the source population and information on the 
accurateness of determined outcomes. Additionally, few studies assessed the presence 
and consequences of lost to follow-up.9, 10, 16 ,21-22, 30 Finally, of all included studies, 
information on the definition of symptom onset was provided in only 28%.9, 10, 16, 21, 30
Study characteristics
The characteristics of the 18 included studies are shown in table 3. The majority of the 
patients were female and, generally, patients were aged >50 years. In all studies, RA was 
classified according to the 1987 American College of Rheumatology (ACR) classification 
criteria, except for one study that used the diagnosis of the rheumatologist.22 The number 
of patients included varied between 40 and 895. Frequencies of symptom duration were 
reported in different ways; mean±SD, median (IQR) or percentages (table 3). Various 
outcome measured were assessed; the majority related to radiographic joint damage 
or remission, though actual measures were variable. Progression of radiographic joint 
destruction was measured using the Larsen score (n=4), the Sharp–van der Heijde 
score (SHS) (n=4), the Sharp score (n=1) or the presence/absence of erosiveness (n=1). 
Remission was defined as a state after treatment (eg, Disease activity score (DAS)-28<1.6, 
DAS-28<2.6, DAS-44<1.6, ACR-remission (n=1, n=2, n=1 and n=2, respectively)), or as the 
resolution of disease persistency, which is DMARD-free sustained remission (n=3). This 
latter outcome was defined as sustained absence of synovitis for at least 1 year after 
cessation of DMARD-therapy, and of all outcomes studies the closest approximation of 
‘cure’. Three studies had included analyses on changes in functional ability using the 
health assessment questionnaire (HAQ).
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Radiographic joint damage in RA
Five HQ studies evaluated joint damage as outcome. Four of these (75%) demonstrated 
that shorter symptom duration was associated with less radiographic progression over 
time.16, 21, 22, 24 This implies that the evidence on the association between symptom 
duration and joint damage progression is strong. One HQ study showed the opposite, 
this study included a severe subset of patients with RA (>6 swollen joints, >9 tender 
joints, 90% anti-citrullinated protein antibody (ACPA) positivity) and compared patients 
with RA with symptom duration of <5 and >5 months at treatment initiation; the patients 
with RA who started >5 months of symptoms had a better outcome.30 Three of the four 
HQ studies that reported a beneficial effect of early initiation of treatment had divided 
patients in groups with symptoms of <3 and >3 months, and observed that patients 
with symptoms <3 months at start of treatment developed less severe joint damage. 
Lukas et al22 reported a mean SHS progression of 0.8 vs 1.7 units after1 year, respectively 
(p=0.033), Nell et al24 showed a mean Larson progression of 3.6 vs 14.7 after 3 years 
(p<0.05) and Van der Linden et al21 reported a 1.3-fold higher rate of joint destruction 
during 6 years follow-up in patients with RA with a symptom duration of >3 months 
(p<0.001). In three of the six LQ studies,12, 13, 27 a significant association was also observed 
between shorter symptom duration and less radiographic progression. Two LQ studies 
showed the same trend in the data, but statistical significance was not achieved (table 
3).18, 25
DMARD-free sustained remission in RA
Three HQ studies assessed DMARD-free sustained remission in patients with RA. With the 
permission of the authors, the raw data were used to perform a meta-analysis.9–11 First, a 
meta-analyses of the univariable association between symptom duration and achieving 
DMARD-free sustained remission was performed, showing a significant beneficial effect 
of a shorter symptom duration (HR on DMARD-free sustained remission 0.990 (95% CI 
0.984 to 0.996) per week increase in symptom duration figure 2A). Then analyses were 
adjusted for age, gender and applied treatment, as these variables possibly modify the 
effect. This revealed an almost unchanged association between symptom duration and 
DMARD-free sustained remission (figure2B). Certain levels of inflammation markers or 
auto-antibodies are a reflection of disease severity, and are also associated with the 
chance of achieving DMARD-free sustained remission. Therefore, analyses were finally 
adjusted for age, gender, treatment, erythrocyte sedimentation rate (ESR) and presence 
of rheumatoid factor (RF) (anti-cyclic citrullinated peptide (CCP) was not available in all 
cohorts). The adjustment factors in the latter analyses allowed differentiating between 
effects of patient characteristics and of symptom duration on DMARD-free sustained 
remission. Also, this analysis revealed that symptom duration was independently 
associated with DMARD-free sustained remission; each week increase in symptom 
duration decreased the chance of achieving DMARD-free sustained remission (HR 0.989, 
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95% CI 0.982 to0.995, p<0.001, figure 2C). Assuming a linear correlation with time in the 
early disease stage, the HR for achieving DMARD-free sustained remission in case of 12 
weeks symptom duration at treatment initiation is 0.88.
Other outcomes in RA
Eight studies reported other outcomes which were collected during DMARD-therapy. 
Five of these eight studies showed a significant association between shorter symptom 
duration and increased frequency of remission.12, 14, 17, 24 Of the four HQ studies, one study 
did not observe a significant association with symptom duration,30 two studies found a 
signification association, 17, 24 and one study assessed two cohorts of differently treated 
patients, showing a significant association in one but not in the other patient group.23 
Based on these findings, the evidence for an association between symptom duration and 
these remission outcomes in RA is moderate. Three of the eight studies had also assessed 
changes in HAQ scores. Two studies (1 HQ and LQ) reported that shorter symptom 
duration was associated with a higher improvement in HAQ scores.24, 28
Legend figure 2. 
(A) Univariable analysis on symptom duration, heterogeneity p=0.72, I2=0.0. (B) Multivariable 
analysis on symptom duration, adjusted for age, gender and treatment, heterogeneity p=0.72, 
I2=0.0. (C) Multivariable analysis on symptom duration, adjusted for age, gender, treatment, 
rheumatoid factor and ESR, heterogeneity p=0.70, I2=0.0. The follow-up durations studied were 
similar as in the articles, 10 years for Early Rheumatoid Arthritis Study group (ERAS), 5 years for 
BeSt and 10 years for the Leiden early arthritis clinic. The number of patients with RA included 
in these three datasets with complete data for current analysis were n=892, n=507 and n=505, 
respectively. De Rooy; in the original article: the term persistency was used; in the meta-analysis 
we used the reverse, namely ‘DMARD-free sustained remission’ A decreased chance on achieving 
a DMARD-free sustained remission is equal to an increased chance on arthritis persistency.
501866-L-sub01-bw-vanNies




Figure 2. Meta-analysis on the association between symptom duration (in weeks) and achieving 
DMARD-free sustained remission over time in rheumatoid arthritis (RA). 
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Table 3. Extended overview of selected articles.
















Outcome of relevance Adjustment 
factors
Relevant results 
Bosello, 201112  OC 1987+ RA ,Italy 121 53.6±13.3 76 5.7±3.5 NR ● Radiographic joint damage 
(defined ≥1 unit increase in 
of SHS/Larson erosions score) 




● Sex, RF, ACPA, 
ESR, SJC
●Not having ‘VERA’  predictor of 
erosiveness at 12 months, OR 2.4 
(95%CI 1.1-5.6)
●’VERA’ predictor for ACR remission ,OR 
5.3 (95% CI 2.1-13.0).  





66 6 (4-11) NR Radiographic outcome at 3 
years (by Larson score; cut off 
median erosions score and the 
worst quartile 
none Symptom duration (weeks) on 
radiographic outcome, OR 1.86 (95%CI 
1.30-2.66).
De Rooy, 20109 OC 1987+ RA, 
Netherlands 
(EAC Leiden)
676 56.4±15.7 67.9 6.1±5.2 Onset of joint 
symptoms 
reported by the 
patient
Arthritis persistency (the 
reverse of DMARD-free 
sustained remission)
Age, sex, inclusion-
period (as proxy for 
treatment strategy)
Symptom duration (weeks) OR 1.011 
on arthritis persistency (95% CI 1.002, 













‘VERA’ on DAS-28 remission, OR 2.03 
(95% CI 1.15;3.30) 
Hodkinson, 
201215
 OC 1987+ RA, 
South-Africa
171  47.1±12.4 81.9 11.7±7.1 NR Low disease activity (LDA) at 
12 months (SDAI≤11) versus 
moderate/high disease activity 
(MDA/HAD; SDAI≥11)
 none LDA symptom duration 9.9±6.9 months 
versus MDA/HDA 11.7±6.8 months. 
(mean±SD)
Not significant  (p-value unknown).
Jansen, 200116 OC 1987+ RA, 
Netherlands
130 65(21-86) 67 3 (0-24) Onset of 
persistent pain 
and swelling 
reported by the 
patient
Delta radiographic damage at 
1 year (by SHS).
none Symptom duration was correlated with 
radiographic progression (p<0.005) 
Jayakumar, 201217 OC 1987+ RA ,UK 
(ERAS)
704 55 (45-64) 65.6 7 (4-12) NR Sustained remission DAS-
28<1.6 after 5 years FU
Sex, TJC, treatment 
and many other 
baseline variables
Symptom duration<6 months  OR 3.15 
(95% CI 1.03; 10.0, p=0.046)  
Kaufmann, 200318  OC 1987+ RA, 
Germany
54 56 (30-38) 83.3 <6months: 27 (50%) NR Radiographic progression 
defined by yearly increase of 
Larsen score ≥5.8
Age, sex, RF, HLA-
DR4 SE, erosions, 
ESR and CRP
Symptom duration (6>months) on 
severe radiographic progression 
OR=1.05,  p-value=0.826 








Onset of swollen 
joints reported by 
the patient
Radiographic progression after 







Symptom duration <3 months versus >3 
months: Estimated marginal means 0.8 




RCT 1987+ RA,  
Finland 
(FIN-RACo)
165 mean  age varied 
46-50 years between 
the arms




NR ACR remission at 2 years FU 
(fatigue and duration criteria 
excluded)
age, sex, SE, RF and 
number of other 
ACR1987 criteria 
fulfilled 
Estimated proportion of remission in:
- the single treatment group for 
symptom duration 
0-4months  ~36% vs. > 4months ~10%, 
P=0.010 
- the combination treatment group  
symptom duration  0-4 months  ~43% 
vs. >4months ~40%, p=0.83
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Finland 
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165 mean  age varied 
46-50 years between 
the arms




NR ACR remission at 2 years FU 
(fatigue and duration criteria 
excluded)
age, sex, SE, RF and 
number of other 
ACR1987 criteria 
fulfilled 
Estimated proportion of remission in:
- the single treatment group for 
symptom duration 
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Table 3. Continued
ACPA, anti-citrullinated protein antibody; ACR, American College of Rheumatology; CRP, C-reactive protein; 
DAS, Disease activity score; EAC, early arthritis clinic; ERAS, Early Rheumatoid Arthritis Study group; ESR, 
erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; FU, follow-up; HAQ, Health 
assessment questionnaire; HDA, high disease activity; LERA, late early rheumatoid arthritis; 
















Outcome of relevance Adjustment 
factors
Relevant results 
Nell, 200424 OC 1987+ RA, 
Austria
40 54 (25-80) 75 VERA
3 (2-4) LERA 
12 (9-30)





All outcomes after 3 years FU
None ● VERA patients had an increase of 
3.6±6.5 units compared to an increase 
of 14.7±9.9 Larson units in LERA, p<0.05. 
(mean±SD)
 ● DAS <2.6 was obtained in 50% of 
VERA and 15% of the LERA patients (p 
<0.05).
● Change in HAQ score: VERA -0.7±0.7 
(-78%), LERA -0.4±0.6 (-44%), p<0.05.
Pascual-Ramos, 
200925




NR Erosive 4.9±2.9 
And non-erosive dise 
6.5±1.8 
NR Joint damage (erosive disease 
yes/no) at 1 year FU
None Symptom  duration (months) on erosive 
disease OR 1.16 (95% CI 0.97-1.4),  
p=0.11
Sanmarti, 200327 OC 1987+ RA, Spain 60 52.2±15.7 78.3  9.5±6.5 NR Radiographic progression at 1 
year (Larson Score; progression 





Multivariable; symptom duration 
n(months) OR 1.15 ( 95% CI 1.03-1.28), 
p<0.05
Soderlin, 201128 OC 1987+ RA, 
Sweden 
(BARFOT)
180 58±15 68 5.8±12 NR ●1 year good-EULAR response 
● mean Δ HAQ change at 1 
year
Age, sex, smoking, 
RF, HAQ, treatment, 
DAS-28
● Patients with a good/moderate 
EULAR response in case of symptom 
duration<12 wks 81%, 13-24 weeks 82% 
and 25-52 wks 76%, p=0.03. 
● HAQ and symptom duration: 
correlation coefficient=0.12, p=0.0001
Van der Linden, 
201021
OC 1987+ RA, 
Netherlands
 (EAC Leiden)
598 56.8±15.8 67.7 4.2 
(2.4-8.1) 
Onset of joint 
symptom 
reported by the 
patient
SHS progression over  6 years 
based on yearly made X-rays
Age, sex, inclusion-
period (as proxy for 
treatment strategy)
Patients with symptom duration 
>12 weeks have a 1.34-fold higher 
progression ratio than patients with 
symptom duration <12 wks, over a 
period of 6 years (p=0.001).
van der Woude, 
20099
OC 1987+ RA, UK
(ERAS)






●Multivariable; Symptom duration  on 
achieving DMARD-free remission , HR  
0.94 (0.89-0.99), p=0.029. 
Van der Woude, 
201211
RCT 1987+ RA, 
Netherlands
(BeSt Trial)
508 54±13.7 68 5.3 
(3.2-12.2)
NR DMARD-free Sustained 
remission 
Age, sex, DAS-44, 
ACPA
● Symptom duration on achieving 
DMARD-free sustained remission,   OR 
0.99 (95% CI 0.98, 1.00), p=0.099. 
Weng, 201030 OC 1987+ RA, USA 
and Mexico






● Annual progression rate by 
total Sharp over 2 years.
● DAS-44<1.6 over 2 years
● Change in HAQ over 2 years
None ‘Early’ patients (<150 days symptom 
duration) versus ‘late’ patients (>150 
days symptom duration at baseline)
● Total Sharp, units per year 3.13±6.49 
versus   1.69±4.43, p=0.3 
● 2 yr DAS 44< 1.6: 25% vs  25%, NS (p 
NR)
● Delta HAQ -0.61±0.57 versus 
-0.42±0.68  NS (p NR)
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Outcome of relevance Adjustment 
factors
Relevant results 
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40 54 (25-80) 75 VERA
3 (2-4) LERA 
12 (9-30)
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VERA and 15% of the LERA patients (p 
<0.05).
● Change in HAQ score: VERA -0.7±0.7 
(-78%), LERA -0.4±0.6 (-44%), p<0.05.
Pascual-Ramos, 
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n(months) OR 1.15 ( 95% CI 1.03-1.28), 
p<0.05
Soderlin, 201128 OC 1987+ RA, 
Sweden 
(BARFOT)
180 58±15 68 5.8±12 NR ●1 year good-EULAR response 
● mean Δ HAQ change at 1 
year
Age, sex, smoking, 
RF, HAQ, treatment, 
DAS-28
● Patients with a good/moderate 
EULAR response in case of symptom 
duration<12 wks 81%, 13-24 weeks 82% 
and 25-52 wks 76%, p=0.03. 
● HAQ and symptom duration: 
correlation coefficient=0.12, p=0.0001
Van der Linden, 
201021
OC 1987+ RA, 
Netherlands
 (EAC Leiden)
598 56.8±15.8 67.7 4.2 
(2.4-8.1) 
Onset of joint 
symptom 
reported by the 
patient
SHS progression over  6 years 
based on yearly made X-rays
Age, sex, inclusion-
period (as proxy for 
treatment strategy)
Patients with symptom duration 
>12 weeks have a 1.34-fold higher 
progression ratio than patients with 
symptom duration <12 wks, over a 
period of 6 years (p=0.001).
van der Woude, 
20099
OC 1987+ RA, UK
(ERAS)






●Multivariable; Symptom duration  on 
achieving DMARD-free remission , HR  
0.94 (0.89-0.99), p=0.029. 
Van der Woude, 
201211
RCT 1987+ RA, 
Netherlands
(BeSt Trial)
508 54±13.7 68 5.3 
(3.2-12.2)
NR DMARD-free Sustained 
remission 
Age, sex, DAS-44, 
ACPA
● Symptom duration on achieving 
DMARD-free sustained remission,   OR 
0.99 (95% CI 0.98, 1.00), p=0.099. 
Weng, 201030 OC 1987+ RA, USA 
and Mexico






● Annual progression rate by 
total Sharp over 2 years.
● DAS-44<1.6 over 2 years
● Change in HAQ over 2 years
None ‘Early’ patients (<150 days symptom 
duration) versus ‘late’ patients (>150 
days symptom duration at baseline)
● Total Sharp, units per year 3.13±6.49 
versus   1.69±4.43, p=0.3 
● 2 yr DAS 44< 1.6: 25% vs  25%, NS (p 
NR)
● Delta HAQ -0.61±0.57 versus 
-0.42±0.68  NS (p NR)
NS, Not statistically significant Trend: almost statistically significant; NR, not reported; OC, observational 
cohort; RCT, randomised controlled trial; RF, rheumatoid factor; SHS, Sharp-van der Heijde Score; TJC, tender 
joint count; VERA, very early rheumatoid arthritis. 
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DISCUSSION
At present, early identification of RA and early start of DMARD therapy have become 
important targets in the treatment of RA. Despite the current focus on the early phases 
of the disease, we questioned whether very early intervention with the disease is indeed 
more effective with regard to modifying the disease outcome, or that positive findings 
are overemphasised in current thinking. We performed a systematic literature review 
to address this question. We identified strong evidence for an association between 
shorter symptom duration and less severe radiographic joint damage in patients 
with early RA. Furthermore a meta-analysis on the outcome DMARD-free sustained 
remission demonstrated that prolonged symptom duration is independently associated 
with a decreased chance on this remission; in case of symptom duration of 12 weeks 
(the suggested period of the window of opportunity) at treatment initiation the HR on 
remission was 0.88. At present, a DMARD-free sustained remission is the closest available 
proxy of ‘cure’ of RA; this outcome is presumably most suited to evaluate whether an 
early period in which the disease is most susceptible to treatment exists. Current data 
supports the presence of a ‘window of opportunity’ effect. 
This study, however, has limitations. First, this study addressed possible citation bias 
but not publication bias. Another major limitation is that heterogeneity in the definition 
of symptom onset, and consequently differences in time periods studied, prohibited 
us from performing a meta-analysis on all 18 selected studies. There were also large 
differences in study designs and study outcomes. A qualitative review was performed 
instead. Strengths of the current approach are that two independent readers scored all 
the articles, that criteria for evaluation of the quality were in line with those of previous 
studies,6, 7 and that predefined and stringent qualitative levels of evidence8 were used to 
summarise the data (strong evidence was defined as ≥75% of the HQ studies reporting 
an effect in the same direction). With this approach, we tried to optimise the accuracy 
of this systematic qualitative literature review. An important drawback of a systematic 
literature review is that by simply counting the number of positive and negative studies, 
the sample sizes and power of the individual studies was ignored. Hence, studies with 
a tendency in the data that were underpowered to obtain a significant result were 
considered equally negative as studies with true negative findings. With a qualitative 
systematic literature review, the data can also not be presented in a funnel plot because 
an overall effect size cannot be generated. 
The fact that a systematic literature review and meta-analysis may result in a slightly 
different answer is illustrated here with the data on achieving DMARD-free sustained 
mission. Three HQ studies were found. Two studies9, 10 were significant; the third11 
was not significant but showed a tendency towards an effect of symptom duration on 
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remission (HR 0.99 (95% CI 0.98 to 1.00), p=0.099 in multivariable analysis). Given the 
predefined levels of evidence (table 1), two out of three positive studies would result 
in the conclusion that there is a moderate level of evidence for an association between 
symptom duration and DMARD-free sustained remission. However, in the meta-analyses 
there was a consistent and independent association between symptom duration and 
DMARD-free sustained remission. 
Another difficulty when interpreting the results of the present study is the fact that 
different studies had included different adjustment factors in the analyses (see table 
3). Not adjusting for patient and disease characteristics and treatment effects may 
potentially result in findings that are not driven by symptom duration but by the 
association of these factors with disease outcome. In 12 of the total 18 studies, 11 of 
the 14 positive studies, and seven of the 10 HQ-studies adjustments for patient and 
disease characteristics were applied, though not exactly the same factors. Four of the 10 
HQ studies applied adjustments for differences in treatment. Furthermore, Mottönen 
et al23 observed a significant association in the single therapy group but not in the 
combination therapy group. In the meta-analyses on DMARD-free sustained remission, 
the association between symptom duration and disease outcome was independent 
of patient characteristics (age, gender), disease characteristics (ESR as marker of 
inflammation and RF as marker of autoantibody positivity) and the applied treatment 
strategies. The drugs used in the studies that applied adjustments for treatment were 
conventional DMARDs 10, 17, 21, 23, 28 and/or biologics.14, 22 
Some studies evaluated symptom duration and had divided patients in groups of, for 
example, symptoms for >5 and <5 months,17, 18, 30 meaning that patients in both groups 
had passed the period of the ‘window of opportunity’ that was previously defined as the 
first 12 weeks. 
Our formulated inclusion and exclusion criteria resulted in a selection of studied articles. 
A large proportion of screened articles was not included in this review because of not 
fulfilling the inclusion criteria. Some studies investigated patients with early ( poly)
arthritis, but not specifically RA, and were, therefore, not included.31, 32 Several of the 
excluded studies did show that patients with RA with shorter symptom duration had 
a better outcome. For example, Green et al33 reported on disease persistency after 
6 months in inflammatory patients with polyarthritis treated with corticosteroids, 
and observed that patients with symptom duration <12 weeks more often achieved 
remission. This study had 6 months of follow-up and did not fulfil our inclusion criteria 
of ≥1 year of follow-up. The latter was also the case for the study of Saevarsdottir et al34 
on the SWEFOT trial, observing that prolonged symptom duration was associated with 
a lower chance on achieving a good EULAR response after 3– 4 months methotrexate 
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treatment. Several papers were excluded because the period between diagnosis and 
treatment onset was studied but not the period between symptom duration and 
treatment onset,35–39 or because the patients studied had symptoms >2 years.40–42 We 
acknowledge that the maximum of 2 years symptom duration as definition of early RA is 
arbitrary, though given our study question, we decided to focus on early RA. 
In conclusion, the present systematic literature review observed that in early patients 
with RA who were mostly treated with conventional DMARDs, there is strong evidence 
that prolonged symptom duration is associated with severe joint damage progression. 
Additionally, a meta-analysis on achieving DMARD-free sustained remission observed 
an independent association for symptom duration. These results, therefore, support 
the notion of the presence of a ‘window of opportunity’. The details of the time frame 
(evaluation of when the window ‘opens’ and ‘closes’) are left to be explored in the near 
future. Many studies using uniform definitions of symptom onset are required to this 
end; definitions for standardised durations were recently proposed.5
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Supplemental file 2. Methodological quality assessment form and search criteria per database.













Definition of study population
Sufficient description of characteristics of study groups
 A ‘1’ is given when a paper describes at least setting and time 
period of the study, ages of patients (and its range) and man:woman 
ratio
Definition of diagnosis
RA diagnosis was according to the 1987 ACR or 2010 ACR/EULAR 
classification criteria . 
Selection bias
Clear description of selection of study subjects.
When a paper described how the study subjects were selected 
(description of in- and exclusion criteria) from the population level to 
the study level, a ‘1’ will be given.
Follow-up
Follow up time ≥ 2 years for RA patients.
More than 2 years was seen as an acceptable follow up duration to 
assess RA outcome (such as sustained DMARD-free or radiographic 
progression).
Organization of follow-up
A ‘1’ was given if there was a structured follow-up applied. So not 
only on patients request.
Participation rate ≥ 80% for study groups
80% was an arbitrary margin chosen to determine the quality of the 
selection of study subjects. 
No differences in lost to follow-up (in both groups).
Including  (quantative and qualitative) information on completers 
and non-completers
Assessment of symptom duration
Symptom onset is clearly defined as symptoms such as pain or 
























Assessment of the outcome: valid measures of disease activity , 
joint-damage or remission
For disease activity; DAS-28, DAS 44 or SDAI. For (radiologic) joint-
damage measures; SHS, LARSON score or RAMRIS. For Remission; 
DMARD-free remission defined by the rheumatologist and the 
DMARD-free remission period should be given
Radiologic outcome assessment was blinded to clinical data (at 
least treatment and symptom duration)
A ‘1’is given if the observers were blinded to the intervention and 
symptom duration when for example scoring the radiographs.
Outcome measure was assessed reproducibly 
For example A ‘1’is given if an ICC/Kappa is provided concerning 
radiographic outcomes. Or if internal or external validation is 
provided in relation to prediction rules. In case of remission; if 
DMARD-free period is given or if (DAS)remission was still present in 
the follow-up visit at the rheumatologist.
Analysis and Data Presentation
Frequencies of symptom duration was given
Frequencies of important outcomes studied were given
Appropriate analysis techniques with estimates were used


















OC     …/13
RCT   …/14
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Overview of the search per database.
Total d.d. 11-5-2012: 836 references, extracted from the following databases:
• MEDLINE (OVID): 452
•	 PubMed: 164, of which 14 unique 
•	 Embase: 606 (of which 164 meeting abstracts): 297 unique 
•	 Web of Science: 278, of which 54 unique 
•	 COCHRANE: 18, of which 1 unique 
•	 CINAHL: 46, of which 13 unique 
•	 Academic Search Premier: 51, of which 5 unique 
•	 ScienceDirect: 10, of which 0 unique
PubMed
(rheumatoid arthritis OR “rheumatoid arthritis” OR “Arthritis, 
Rheumatoid”[Mesh:noexp] OR rheumatoid OR arthritis[tiab] OR arthritic) AND 
(“symptom duration” OR “complaint duration” OR ((symptom*[ti] OR complaint*[ti]) 
AND duration*[ti]) OR ((symptom*[ti] OR complaint*[ti]) AND “Time Factors”[mesh]))
MEDLINE (OVID-version)
(rheumatoid arthritis.mp OR “rheumatoid arthritis”.mp OR Arthritis, Rheumatoid/ 
OR rheumatoid.mp OR arthritis.ti,ab OR arthritic.mp) AND (“symptom duration”.
mp OR “complaint duration”.mp OR ((symptom*.ti OR complaint*.ti) AND duration*.
ti) OR ((symptom*.ti OR complaint*.ti) AND exp Time Factors/) OR (symptom* ADJ6 
duration*).mp OR (complaint* ADJ6 duration*).mp)
Embase (OVID-version)
(rheumatoid arthritis.mp OR “rheumatoid arthritis”.mp OR rheumatoid arthritis/ OR 
rheumatoid.mp OR arthritis.ti,ab OR arthritic.mp) AND (“symptom duration”.mp OR 
“complaint duration”.mp OR ((symptom*.ti OR complaint*.ti) AND duration*.ti) OR 
(symptom* ADJ6 duration*).mp OR (complaint* ADJ6 duration*).mp)
Web of Science 
(TS=(rheumatoid arthritis OR “rheumatoid arthritis” OR rheumatoid) OR TI=arthriti*) 
AND (TS=(“symptom duration” OR “complaint duration”) OR TI=((symptom* OR 
complaint*) AND duration*) OR TS=((symptom* NEAR/5 duration*) OR (complaint* 
NEAR/5 duration*)))
Cochrane Library
(rheumatoid arthritis OR “rheumatoid arthritis” OR rheumatoid OR arthriti*) AND 
(“symptom duration” OR “complaint duration” OR “duration of symptoms” OR 
“duration of symptom” OR “duration of complaints” OR “duration of complaint”)
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(rheumatoid arthritis OR “rheumatoid arthritis” OR rheumatoid OR arthriti*) AND 
(“symptom duration” OR “complaint duration” OR “duration of symptoms” OR 
“duration of symptom” OR “duration of complaints” OR “duration of complaint”)
Academic Search Premier 
(rheumatoid arthritis OR “rheumatoid arthritis” OR rheumatoid OR arthriti*) AND 
(“symptom duration” OR “complaint duration” OR “duration of symptoms” OR 
“duration of symptom” OR “duration of complaints” OR “duration of complaint”)
A. ScienceDirect
TITLE-ABSTR-KEY((rheumatoid arthritis OR “rheumatoid arthritis” OR rheumatoid 
OR arthriti*) AND (“symptom duration” OR “complaint duration” OR “duration of 
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CHAPTER 5
Evaluating relationships between symptom 
duration and persistence of rheumatoid 
arthritis: does a window of opportunity exist? 
Results on the Leiden Early Arthritis Clinic and 
ESPOIR cohorts
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A prolonged symptom or disease duration at treatment initiation is associated with 
unfavourable outcomes in rheumatoid arthritis (RA). It is unknown whether this relation 
is linear, referring to a common ‘the-earlier-the-better principle’, or whether a transient 
time frame in which the disease is more susceptible to treatment exists, referring to a 
‘window of opportunity’. To elucidate this, we evaluated the shape of the associations of 
symptom duration with persistence of RA.
Methods 
Patients with 1987 RA treated with disease modifying antirheumatic drugs (DMARDs) 
in the Leiden Early Arthritis Clinic (EAC, n=738) and Evaluation et Suivi de POlyarthrites 
Indifférenciées Récentes (ESPOIR) (n=533) were studied. Cox proportional hazards 
regression models using natural cubic splines were performed; the log-HR on DMARD-
free sustained remission (the opposite of RA persistence) during 5-year follow-up was 
plotted against symptom duration. Discrimination was measured using time-dependent 
receiver operator characteristic curves. Subanalyses were performed stratified for the 
DMARDs used (methotrexate or other conventional DMARDs) and for anticitrullinated 
peptide antibody (ACPA).
Results 
11.5% (85/738) and 5.4% (29/533) of EAC and ESPOIR RA patients achieved DMARD-free 
sustained remission. In both cohorts and all analyses, the curves depicting the log-HRs 
on remission in relation to symptom duration were not linear. The symptom duration 
with optimal discriminative ability was 14.9 weeks (95% CI 12.3 to 16.0; area under the 
curve (AUC) 0.61) in the EAC and 19.1 weeks (95% CI 12.3 to 28.0; AUC 0.59) in ESPOIR. 
For ACPA-positive RA, this was 11.4 weeks (95% CI 7.7 to 79.0; AUC 0.56) and for ACPA-
negative RA 15.0 weeks (95% CI 9.7 to 48.7; AUC 0.56).
Conclusions 
The association between symptom duration and RA persistence is not linear, suggesting 
the presence of a confined period in which RA is more susceptible to treatment
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Many studies within rheumatoid arthritis (RA) have shown that a prolonged disease 
duration or symptom duration at treatment initiation is unfavourable. It is associated 
with more severe radiographic joint destruction, a higher need of orthopaedic surgery, 
a higher mortality rate and a lower chance to achieve disease modifying antirheumatic 
drug (DMARD)-free sustained remission.1–5 The shape of the association between the 
risk on an unfavourable disease course and the symptom duration at treatment start, 
however, is not known. 
Two profiles may possibly explain the mentioned observations. First, a transient window 
during which outcomes can be more effectively modulated by therapy may be present. 
This refers to the ‘window of opportunity’ hypothesis and implies that whenever 
certain master-switches (crucial processes) have turned on or off the responsiveness to 
treatment is reduced. A small observational study aiming to evaluate the optimal time 
point of DMARD introduction showed that patients with a median disease duration of 3 
months achieved lower disease activity score (DAS) scores and less radiographic damage 
than patients with a median disease duration of 12 months at first DMARD initiation.6 
Two larger cohort studies observed that patients with symptom durations ≤12 weeks 
developed less joint destruction2, 7 and achieved DMARD-free sustained remission more 
often2 than patients with symptom durations >12 weeks. Although these observations 
may support the presence of a temporary window of opportunity, it has never been 
shown that after a certain symptom duration the effect of initiated treatment starts to 
diminish. 
The alternative explanation of the association between the time till intervention and the 
outcome of RA relates to the ‘the-earlier-the-better’ principle that is universally valid in 
the context of the initiation of treatment for many diseases.8 With regard to RA, it can 
be presumed that the total inflammatory load at the time of treatment onset is related 
to the disease outcome. Since the total inflammatory load is the product of the severity 
and the duration of inflammation, a linear association between the symptom duration 
and the outcome of RA can be hypothesised. Then the effect of early intervention is not 
confined to a very early window. In 1995, a randomised clinical trial in recent onset RA 
patients was published;9 patients started treatment with auranofin directly or after a 
delay of 8 months. The early treatment group had better outcomes and this effect was 
maintained after 5-year follow-up. A similar trial was performed using hydroxychloroquine 
and similar findings were obtained.10 The timing of intervention in most patients in 
both arms of both studies was considerably later than <3 months of symptom onset 
and still early treatment initiation was beneficial. Therefore, the advantageous effect 
of early treatment might not be restricted to a very early and temporary time frame. 
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Furthermore, the difference in outcome observed in cohort studies comparing patients 
with < or ≥3 months symptoms2, 6 , 7 can also be found in case symptom duration is linearly 
associated with the outcome. Moreover, a recent study evaluating symptom duration on 
a continuous scale using regular cox regression, thus assuming that every increase in 
symptom duration is equally deleterious and hence assuming linearity, also observed 
significant associations for symptom duration.1 
Altogether, these studies do not allow differentiating between a linear effect and 
a window of opportunity. This study, therefore, set out to elucidate the shape of the 
relationship between the symptom duration at treatment initiation and the risk on 
a persistent course of RA. Persistence was defined as the absence of DMARD-free 
sustained remission; of possible disease outcomes, this outcome is the closest available 
proxy of cure of RA. We studied RA patients treated with conventional DMARDs that 
were included in two early arthritis cohorts. Symptom duration was kept continuous. 
The cox regression model applied did not assume a particular form of the relationship 
and the model that fitted the data best was presented.
METHODS
Patients
RA patients were classified according to the 1987 American College of Rheumatology 
(ACR) criteria and derived from the Leiden Early Arthritis Clinic (EAC) and the French 
Evaluation et Suivi de POlyarthrites Indifférenciées Récentes (ESPOIR) cohort. 
The EAC is an inception cohort that started in 1993 and has been described previously.11 
Inclusion took place when arthritis was confirmed by physical examination and symptom 
duration was <2 years. At study entry, patients used no DMARDs or glucocorticoids. For 
the current research question, RA patients who were promptly treated with DMARD 
therapy after inclusion were selected. Between 1996 and 2011, this concerned 802 RA 
patients; 738 of these had information on dates of symptom onset and were studied. 
The 63 patients without this information and the 738 studied patients did not differ 
in baseline characteristics (data not shown). Information on the initiated DMARDs is 
presented in table 1. None of the patients included in the years 1993–1995 were 
evaluated, as initial therapy concerned nonsteroidal anti-inflammatory drugs (NSAIDs) 
but not DMARDs. 
ESPOIR is a longitudinal cohort including patients with RA or a suspicion to develop RA 
from 14 rheumatology centres in France.12 Patients had to be aged 18–70 years and 
have ≥2 swollen joints for >6 weeks and <6 months. Out of the 813 RA patients included 
between 2002 and 2005, 533 were treated with DMARDs and studied here. 
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In both cohorts, patients filled in questionnaires at baseline, joint counts were performed 
and laboratory evaluations done. The yearly follow-up visits included clinical, laboratory 
and radiographic evaluations. 
Symptom onset in EAC and ESPOIR was delineated identically and defined as the 
first musculoskeletal symptom (either being pain or swelling) relevant to the current 
presentation.13 The symptom duration was defined as the duration between this patient 
reported symptom onset and inclusion and was determined by subtraction of dates, 
expressed in weeks.
Outcome
The main outcome was DMARD-free sustained remission; this is the opposite of disease 
persistence and was defined as the sustained absence of arthritis (absence of swelling 
by physical examination) after discontinuation of DMARD therapy, including biologics 
and glucocorticoids (systemic and intra-articular), for the entire period of follow-up (at 
least 1 year, up to 5 years). In the EAC, all medical files were explored until 5 April 2012. 
In ESPOIR, all structured visits in the database were reviewed.
Subanalyses
Because it is not known whether treatment with different DMARDs differently affects the 
associations between symptom duration and the log-hazard on DMARD-free sustained 
remission, analyses were stratified for the use of methotrexate (the current first-line 
therapy) and other conventional DMARDs. Further, since the biological pathway of 
development of anticitrullinated peptide antibody (ACPA)-positive and ACPA-negative 
RA is different, and ACPA-positive RA patients achieve DMARD-free sustained remission 
less often than ACPA-negative patients, it is possible that the associations between 
symptom duration and the log-hazard on DMARD-free sustained remission differ for 
ACPA-positive and ACPA-negative RA. Analyses were therefore also stratified for ACPA. 
Finally, we assessed the shape of the association of symptom duration with other 
outcomes. Although the outcome DMARD-free sustained remission (and its counterpart 
RA persistence) most closely fits with the window-of-opportunity hypothesis, DMARD-
free sustained remission is achieved infrequently and for clinical daily practice other 
outcomes are relevant as well. The first alternative outcome was radiological joint 
destruction. The time between baseline and achieving a certain progression in joint 
destruction was assessed; two cut-offs were chosen rather arbitrarily and applied in 
the EAC in 485 RA patients who were included between 1996 and 2006 with scored 
radiographs (by one experienced reader with an intraclass observer correlation 
coefficients of 0.91): a delta increase of 5 and 15 Sharp- van der Heijde Score (SHS) 
points. The other outcome was time till sustained remission irrespective of DMARD 
therapy. Sustained remission was derived from the ESPOIR database and defined as 
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the sustained absence of swollen joints count (=0) for at least 1 year irrespective of 
DMARD therapy and subsequently absence of swollen joints for the entire follow-up 
(the maximal follow-up was 5 years).
Statistics
Cox proportional hazards regression models using natural cubic splines were used to 
model the effect of the symptom duration on time to DMARD-free sustained remission.14, 
15 The use of cubic spline functions allows investigation of the shape of the effect; in 
contrast to regular cox regression, it does not assume linearity. HRs generally have a 
non-linear relationship with covariates; this is not the case for log-HRs. Therefore, the 
log-HR for increasing symptom duration values was plotted based on the model that 
fitted the data best. Time-dependent receiver operator characteristic (ROC) curves 
were used to evaluate the discriminative capability of symptom duration; the optimal 
cut-off value for symptom duration was determined using Youden’s index (optimal 
sensitivity+specificity-1). All analyses were done in the statistical software R;16 in 
particular, the R-packages survival and survival ROC were used.17, 18
RESULTS
Symptom duration in relation to log-HR on DMARD-free sustained remission 
Characteristics of the RA patients are presented in table 1. The median symptom 
duration at inclusion was 18.7 weeks (IQR 9.3–35.3) in the EAC and 21.3 weeks (IQR 
13.4–33.5) in ESPOIR. In all, 67% and 76% of the patients started treatment with 
methotrexate; the majority of the remaining patients were treated with sulfasalazine 
or hydroxychloroquine. During 5-year follow-up, DMARD-free sustained remission was 
obtained in 11.5% (85/738) and 5.4% (29/533) in the EAC and ESPOIR, respectively. 
First, the log-HR on DMARD-free sustained remission (the opposite of RA persistence) 
during 5-year follow-up was plotted against the symptom duration in the EAC (figure 1A). 
The log-HRs were negative, indicating a decreased chance on DMARD-free sustained 
remission, which equals an increased chance on disease persistence. The curve was not 
linear and the steepness changed at a point in time (figure 1A). For RA patients included 
in ESPOIR, a non-linear profile was also observed; after an almost linear start, the curve 
flattened towards an almost horizontal line (figure 1B). In order  to comprehend the 
HRs more easily, the profile plotting the HR on DMARD-free sustained remission against 
symptom duration is presented as well (figure 1C, D).
Time integrated ROC curves
To evaluate the discriminative capability of symptom duration, time-dependent ROC 
curves were constructed with DMARD-free sustained remission as outcome. In both 
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cohorts, the areas under the ROC curves were rather low: 0.61 in EAC and 0.59 in 
ESPOIR (figure 1E, F). These low values reduced  the certainty with which the optimum 
of the ROC curve can be identified. The symptom duration with the best discrimination 
of patients with DMARD-free sustained remission from patients with persistent disease 
was 14.9 weeks (95% CI 12.3 to 16.0) in the EAC. Similarly, the symptom duration with 
best combination of sensitivity and specificity was 19.1 weeks (95% CI 12.3 to 28.0) in 
ESPOIR.
Table 1. Characteristics of the RA patients studied
EAC n=738 ESPOIR n=533
Age, years, mean±SD 57.2±15.7 48.8±11.9
Gender, n(%) 484 (65.6) 404 (75.8)
Symptom duration at first visit, 
weeks, median(IQR)
18.7 (9.3-35.3) 21.3 (13.4-33.5)
SJC, median(IQR) 8.0 (4.0-13.5) 7.0 (4.0-12.0)
RF positive, n (%) 430 (58.7) 309 (58.0)
ACPA positive, n (%) 370 (52.4) 268 (50.3)
ESR, mm/h, median(IQR) 31.0 (17.0-50.0) 24.0 (12.0-44.5)
Initiated DMARD, n (%)
      Methotrexate 563 (76.3) 357 (67.0)
      Sulfasalazine 100 (13.6) 62 (11.6)
      Hydroxychloroquine 63 (8.5) 64 (12.0)
      Leflunomide - 30 (5.6)
      Other DMARDs* 12 (1.6) 20 (3.8)
Missing data were as follows: in the EAC, SJC n=17, RF n=5, ACPA n=37, ESR n=6; in ESPOIR, ESR n=5.
*Including glucocorticoids.
ACPA, anticitrullinated peptide antibody; DMARD, disease modifying antirheumatic
drug; EAC, Early Arthritis Clinic; ESPOIR, Evaluation et Suivi de POlyarthrites
Indifférenciées Récentes; ESR, erythrocyte sedimentation rate; RA, rheumatoid
arthritis; RF, rheumatoid factor; SJC, swollen joint count
Subanalyses on initiated DMARD
To evaluate the influence of treatment on the relation between the log-hazard on 
DMARD-free sustained remission and symptom duration, analyses on 5-year follow-up 
data were repeated for patients treated with methotrexate and patients treated with 
other conventional DMARDs separately. In both groups of patients in both cohorts, 
the profiles of the association between symptom duration and DMARD-free sustained 
remission were not linear (figure 2). The optimum symptom duration (determined using 
ROCs) in the EAC was 14.4 weeks (95% CI 10.3 to 46.3; area under the curve (AUC) 0.61) 
for methotrexate users and 18.3 weeks (95% CI 10.7 to 39.9; AUC 0.60) for patients 
treated with other DMARDs. In ESPOIR, this was 19.1 weeks (95% CI 7.0 to 168.3; AUC 
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0.55) and 20.7 weeks (95% CI 13.4 to 25.7; AUC 0.67, see online supplementary figure 
S1), espectively. 
Figure 1. Symptom duration in relation to the log-hazard (A and B) and HR (C and D) on DMARD-
free sustained remission in rheumatoid arthritis patients in the EAC (A and C) and Evaluation et 
Suivi de POlyarthrites Indifférenciées Récentes (ESPOIR) (B and D) and the HR in the EAC (C) and 
ESPOIR (D) during 5-year follow-up. Time-dependent receiver operator characteristic curves of 
symptom duration with DMARD-free sustained remission as outcome in the EAC (E) and ESPOIR 
(F). (E and F) The symptom duration with the best discriminative ability was determined using 
Youden’s index. DMARD, disease modifying antirheumatic drug; EAC, Early Arthritis Clinic.
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Subanalyses on ACPA 
Because ACPA-positive and ACPA-negative RA differ in the processes underlying disease 
development and disease outcomes, analyses were also stratified for ACPA. In the EAC, 
n=67 (19.9%) of ACPA-negative RA patients achieved DMARD-free sustained remission 
during 5 years and n=13 (3.5%) of ACPA-positive RA patients. Also here, the curves 
plotting the log-HRs on DMARD-free sustained remission against symptom duration 
were not linear (data not shown). The optimum symptom duration was 11.4 weeks 
(95% CI 7.7 to 79.0; AUC 0.56) for ACPA-positive RA patients and 15.0 weeks (95% CI 9.7 
to 48.7; AUC 0.56, see online supplementary figure S2) for ACPA-negative RA patients. 
In ESPOIR, only n=3 (1.1%) ACPA-positive patients obtained DMARD-free sustained 
remission, prohibiting stratified analyses in this cohort. 
Figure 2. Symptom duration in relation to the log-hazard on DMARD-free sustained remission during 
5-year follow-up in rheumatoid arthritis patients treated with methotrexate (A and C) or other 
conventional DMARDS (B, D) in the Leiden EAC (A and B) and Evaluation et Suivi de POlyarthrites 
Indifférenciées Récentes (ESPOIR) (C and D). DMARD, disease modifying antirheumatic drug; EAC, 
Early Arthritis Clinic.
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Subanalyses using other outcomes 
Although the outcome DMARD-free remission fits most closely to the window of 
opportunity hypothesis, the shape of the association between symptom duration and 
other outcomes was evaluated as well. First, the time till a certain level of radiographic 
progression was achieved (an increase of 5 and 15 SHS points from baseline onwards, 
respectively) was assessed. These outcomes were obtained in 294 (61%) and 148 
(31%) of the RA patients after a median follow-up of 3 (IQR 1–5) and 5 (4–5) years, 
respectively. The cox regression analyses using these outcomes also showed non-linear 
curves (figure 3A, B). Sustained remission was studied as well, although this outcome 
might reflect an individual patient’s susceptibility to certain treatments in addition to 
changes in underlying disease mechanisms. Sustained remission was obtained in 212 
(40%) patients. The profile was not linear here also; after an almost linear start, the 
steepness of the curve changed substantially at a certain point in time (figure 3C).
Figure 3. Symptom duration in relation to the log-hazard on an increase in SHS scores of 5 (A) 
and 15 (B) from inclusion onwards in the Leiden EAC and the log-hazard on sustained remission 
irrespective of DMARD therapy (C) in Evaluation et Suivi de POlyarthrites Indifférenciées Récentes 
(ESPOIR), all assessed during 5-year follow-up in rheumatoid arthritis patients. Achievement of an 
increase of SHS of 5 and 15 points is an unfavourable outcome and therefore the log-HRs were 
above 0. Sustained remission, in contrast, is a favourable outcome and therefore the HRs were 
below 0. DMARD, disease modifying antirheumatic drug; EAC, Early Arthritis Clinic.
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During the last two decades, many studies have observed that the time to intervention is 
associated with the efficacy of this intervention. A window of opportunity for therapeutic 
interventions, a time frame within which there is a disproportionate response to therapy 
resulting in long-term sustained benefits, is proposed to be present. The concept of this 
window was first hypothesised in the early 1990s.19 The studies available on this subject 
have either compared ‘early’ versus ‘late’ or analysed the duration as a continuous 
variable presuming that every increase in units of time was equally deleterious.1–3, 
6, 20 Although both type of studies reported inverse associations between time to 
intervention and disease outcomes, the issue is still open whether there truly is an early 
period when RA patients respond to intervention in a fundamentally different way than 
they would if therapy was delayed.21 This caveat prompted us to study the shape of the 
association between log-HRs on achieving DMARD-free sustained remission (absence 
of RA persistence) and symptom duration in RA patients treated with conventional 
DMARDs. The patients studied were included in ESPOIR and the Leiden EAC; previous 
studies on these cohorts have already shown that a prolonged symptom association was 
statistically significantly associated with an unfavourable course of RA.2,7 We here applied 
methodology that allowed elucidating the shape of the relationship. We observed a non-
linear association; the log-hazard on DMARD-free sustained remission decreased after 
a certain symptom duration. These data suggest that a confined period in which the 
disease is more susceptible to treatment is present indeed. 
The duration of the window is unknown. In 1991, the window was supposed to endure 
2 years22 and at present it is considered to be the first 3 months. However, these 
suggestions are based on expert opinion rather than on scientific data. Although the cut-
off of 3 months or 12 weeks is often referred to,8, 23,  24 we did not find literature with data 
supporting this time-point. Several studies compared patients with symptoms for < or ≥3 
months,2, 6,  7 but a rationale for this categorisation was not provided and it is unknown 
whether results would have been even stronger when another cut-off was chosen. In the 
present data, the steepness of the curve plotting the log-HR against symptom duration 
diminished around 15–20 weeks after symptom onset (figure 1). It cannot be concluded 
that the window ‘is closed’ after this period, but the data of the present cohorts clearly 
showed that the hazard on remission was less after this period, and so possibly it ‘starts 
to close’ at this point in time. In other words, we do not suggest that DMARD treatment 
after a certain window is futile, but that initiating a DMARD in this particular window 
might yield a better outcome. In case a patient is identified after this period has passed, 
DMARD therapy should certainly not be withheld.
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The symptom duration with the optimum discriminative ability of disease persistence 
was estimated at 14.9 weeks in the EAC and 19.1 weeks in ESPOIR. The time point at 
which the curve plotting the log-HR against symptom duration started to flatten does 
not necessarily coincide with the symptom duration with the best Youden’s index 
determined using an ROC. Nonetheless, in the present data both time indications were 
roughly similar. Importantly, the time estimation obtained using the ROC curves should 
be interpreted with care. First, because the ROC curves were relatively flat and the AUCs 
low, making the identification of a single time point less reliable compared with ROC 
curves with high AUCs. This uncertainty is reflected by the broad CIs. Second, the exact 
dates at which patients started to take DMARDs were not known in all patients (in the 
EAC, these data were incomplete; in ESPOIR, the median duration between inclusion and 
DMARD start was 1.4 weeks). We therefore performed the analyses defining symptom 
duration as the period between symptom onset and the first visit. Consequently, the 
obtained time estimation may be too ‘narrow’. Third, the time indications are obtained 
on group level and may not be identical in every individual patient with RA. Because 
of these limitations, we cannot give definite answers on the length of the window of 
opportunity. Still, the observed results on symptom duration are rather consistent, 
which suggests some validity of these results. 
The validity of the results on non-linear associations of symptom duration with the course 
of RA are strengthened by the finding that non-linear curves were also observed for 
radiographic progression and sustained remission. The curves on DMARD-free sustained 
remission of the EAC and ESPOIR cohort were not completely similar as the change in 
steepness was more profound in the results of the ESPOIR cohort. Nevertheless, when 
evaluating the results of both cohorts and the different outcomes, the general picture 
is that the association of symptom duration with the chance of either a favourable 
outcome (remission) or unfavourable outcome ( joint damage) is not linear. 
This study has limitations. It has been noted previously that studies evaluating the 
symptom or disease duration should indicate precisely how symptom onset or disease 
onset is defined in order to allow comparisons between studies.13 In both cohorts, the 
onset of symptoms was defined identically as the first symptoms noticed by patients 
themselves. The fact that the symptom start was reported by patients may have 
induced some heterogeneity due to inter-individual differences in symptom awareness 
or symptom recollection.25 Another issue is that we evaluated data of longitudinal 
observational cohort studies. These data reflect the daily care of patients and decisions 
to start and stop DMARDs were left to the patients and rheumatologists and not 
protocolised. In ESPOIR, mainly in the first years of its existence, quitting DMARD therapy 
was uncommon. Consequently, the observed frequency of DMARD-free sustained 
remission may be underestimated. Finally, whether DMARD-free sustained remission was 
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achieved was determined slightly differently in the cohorts. In the EAC, all medical files 
were checked to ensure that DMARD-free sustained remission was present. In ESPOIR, 
the data of the structured visits with yearly intervals were studied. It is possible that 
more patients included in ESPOIR would have achieved DMARD-free sustained remission 
when all information present in medical files was evaluated. Though, differences in 
common practice on discontinuing DMARD therapy might be the most important cause 
for the higher frequency of DMARD-free sustained remission in the EAC than in ESPOIR.
It is not known which DMARD is most effective in taking advantage of the early, 
treatment susceptible, disease period. None of the patients studied were treated with 
biologics as first therapy. Since methotrexate is the treatment of first choice according 
to European league against rheumatism (EULAR) recommendations,26 patients treated 
with methotrexate were studied in detail. The results of this subanalysis were in line 
with the results of the total group. Although it is known that methotrexate therapy 
reduces the severity of radiographic progression, 27,28 thus far evidence demonstrating 
that methotrexate is able to increase the chance on DMARD-free sustained remission 
when initiated early is absent. Current data therefore add importantly to the conception 
of methotrexate being disease modifying.26
The biological mechanisms underlying the concept of the window of opportunity are 
unclear. Pathophysiologically, ACPA-positive and ACPA-negative RA are considered to be 
different subsets of RA. Analyses stratified for ACPA were possible in one cohort and 
revealed a slightly shorter window in ACPApositive than in ACPA-negative patients (11.4 
vs 15.0 weeks). Because the CIs were broad, no definite conclusions can be drawn on 
these comparisons, though the tendency in the data may lead to the speculation that 
the presence of ACPA is related to a master-switch leading to an earlier closing of the 
window. 
Present guidelines on the treatment of RA contain indications on the time ideally elapsed 
until access to rheumatological care is obtained or treatment is started.26,29 More studies 
are required to determine what is ‘in time’ or ‘too late’ for specific groups of RA patients. 
In conclusion, the present study demonstrated that the HRs on DMARD-free sustained 
remission decreased considerably before a certain time point. This study is the first 
providing strongly suggestive evidence that a confined period in which RA is more 
susceptible to treatment exits. Further proof might be obtained by performing clinical 
trials in patients with symptoms of very recent onset randomising for direct or delayed 
treatment. However, given the present knowledge this may be considered unethical.
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Supplementary Figure 1. Time-dependent receiver-operator-characteristic curves of symptom 
duration with  DMARD-free sustained remission during 5-year follow-up as outcome for 
methotrexate users (A,C) and patients using other conventional DMARDs (B,D) in the EAC (A,B) 
and ESPOIR (C,D); the symptom duration with the best discriminative ability was determined using 
Youden’s index.
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Supplementary Figure 2. Time-dependent receiver-operator-characteristic curves of symptom 
duration with DMARD-free sustained remission during 5-year follow-up as outcome for ACPA-
positive (A) and ACPA-negative (B) RA-patients in the EAC.
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Morning stiffness is assessed daily in the diagnostic process of arthralgia and arthritis, 
but large-scale studies on the discriminative ability are absent. This study explored the 
diagnostic value of morning stiffness in 5,202 arthralgia and arthritis patients and the 
prognostic value in early rheumatoid arthritis (RA).
Methods
In arthralgia patients referred to the Early Arthritis Recognition Clinics (EARC) of Leiden 
(n = 807) and Groningen (n = 481) or included in the Rotterdam Early Arthritis Cohort 
(REACH) study (n = 353), the associations (cross-sectional analyses) between morning 
stiffness and presence of arthritis at physical examination were studied. In early arthritis 
patients, included in the Leiden Early Arthritis Clinic (EAC) (n = 2,748) and Evaluation 
et Suivi de POlyarthrites Indifférenciées Récentes (ESPOIR) (n = 813), associations with 
fulfilling the 2010-RA criteria after one year were assessed. In 2010-RA patients included 
in the EAC (n = 1,140) and ESPOIR (n = 677), association with the long-term outcomes 
of disease-modifying antirheumatic drug (DMARD)-free sustained remission and 
radiological progression were determined. Morning stiffness was defined as a duration 
≥60 minutes; sensitivity analyses were performed for other definitions.
Results
In arthralgia, morning stiffness (≥60 minutes) associated with the presence of arthritis; 
Leiden EARC odds ratio (OR) 1.49 (95% CI 1.001 to 2.20), Groningen EARC OR 2.21 (1.33 
to 3.69) and REACH OR 1.55 (0.97 to 2.47) but the areas under the receiver operating 
characteristic curve (AUCs) were low (0.52, 0.57, 0.54). In early arthritis, morning stiffness 
was associated with 2010-RA independent of other predictors (Leiden EAC OR 1.72 (95% 
CI 1.31 to 2.25, AUC 0.68), ESPOIR OR 1.68 (1.03 to 2.74, AUC 0.64)). Duration of ≥30 
minutes provided optimal discrimination for RA in early arthritis. Morning stiffness was 
not associated with radiological progression or DMARD-free sustained remission.
Conclusions
Morning stiffness in arthralgia and early arthritis is associated with arthritis and RA 
respectively. This supports the incorporation of morning stiffness in the diagnostic 
process. 
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Morning stiffness is common in patients with rheumatoid arthritis (RA); it affects the 
ability to function in the morning 1, the quality of life and is associated with work loss 2. 
Presence of morning stiffness, together with fatigue, are often mentioned as one of the 
first symptoms of RA. Therefore, morning stiffness is usually assessed in the diagnostic 
process of patients presenting with arthralgia or arthritis 3. 
The scientific data on the diagnostic value of this symptom are surprisingly scanty. In the 
literature, it has been mentioned that morning stiffness is a poor discriminator between 
RA and other rheumatologic disorders 4,5. However, these conclusions are predominantly 
based on two studies, with relatively small sample sizes. The first study compared 93 
RA patients and 46 patients with non-inflammatory joint diseases [4]. The second study 
compared 31 RA patients with 23 systemic lupus erythematosus (SLE) patients and 
34 osteoarthritis (OA) patients 5. It has also been suggested that morning stiffness is 
commonly present in the general population and not specific for RA 6,7. This notion is also 
based on only two studies. A large study revealed a prevalence of morning stiffness of 
37% when defined as stiffness of ≥15 minutes; this definition is generally not considered 
as typical for RA 6. The other study originated from the early 1950s and reported morning 
stiffness in 19% of persons without RA, but a definition of morning stiffness was not 
provided 7. Altogether, there is not much evidence on the diagnostic value of morning 
stiffness. It is also not part of the 2010 American College of Rheumatology (ACR)/
European League Against Rheumatism (EULAR) classification criteria for RA, whereas 
it had been included in the 1958 American Rheumatism Association (ARA) criteria and 
the 1987 ACR criteria for RA 8-10. Because of the paradox of the lack of large-scale studies 
focusing on morning stiffness, and the use of morning stiffness in daily practice by 
rheumatologists and general practitioners, we set out to study the diagnostic value of 
morning stiffness in arthralgia and early arthritis by studying different European datasets 
and cohorts. The basic aim to this study was to evaluate the diagnostic value of morning 
stiffness. Because the diagnostic value is dependent on the patient population in which 
a test is performed, we studied the discriminative ability of morning stiffness in two 
situations. First, in cross-sectional analyses on patients with arthralgia, the association 
between morning stiffness and the presence of arthritis at physical examination was 
studied. This information is relevant for general practitioners (GPs) and other physicians 
who encounter patients with joint symptoms in their practices and who have limited 
experience in joint examination. Second, in early arthritis, the ability of morning stiffness 
to discriminate patients with RA from other early arthritis patients was assessed. 
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Although it is known that morning stiffness is associated with the disease activity 
11, functional disability 12 and work loss 2 in RA, it is undetermined whether morning 
stiffness at first presentation is a risk factor for a more severe disease reflected by 
structural damage or disease persistence. To evaluate this, associations with radiographic 
progression and achieving DMARD-free sustained remission (the absence of disease 
persistence) were assessed in two longitudinal cohort studies.
METHODS
Patients
All datasets and cohorts used are described in more detail elsewhere 13-16. 
In short, the arthralgia patients were referred to the Early Arthritis Recognition Clinics 
(EARC) from Leiden and Groningen (the Netherlands) or included in the Rotterdam Early 
Arthritis Cohort (REACH) (the Netherlands). The EARCs were initiated to reduce referral 
delay by GPs. It was observed that the GP delay contributed to two-thirds of the total delay 
between symptom onset and first visit to a rheumatologist in the Netherlands and that 
GPs frequently applied a ‘wait and-see’ approach if they were unsure of the presence of 
arthritis. Therefore, GPs were instructed to refer to the EARC if they were undecided. The 
EARCs are early access clinics in which experienced rheumatologists screen patients on 
the presence of arthritis by physical examination; no laboratory investigations are done 
13,17. The studied arthralgia patients visited the Leiden EARC between September 2010 
and August 2013 and the Groningen EARC between October 2010 and January 2014. 
The EARC is primarily part of our care. Patients visiting the EARCs were not subjected to 
procedures that were done for scientific purposes, such as blood taking for biobanking. 
Therefore, in line with the Dutch law ‘Wet medisch- wetenschappelijk onderzoek met 
mensen’ (translated as ‘the law on medical and scientific research involving people’), 
patients were not asked to sign an informed consent form.
The REACH study is an inception cohort that was initiated in the Rotterdam area, the 
Netherlands, in 2004. Inclusion required either pain or loss of movement in ≥2 joints or 
>1 swollen joint and ≥2 of the following items: unable to clench a fist in the morning, 
pain when shaking someone’s hand, pins and needles in the fingers, difficulties wearing 
rings or shoes, a family history of RA, morning stiffness >1 hour, unexplained fatigue, all 
<1 year 14. The patients studied here were referred with joint symptoms by GPs between 
2004 and 2009 and the presence of arthritis was assessed at the first visit. REACH was 
approved by the ethics committees of all three participating hospitals (Erasmus MC 
University Medical Center Rotterdam, Sint Franciscus Gasthuis Rotterdam and Maasstad 
Ziekenhuis Rotterdam); all patients gave written informed consent. 
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The early arthritis patients were included in the Leiden Early Arthritis Clinic (EAC) and 
the Evaluation et Suivi de POlyarthrites Indifférenciées Récentes (ESPOIR) cohort. 
The Leiden EAC is a population-based inception cohort that started in 1993. Inclusion 
required the presence of arthritis of ≥1 joint at physical examination and symptom 
duration <2 years 15. The patients studied were included between 1993 and 2011. 
The EAC was approved by the local Leiden University Medical Center (LUMC) ethics 
committee, all patients gave informed consent. ESPOIR is a nationwide cohort in which 
14 rheumatology centres throughout France collaborate. Early arthritis patients are 
included if the treating rheumatologists suspected them of having or developing RA. 
Further, for inclusion patients had to be aged 18 to 70 years and to have ≥2 swollen 
joints for >6 weeks and <6 months. Patients studied were included between 2002 and 
2005 16. ESPOIR was approved by the ethics committee of Montpellier; all patients gave 
written informed consent. In both the EAC and ESPOIR questionnaires were filled in, 
joint counts performed and laboratory evaluations done at baseline. Patients were 
followed prospectively with yearly follow-up visits; these included clinical and laboratory 
evaluations and radiographs of hands and feet.
Assessment of morning stiffness
In all cohorts the duration of morning stiffness was reported in minutes. In the EARCs, 
patients answered questionnaires on the presence and duration of morning stiffness 
(Additional file 1). In the EAC, ESPOIR and REACH the questions on presence and 
duration of morning stiffness were asked by trained research nurses (Additional file 1). 
Patients were not asked for specific locations of stiffness. Morning stiffness duration was 
dichotomized into <60 and ≥60 minutes. Sensitivity analyses were performed with ≥30 
and ≥90 minutes as cutoffs. To evaluate the consistency in results when morning stiffness 
was assessed differently, analyses on arthritis patients were repeated with the severity 
of morning stiffness instead of the duration. The severity was assessed using a visual 
analogue scale (VAS) in 1,959 EAC patients included between 1993 and February 2010 
and in all ESPOIR patients. For analyses, the VAS was divided into the three categories; 
mild 0 to 33 millimeter (mm), moderate 34 to 67 mm and severe 68 to 100 mm. In 
the arthralgia datasets the severity was not recorded. In all patients studied, morning 
stiffness was assessed at the first visit, when patients were not treated with disease-
modifying antirheumatic drugs (DMARDs).
Outcomes
The outcomes were different in the three parts of this study (Figure 1). 
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Diagnostic value in arthralgia 
In arthralgia patients, the outcome was the presence of arthritis ascertained at physical 
examination by experienced rheumatologists (assessed at the same visit when morning 
stiffness was evaluated). In both EARCs, a small proportion of patients (58 and 25) had 
no evident arthritis but were also not classified as having ‘no arthritis’ because the 
rheumatologists suspected these patients of RA development; these patients were 
excluded from analyses.
Diagnostic value in early arthritis
In early arthritis, we aimed to assess the diagnostic value of morning stiffness and here 
the outcome was the presence of RA after one year. RA was defined as fulfilling the 2010 
ACR/EULAR criteria for RA during the first year. An advantage of the 2010-RA criteria 
is that morning stiffness is not included, preventing circle reasoning. Since during the 
first weeks the diagnoses may not yet be definitive, the classification after year one was 
evaluated. These first two parts evaluated the diagnostic value.
Prognostic value within RA
Third, within 2010-RA patients, the prognostic value was assessed by studying two 
long-term outcomes. Structural damage was assessed using serial hands and feet 
radiographs that were scored according to the Sharp/van der Heijde (SHS) method with 
known time order and blinded to clinical data. In the EAC, radiographs were scored of 
patients included between 1993 and 2006. The follow-up was seven years in the EAC and 
three years in ESPOIR. The within-reader intraclass correlation coefficients (ICCs) were 
0.91 and 0.87 for two readers in the EAC and 0.97 in ESPOIR. DMARD-free sustained 
remission, the opposite of disease persistence, was defined as the sustained absence of 
arthritis after discontinuation of DMARD therapy, including biologics and glucocorticoids 
(systemic and intra-articular), for the entire period of follow-up, which was at least one 
year 18. In the EAC, it was assessed by exploring the medical files until 10 years of follow-
up. In ESPOIR, it was assessed over five years of follow-up by reviewing the structured 
visits in the ESPOIR database.
Analyses
Characteristics were compared using Student t tests,Mann–Whitney tests or chi-
square tests when appropriate. Associations of morning stiffness in arthralgia and early 
arthritis were done using logistic regression analyses. All analyses were adjusted for 
age and gender (although morning stiffness was not correlated with age in arthralgia 
or early arthritis). In early arthritis further adjustments were made for anti-citrullinated 
protein antibody (ACPA), rheumatoid factor (RF), swollen joint count (SJC), erythrocyte 
sedimentation rate (ESR) and symptom duration at baseline. The test characteristics 
(sensitivity, specificity), positive/negative predictive values (PPV/NPV) and area under 
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the receiver operating characteristic curve (AUC) were calculated. This curve was used 
to derive the morning stiffness duration with the optimal discriminative ability (Youden’s 
index). Associations between morning stiffness at baseline and radiographic progression 
were studied using multivariate normal regression analysis with log-transformed 
radiographic data as response variable as described elsewhere 19,20. Analyses on DMARD-
free sustained remission were done by Kaplan-Meier survival curves and Cox proportional 
hazard regression models with morning stiffness as an independent variable. Analyses 
on radiographic progression and DMARD-free sustained remission were adjusted for 
age, gender, ACPA and inclusion period as a proxy for differences in treatment strategy 
as described elsewhere 17. SPSS version 20.0 was used (IBM Corp, Armonk, NY, USA).
Figure 1. Outline of study questions. 
Legend Figure 1. Of the 2010-RA patients in the EAC, radiographs were scored for the patients 
included between 1993 and 2006 (n = 636). Baseline characteristics of RA patients included before 
or after 2006 were not different. In ESPOIR, radiographic data was available for 659 of 677 RA 
patients. Here also, baseline characteristics of patients with and without radiographs were not 
different. EAC, Early Arthritis Clinic; ESPOIR, Evaluation et Suivi de POlyarthrites Indifférenciées 
Récentes; RA, rheumatoid arthritis.
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Diagnostic value of morning stiffness in arthralgia
In the Leiden EARC, 807 arthralgia patients were seen, in the Groningen EARC, 481 
arthralgia patients and in the REACH, 353 patients were included. Arthritis was observed 
in 372 (46%), 267 (56%) and 181 (51%) patients respectively. Table 1 presents baseline 
characteristics. The median (interquartile range (IQR)) duration of morning stiffness was 
10 (0 to 30), 10 (0 to 30) and 30 (0 to 60) minutes respectively. The odds ratios (ORs) of 
morning stiffness (≥60 minutes) for the presence on arthritis were 1.49 (95% confidence 
interval (CI) 1.001 to 2.20), 2.21 (1.33 to 3.69) and 1.55 (0.97 to 2.47) for the Leiden 
EARC, Groningen EARC and REACH respectively. The specificities ranged between 73 to 
85% but the sensitivities were low (21 to 38%). The low sensitivity indicated that the 
majority of all patients with arthritis did not have morning stiffness for ≥60 minutes. 
The PPVs were 54%, 69% and 60% respectively (Table 2) and all higher than the absolute 
chances on arthritis without assessing morning stiffness (these were 46%, 56%, 51%). The 
AUCs were very low (Leiden EARC 0.52, Groningen EARC 0.57, REACH 0.54); therefore, 
no duration with optimal discriminative ability was ascertained. When morning stiffness 
was defined as ≥90 minutes (present in 10 to 21% of arthralgia patients), the specificity 
increased to 85 to 93% (Table 2). This indicated that almost all arthralgia patients without 
arthritis did not have morning stiffness for ≥90 minutes.
Table 2. The diagnostic value of morning stiffness (different durations) in arthralgia for the 
presence of arthritis. 
OR (95%CI) 
adjusted for age & gender
Sensitivity Specificity PPV NPV
Leiden EARC
≥30 minutes 1.24 (0.89-1.73) 31.9% 72.1% 49.5% 55.2%
≥60 minutes 1.49(1.001-2.20) 21.2% 84.2% 53.5% 55.5%
≥90 minutes 1.98 (1.18-3.30) 13.5% 92.9% 62.0% 55.6%
Groningen EARC
≥30 minutes 1.63 (1.07-2.47) 40.3% 70.0% 62.3% 48.7%
≥60 minutes 2.21 (1.33-3.69) 27.0% 85.3% 69.3% 48.6%
≥90 minutes 2.16 (1.14-4.10) 16.8% 91.8% 71.7% 47.2%
REACH
≥30 minutes 1.07 (0.69-1.65) 54.4% 48.2% 53.0% 50.3%
≥60 minutes 1.55 (0.97-2.47) 37.8% 72.6% 59.7% 47.9%
≥90 minutes 2.05 (1.18-3.58) 26.7% 85.1% 65.8% 48.0%
OR, odds ratio; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive 
value; EARC, Early Arthritis Recognition Clinic; REACH, Rotterdam Early Arthritis Cohort.
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Diagnostic value of morning stiffness in early arthritis
A total of 2,748 early arthritis patients were included in the EAC and 813 in ESPOIR. The 
median duration of morning stiffness at baseline was 30 (0 to 90) and 60 (15 to 120) 
minutes. Other baseline characteristics are presented in Table S1 in Additional file 1. In 
total, 42% and 83% of the patients were classified as 2010-RA after year one respectively. 
Figure 2 shows the duration of morning stiffness per diagnosis of early arthritis patients 
included in the EAC; the median duration in RA was 60 minutes and longer than that 
of other early arthritis patients (except for SLE patients). Since ESPOIR included early 
arthritis patients with a clinical suspicion of RA and not patients with other diagnoses, 
this figure was not derived for ESPOIR. 
Figure 2. The duration of morning stiffness per diagnosis in the Leiden EAC. 
Legend Figure 2. The black horizontal line indicates the median duration. Number of patients 
per diagnosis after one year of follow-up: 2010-RA n = 1,140, SLE with peripheral arthritis n = 21, 
sarcoidosis n = 78, RS3PE n = 60, inflammatory arthritis n = 133, reactive arthritis n = 108, SpA/
PsA with peripheral arthritis n = 287, crystal arthritis n = 119. Two data points (2010-RA n = 1 and 
SpA/PsA with peripheral arthritis n = 1) are outside the axis limits. EAC, Early Arthritis Clinic; PsA, 
psoriatic arthritis; RA, rheumatoid arthritis; RS3PE, remitting seronegative symmetrical synovitis 
with pitting edema; SLE, systemic lupus erythematosus; SpA, spondyloarthritis.
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Morning stiffness (≥60 minutes) was significantly associated with RA in the EAC (OR 2.92, 
95% CI 2.47 to 3.44) and ESPOIR (OR 2.33, 95% CI 1.59 to 3.44), also after additional 
adjustments for ACPA, RF, SJC, symptom duration and ESR (OR 1.72. 95% CI 1.31 to 2.25 
in EAC and OR 1.68, 95% CI 1.03 to 2.74 in ESPOIR). In both cohorts the sensitivity and 
specificity were around 60%. The PPV was 56.7% in EAC and 88.7% in ESPOIR, these 
absolute chances were a little higher than the pre-test chances on RA (42% and 83%). 
When morning stiffness was defined as ≥30 or ≥90 minutes consistent results were 
observed (Table 3). The AUCs of the presence of morning stiffness for RA in both cohorts 
were 0.68 (95% CI 0.66 to 0.70) and 0.64 (95% CI 0.58 to 0.69). The duration with the 
optimal combination of sensitivity and specificity for RA was 27.5 minutes in the EAC and 
25.0 minutes in ESPOIR (Figure 3). Both cohorts also recorded the severity of morning 
stiffness. In both cohorts morning stiffness duration and severity were correlated 
(Spearman rho 0.42, P <0.001 in EAC and Spearman rho 0.54, P <0.001 in ESPOIR) Early 
arthritis patients with moderate severity (VAS 34 to 67 mm) had an OR on RA of 1.87 
(95% CI 1.48 to 2.36) and 2.04 (1.32 to 3.17) and the patients in the most severe category 
(VAS ≥68 mm) had ORs of 2.38 (95% CI 1.89 to 3.00) and 2.46 (95% CI 1.53 to 3.96) 
respectively. Using the VAS, the AUCs were 0.62 (95% CI 0.60 to 0.65) in EAC and 0.62 
(95% CI 0.57 to 0.68) in ESPOIR. The AUCs of morning stiffness duration and morning 
stiffness severity were not statistically significantly different.
Table 3. The diagnostic value of morning stiffness (duration and severity) in early arthritis for 
classifying RA 
OR (95%CI) 




age, gender, SJC, 
ACPA, RF, ESR 
and symptom 
duration
Sensitivity Specificity PPV NPV
Leiden EAC
≥30 minutes 3.37 (2.83-4.03) 2.22 (1.66-2.96) 77.0% 51.5% 53.5% 75.5%
≥60 minutes 2.92 (2.47-3.44) 1.72 (1.31-2.25) 61.2% 66.1% 56.7% 70.1%
≥90 minutes 2.44 (2.04-2.92) 1.61 (1.19-2.18) 39.1% 80.3% 59.0% 64.5%
VAS 34-67mm 1.87 (1.48-2.36) 2.10 (1.43-3.09) 56.5% 60.0% 49.1% 66.8%
VAS ≥68mm 2.38 (1.89-3.00) 1.93 (1.32-2.83) 60.7% 61.8% 55.3% 66.8%
ESPOIR
≥30 minutes 2.64 (1.81-3.87) 1.76 (1.07-2.88) 74.2% 47.8% 87.6% 27.1%
≥60 minutes 2.33 (1.59-3.44) 1.68 (1.03-2.74) 55.4% 64.7% 88.7% 22.6%
≥90 minutes 2.02 (1.28-3.20) 1.64 (0.92-2.92) 32.5% 80.9% 89.4% 19.4%
VAS 34-67mm 2.04 (1.32-3.17) 1.93 (1.10-3.37) 61.0% 56.3% 85.7% 25.1%
VAS 68-100 mm 2.46 (1.53-3.96) 1.65 (0.88-3.11) 57.3% 63.7% 87.6% 25.1%
RA is classified according to the 2010 ACR-EULAR criteria. VAS: (0-100mm). In the analyses of 
VAS Morning stiffness 3 categories were formed, the reference group was a VAS 0-33 mm. The 
sensitivity, specificity, PPV and NPV of the VAS morning stiffness were calculated against this 
reference group. 
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Prognostic value of morning stiffness in early RA
RA patients reporting morning stiffness (≥60 minutes) at baseline did not have more 
severe radiographic progression (Figure S1A, B in Additional file 1) over time. During 
10 years of follow-up, 23% (n = 257) of the RA patients in the EAC obtained DMARD-
free sustained remission; in ESPOIR this was 10% (n = 65) during five years of follow-
up. Morning stiffness (≥60 minutes) was not associated with achieving remission (Figure 
S1C, D in Additional file 1). Defining morning stiffness as ≥30 or ≥90 minutes or using VAS 
scores did not evidently change the results (Figure S1E-H in Additional file 1). In 128 EAC 
RA patients that achieved remission (after median 2.4 years) the VAS at inclusion and at 
time of remission were available; it declined from 52.5 mm at baseline (IQR 25.8 to 75.8) 
to 13.5 mm (IQR 1.3 to 35.8, P <0.005).
Figure 3. ROC curves on morning stiffness in early arthritis patients of the EAC (A) and ESPOIR (B). 
Legend figure 3.The AUCs were 0.68 in the EAC and 0.64 in ESPOIR. In the EAC, the optimal 
cutoff point (crossing of dashed lines) reflected a sensitivity of 77% and a specificity of 52%; 
morning stiffness duration at this point was 27.5 minutes. When selecting the point with 80% 
specificity, the sensitivity was 40% and the morning stiffness duration 67.5 minutes (EAC) and a 
sensitivity of 33% and a morning stiffness duration 62.5 minutes (ESPOIR). AUC, area under the 
receiver operating characteristic curve; EAC, Early Arthritis Clinic; ESPOIR, Evaluation et Suivi de 
POlyarthrites Indifférenciées Récentes.
DISCUSSION
Morning stiffness is one of most commonly evaluated symptoms in the diagnostic process 
of joint symptoms because its presence is thought to be characteristic for arthritis or RA. 
Others, however, have doubted the value of morning stiffness in this respect 4,5. The 
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absence of large-scale studies on the diagnostic value of morning stiffness prompted 
us to initiate the present study. The subject is timely because of the current focus on 
early identification of arthritis and RA 17,21. Furthermore, assessing the presence of or 
duration of morning stiffness is relatively easy, illustrating its potential utility. We aimed 
to determine the diagnostic and prognostic value of morning stiffness. To this end we 
performed a comprehensive study in different types of patients. We observed that 
arthralgia patients with morning stiffness for ≥60 minutes more often had arthritis than 
patients without morning stiffness, but the discriminative ability of this single variable 
(AUC) was low. Among early arthritis patients, RA patients experienced morning stiffness 
more frequently. Also here the discriminative ability of morning stiffness alone was 
moderate. This indicates that evaluation of morning stiffness is helpful in the diagnostic 
process in clinical practice but that it should be combined with other characteristics for 
optimal discrimination. 
Advantageous in this study is that morning stiffness was evaluated in many arthralgia 
and early arthritis patients (>5,000 in total) included in several European cohorts. The 
arthralgia datasets had different inclusion criteria. The studied EARC arthralgia patients 
were referred by their GPs because they doubted the presence of arthritis. The threshold 
for referral to the EARCs was low and the GP delays short. 13 Although the diagnostic 
value of morning stiffness of persons with joint symptoms in general practices was not 
studied, the arthralgia patients studied here represent the subset of arthralgia patients 
in which GPs were concerned about the presence of arthritis. Patients in REACH had 
to fulfil several criteria. Presence of morning stiffness was a criterion, explaining the 
higher median duration of morning stiffness in REACH patients. Despite the differences 
in patients’ selection, the test characteristics of morning stiffness for arthritis in the 
different arthralgia datasets were comparable, which strengthens the validity of the 
findings. 
The early arthritis cohorts also had different inclusion criteria. ESPOIR included patients 
that were considered susceptible to have or develop RA, whereas the EAC included all 
types of early arthritis patients. Consequently, the percentage of patients fulfilling the 
2010 criteria at year one and the PPV were higher in ESPOIR than in the EAC and the 
difference in morning stiffness between RA and non-RA patients was larger in the EAC. 
Nonetheless, the ORs, AUCs and test characteristics were almost similar between the 
cohorts, supporting the consistency of the findings. 
Emery et al. proposed that the suspicion of RA is increased in the presence of ≥3 swollen 
joints, a positive squeeze test or morning stiffness ≥30 minutes. Data supporting the 
latter recommendation were not published before 3 but the present data support this 
recommendation as in early arthritis with RA as outcome, the best sensitivity-specificity 
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combination (sensitivity 74 to 77%, specificity 48 to 52%) was present for morning 
stiffness enduring ≥30 minutes. However, it should be noted that the AUCs were not high 
and that it remains debatable whether the discriminative ability of ≥30 minutes is clearly 
superior to other durations. In addition, when one should aim for a specificity of 80%, 
to reduce false positive results, a cutoff of ≥60 minutes is required (EAC 67.5 minutes, 
ESPOIR 62.5 minutes, Figure 3). 
The outcome in early arthritis was fulfilling the 2010-RA criteria after one year; generally 
diagnoses are definite then 22. We did not intend to evaluate the predictive ability of 
morning stiffness for RA in undifferentiated arthritis as done previously 22,23. We aimed 
to determine the discriminative ability of morning stiffness in early arthritis for RA and to 
this end the diagnosis had to be ascertained with as much certainty as possible.
Our findings that morning stiffness is associated with 2010-RA, independent of other 
characteristics (for example ACPA, RF, SJC, ESR), are in contrast with the absence of 
morning stiffness in the 2010 criteria 22. This is noteworthy as the cohorts studied here 
were also included in the first phase of the derivation of the criteria. Several factors 
may play a role. First, in the derivation process patients with diagnoses other than 
RA or unclassified arthritis (UA) were excluded, diminishing the contrast between the 
groups (for comparison we observed a larger difference within the EAC than within 
ESPOIR). Second, the outcome was methotrexate initiation whereas we here studied 
fulfilling the 2010 criteria. Furthermore, morning stiffness was missing in 760 out of 
3,115 patients included in phase 1 and morning stiffness was assessed differently in the 
different cohorts (present/absent, </≥1 hour or some categories on duration) 10. This 
heterogeneity in data collection contributed to the fact that morning stiffness was voted 
out in phase 1 10. Nevertheless, the present data reveal that patients with 2010-RA more 
often suffer with morning stiffness than other early arthritis patients. This association is 
independent of the variables in the 2010 classification criteria for RA. In our view, the 
present data suggest that it is helpful to evaluate morning stiffness in addition to the 
other items of the 2010 criteria. However, we did not intend to refine the 2010 ACR/
EULAR criteria for RA. For refinement of existing criteria, a different approach, involving 
many rheumatologists from Europe and the USA and focusing on reaching consensus, 
would be required. 
Our study in early arthritis assessed morning stiffness in two ways: the questions related 
to the duration and the severity (on a VAS). It has been reported that such descriptions 
poorly define the experiences of patients, which encompass temporal patterns, 
intensities and functional disability in the early morning 24,25. To our knowledge, no 
validated method is available to evaluate these items. Thus, exploration of such items 
may increase the diagnostic ability of morning stiffness but were not explored here. 
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A limitation of our data on the severity of morning stiffness is that VAS data were 
missing in 19% of EAC RA patients at baseline and in almost 50% of the RA patients who 
achieved DMARD remission at the time of remission. A previous study on 143 patients 
reported that morning stiffness severity is more responsive than morning stiffness 
duration 26. We did not study the responsiveness of morning stiffness but noted that 
morning stiffness had almost disappeared when DMARD-free sustained remission was 
achieved. Furthermore, we also did not intend to study in detail whether the severity or 
the duration of morning stiffness is a better discriminator. Nonetheless, we did observe 
in early arthritis patients that both measures correlated moderately and that the AUC of 
morning stiffness severity was not superior to that of morning stiffness duration.
Another limitation of this study is that no longitudinal evaluations on the arthralgia 
patients were done. Recently, a prediction rule for arthritis development in ACPA positive 
arthralgia patients was derived and morning stiffness ≥1 hour was part of this rule 27. 
This supports the notion that including morning stiffness in the diagnostic process is 
valuable. More longitudinal studies on arthralgia patients are needed. 
Although the circadian rhythm is associated with nightly activation of the inflammatory 
processes and elevation of pro-inflammatory cytokines (for example TNF-α and IL-6) 28-
30, the exact mechanisms causing the stiffness in the early morning are unknown. In 
addition. The cortisol rhythm might contribute to the increased inflammation at night 
due to the low nocturnal levels of cortisol 31. Despite the association with inflammation, 
morning stiffness at first presentation of RA was not associated with radiological 
progression or RA persistence over time. Other studies reported that morning stiffness 
is associated with functional disability, and work loss and therefore impacts on individual 
RA patients’ lives 2,11,12.
CONCLUSIONS
The additional relevance of present data is that it provides evidence, for the first time 
on a large study, that incorporating morning stiffness in the diagnostic process of joint 
symptoms in daily practice is valuable. A duration of morning stiffness of 30 minutes had 
the best combination of sensitivity and specificity (74 to 77% and 48 to 52% respectively). 
However, in case one prefers to be specific (specificity ≥80%) a cutoff duration of 60 
minutes is preferable.
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Supplemental Table 1. Baseline characteristics of the early arthritis patients subdivided into 2010-
RA and other 
Leiden EAC ESPOIR





Other    
n=1608









52.1±17.1 55.9±15.9 49.4±17.4 48.1±12.6 48.6±12.3 45.3±13.6
Female, n (%) 1640 (60) 365 (32) 743 (46) 189 (23) 524 (77) 100 (74)
Symptom duration, 
weeks
14.9    
(6.4-31.7)
19.4    
(10.0-36.3)
12.0        
(4.4-28.3)
21.3      
(13.2-30.9)
21.4   
(13.4-31.4)
20.0   
(12.1-28.8)
Swollen joints 4 (2-9) 8 (4-13) 2 (1-5) 6 (3-10) 7 (4-11) 3 (2-4)
ACPA positive, n (%) 628 (28) 556 (53) 72 (6) 316  (39) 316 (47) 0
RF positive, n (%) 800 (30) 651 (57) 149 (10) 385 (47) 379 (56) 6 (4)















≥30 minutes, n (%) 1585 (61) 848 (77) 737 (49) 573 (71) 502 (74) 71 (52)
≥60 minutes, n (%) 1189 (45) 674 (61) 515 (34) 423 (52) 375 (55) 48 (35)
≥90 minutes, n (%) 730 (28) 431 (39) 299 (20) 246 (30) 220 (33) 26 (19)
VAS-MS ≤33mm 699 (36) 232 (26) 467 (44) 231 (29) 173 (26) 58 (43)
VAS-MS 34-67mm 613 (31) 301 (34) 312 (29) 315 (39) 270 (40) 45 (33)
VAS-MS ≥68mm 647 (33) 358 (40) 289 (27) 265 (33) 232 (34) 33 (24)
Median (Interquartile range) unless indicated otherwise. VAS-MS: VAS morning stiffness. 
Missingness per variable as follows in all early arthritis patients; Symptom duration EAC n=220 
,  Swollen joint (based on 66-Swollen joint count)  EAC n=137;ACPA EAC n=506, ESPOIR n=1; RF 
EAC n=37, ESPOIR n=1; ESR EAC n=21, ESPOIR n=11, morning stiffness EAC  n=127, VAS morning 
stiffness EAC n=532, ESPOIR n=2. 
Supplemental Methods. Questions asked on presence mornings stiffness per data-set or cohort
EARC Leiden and Groningen: via self-reported questionnaire
Do you experience stiffness when you get up in the morning?
Answers: no or yes. If so for how many minutes … ?
REACH study: via research nurse 
Do you experience morning stiffness? If yes, for how long?
Leiden EAC: via research nurse
Do you experience in stiffness in your joints in the morning. 
And if so, how long does this stiffness endures?
ESPOIR: via research nurse
Do you experience in stiffness in your joints in the morning. 
And if so, how long does this stiffness endures?
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Supplementary Figure 1. The severity of joint destruction (A, B, E , F) and the percentage of 
patients with DMARD-free sustained remission (C, D, G, H) in 2010 RA-patients in Leiden EAC (A, 
C, E and G)  and ESPOIR (B, D, F and H) with the presence (≥60 minutes) and absence of mornings 
stiffness at baseline and VAS morning stiffness. 
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SHS- Sharp-van der Heijde score (SHS) 
A: β 0.98 (95%CI 0.96-1.00) p=0.054  
B: β1.05 (95%CI 1.00-1.10) p=0.076 The beta of morning stiffness is presented with an interaction 
with time, indicating the relative difference in progression rate of patients with morning stiffness 
compared to patients without morning stiffness per year of follow-up. 
C: EAC log rank p=0.21, HR 0.85 (95%CI 0.65-1.11).  
D: ESPOIR log rank p=0.34, HR 0.80 (95%CI 0.50-1.29). 
E: β34-67mm 1.00 (95%CI 0.97-1.03) p=0.75, β68-100mm 1.01 (95%CI 0.98-1.04) p=0.48 
F: β34-67mm 1.03 (95%CI 0.96-1.10) p=0.53, β68-100mm 1.02 (95%CI 0.96-1.09) p=0.45 VAS morning 
stiffness of 0-33mm is used as reference group.
G: EAC log rank p=0.919, HR34-67mm 0.72 (95%CI 0.49-1.04) HR68-100mm 0.79 (95%CI 0.55-1.12) VAS 
morning stiffness of 0-33mm is used as reference group 
H: HR34-67mm 0.60 (95%CI 0.34-1.06) HR68-100mm 0.52 (95%CI 0.28-0.98) VAS morning stiffness of 
0-33mm is used as reference group
Performing similar analyses for the severity of joint destruction when defining morning stiffness 
as ≥30minutes revealed the following results: EAC β 1.00 (95%CI 0.97-1.03) p=0.98, ESPOIR β1.06 
(95%CI 1.00-1.12) p=0.058. When morning stiffness was defined as ≥90minutes the results were: 
EAC β 0.98 (95%CI 0.96-1.00) p=0.11, ESPOIR β1.04 (95%CI 0.99-1.10) p=0.13. Sensitivity analyses 
on DMARD-free sustained remission were as follows with morning stiffness defined as ≥30minutes: 
log rank p=0.91 HR0.90 (95%CI 0.65-1.23) in EAC and log rank p=0.65 HR0.83 (95%CI 0.349-1.41) 
in ESPOIR and when morning stiffness was defined as ≥90minutes: log rank p=0.55 HR 0.94 (95%CI 




The PTPN22 susceptibility risk variant 
is not associated with the rate of 
joint destruction in anti-citrullinated 
protein antibody-positive rheumatoid 
arthritis
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A missense single-nucleotide polymorphism in the protein tyrosine phosphatase non-
receptor 22 (PTPN22) gene, which encodes a negative regulator of T-cell activation, is an 
important genetic risk factor for rheumatoid arthritis (RA) susceptibility.1 The association 
of the PTPN22 susceptibility risk allele and the severity of joint destruction is unclear 
as a result of contradictory observations.2–6 To determine an individual patient’s rate of 
joint destruction accurately, it is required that radiological measurements are collected 
by means of standard procedures, scored quantitatively and sensitively and are repeated 
in time. Consequently, differences in used measurements and analysis methods may 
contribute to the occurrence of contrasting findings. Second, although the effect of 
PTPN22 on RA susceptibility is confined to the anti-citrullinated protein antibody (ACPA)-
positive group,2, 6 most studies on PTPN22 and joint destruction did not analyse the ACPA-
positive subset.2–5 The present study studied the effect of the PTPN22 susceptibility risk 
variant on the rate of joint destruction in two large cohorts of ACPA positive RA patients, 
using sensitive methods for measurement and analysis. 
The first cohort consisted of 593 RA patients from the Leiden Early Arthritis Clinic,7 of 
whom 55% were ACPA-positive. Radiographs were made at baseline and on consecutive 
years. The radiographs were scored by one experienced scorer. The intraclass observer 
correlation coefficient was 0.91. The progression in Sharp van der Heijde score (SHS) 
during 6 years of follow-up was compared between RA patients with and without the 
risk variant (T allele) of rs6679677, a perfect proxy for rs2476601/C1858T (r2=1), using 
a repeated measurement analysis. Such analysis takes advantage of the longitudinal, 
repetitive character of the data and does not exclude patients with incomplete follow-up 
data, avoiding selection bias. In a linear mixed model with radiological score as response 
variable, the effect of time was assumed to be linear in the interaction terms. PTPN22 
and its interaction with time were entered in the model, to test whether PTPN22 T/
non-T carriers had different radiological scores over time. Age, gender and inclusion 
period (a proxy for treatment strategy) were entered in the model to correct for possible 
confounding effects.8 
The replication cohort consisted of 397 ACPA-positive RA patients from the North American 
Rheumatoid Arthritis Consortium with cross-sectional radiological measurements (SHS) 
and genotypic data of rs2476601. Estimated radiological progression rates per year were 
compared using the Mann– Whitney test. In this cohort, no corrections were made for 
age, gender or treatment. 
In the first cohort, 69.0% of RA patients were women and the mean age was 56.4±15.8 
years. The genotype frequencies (GG/GT/TT) were 462/120/11 (77.9%/20.2%/1.9%). 
The presence of the T allele (TT+TG genotype) was not associated with a higher rate of 
radiological joint destruction compared with the absence of this allele (GG genotype) 
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(p=0.10 and p=0.93, respectively, in ACPA-positive and in all RA patients) (figure 1). In 
the second cohort, 72.8% of the patients were women and the mean age was 40.8±12.0 
years. The genotype frequencies (CC/CT/TT) were 282/105/10 (71%/26%/3%). Again, no 
significant difference in estimated radiological progression per year was found (median 
2.11 Sharp units per year in the CC group vs 2.4 Sharp units per year in the TT+TC group, 
p=0.22). The exclusion of 10 genetic outliers did not change these results. 
Using the present Early Arthritis Clinic data, this study had a power of 0.986 to detect 
a difference of 2.14 SHS scores with a SD of 4.07 (difference in increase in SHS over 6 
years) and an α of 0.05; indicating that this study was sufficiently powered to prevent 
false-negative findings. 
In conclusion, this study shows that PTPN22, although it predisposes to ACPA-positive RA, 
is not associated with RA severity measured by the radiological rate of joint destruction, 
proving a further indication that the contribution of PTPN22 to RA is primarily found in 
setting the balance involved in the emergence of ACPA.
A total of 315 ACPA-positive patients had radiographs available. The number of 
radiographs declined from 303 to 267, 251, 212, 185, 169 and 139, respectively, from 
baseline to the 6-year follow-up. The available radiographs of the total RA population 
were in total 593, this declined to 577, 488, 442, 365, 309, 263 and 212, respectively, 













Figure 1. Median Sharp van der Heijde score (SHS) during 6 years of follow-up for patients with 
and without the T allele of protein tyrosine phosphatase non-receptor 22 (PTPN22) (A) in anti-
citrullinated protein antibody-positive rheumatoid arthritis (RA); (B) as well as all RA in the Early 
Arthritis Clinic.
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Evaluating processes underlying the 
predictive value of baseline erosions 
for future radiological damage in 
early rheumatoid arthritis 
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Baseline erosions are characteristic for rheumatoid arthritis (RA) and predictive 
for a severe disease course. The mechanisms leading to baseline erosions being a 
strong predictor for radiological progression are unknown. We aimed to increase this 
understanding by mediation analyses in an observational cohort and a cross-sectional 
MRI study.
Methods 
3256 hands and feet radiographs of 653 early RA patients assessed during 7 years of 
disease were scored using the Sharp-van der Heijde-method. Mediation models and 
multivariate regression analyses were used to explore the association between baseline 
erosions, other predictors and radiological damage over time. 603 joints (MCP2-5 and 
MTP1-5) of 67 RA patients underwent 1.5 T MRI at baseline. Data on MRI inflammation 
were compared with clinical inflammation and baseline radiological erosions. 
Results 
Patients with baseline erosions had, at any point in time during 7 years, 3.45 times 
more joint damage than patients without erosions (p<0.001, 95% CI 3.00 to 3.98). 
Baseline erosions were an independent predictor and not a mediator between symptom 
duration, systemic or local clinical inflammation (erythrocyte sedimentation rate (ESR), 
swollen joint count (SJC)) or autoantibodies (anti-citrullinated-peptide antibodies, 
rheumatoid factor) and radiological damage. Subclinical MRI inflammation was studied 
in relation to erosions, revealing that 83% of the non-swollen joints with baseline 
erosions had subclinical MRI inflammation compared with 25% of the non-swollen joints 
without baseline erosions (OR 15.2 95% CI 3.1 to 102.1). The association between MRI 
inflammation and baseline erosions was independent of symptom duration, ESR, SJC and 
autoantibodies. 
Conclusions 
Baseline erosions are a predictor for future joint damage, independent of known 
predictors as time, autoantibodies or clinical measurable inflammation. Subclinical 
inflammation is suggested as an underlying mechanism.
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Erosions are characteristic for rheumatoid arthritis (RA) and occur in a majority of RA 
patients during the disease. A proportion of patients have erosions on hands or feet 
radiographs already at first presentation. For decades, information on the presence of bone 
erosions is used to classify RA. In the 1958 ARA criteria, radiographic changes typical of RA 
were part of the criteria; this concerned decalcification of joints that was not confined to 
hands or feet.1 Presence of erosions on hand or wrist radiographs was one of the seven 
1987 ACR classification criteria.2 Here it was not defined what type of erosive lesions or 
what number of lesions were required for satisfying this criterion. According to the 2010 
American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 
criteria, RA can be classified in two ways: by scoring six points on the basis of these criteria, 
or by having RA-specific erosiveness.3,4 According to the definition developed by an EULAR 
task force, RA-specific erosiveness concerns three or more metacarpal phalangeal (MCP), 
wrist or metatarsophalangeal (MTP) joints with a cortical break.4 Altogether, baseline 
erosions are considered typical for RA and are relevant to classifying RA.
Presence of erosions at first presentation is also a predictor for the further progression 
of structural damage.5,6 It has thus far not been thoroughly explored whether the 
association between baseline erosions and disease outcome is mediated by associations 
between other predictors and radiological progression. In a study on 112 RA patients 
multivariable analyses were performed and it was concluded that the baseline erosion 
score was the most important prognostic factor for the severity of joint damage after 10 
years.7 Nonetheless, it remains undetermined whether baseline erosions have a direct 
relationship with structural damage or that it acts in the path of other risk markers for a 
severe destructive disease course. 
In other words, although it is common practice to screen early arthritis patients for the 
presence of erosions with hand and foot radiographs, it has to the best of our knowledge 
not yet been thoroughly explored by what mechanism baseline erosions are associated 
with the development of further joint damage. Several possible mechanisms can be 
hypothesized. It is possible that RA patients with erosions at first presentation have a 
more advanced disease than patients without baseline erosions. This would imply that 
patients with baseline erosions do not have a more severe disease but they just visit 
rheumatologists at a later point in time. An alternative explanation is that the presence 
of baseline erosions is a hallmark of severe disease. Then baseline erosions are expected 
to be more frequently present in RA patients with high levels of inflammation or in RA 
patients carrying autoantibodies. Interesting in this respect are the recent observations 
suggesting that anticitrullinated peptide antibodies (ACPA) themselves stimulate 
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osteoclast differentiation and bone loss.8 Other hypotheses for the method by which 
baseline erosions reflect a marker for more severe progression may also be proposed.
We aimed to increase the understanding of mechanisms leading to baseline erosions 
being a strong predictor for structural damage. We addressed this question by evaluating 
the relationships between different predictors for structural damage using mediation 
models and multivariate regression analyses. Data of two sets of RA patients were 
explored to this end: a set of 653 RA patients with radiological follow-up over 7 years of 
disease and a set of 67 RA patients with baseline radiographs and MRI data. 
METHODS
Patients
All RA patients that were studied fulfilled the 2010 ACR/EULAR criteria by scoring 
six points and were included in the Leiden Early Arthritis Clinic (EAC) Cohort, a large 
inception cohort that started in 1993.9 Inclusion took place when synovitis was confirmed 
by physical examination and symptom duration was <2 years. At baseline, patients were 
asked about their joint symptoms and subjected to physical examination, including a 66 
swollen joint count (SJC). Blood samples were taken, amongst others, for determination 
of the erythrocyte sedimentation rate (ESR), rheumatoid factor (RF) and ACPA. Follow-
up visits occurred yearly. Radiographs of hands and feet were taken at baseline and 
thereafter annually. Since August 2010, extremity MRI was added to the baseline visit. 
Two sets of RA patients were extracted from the EAC database. First, in order to evaluate 
structural damage over 7 years of disease, we studied RA patients consecutively included 
between 1993 and 2006 (dataset A). Different treatment strategies were used over time. 
Patients included between 1993 and 1995 were initially treated with non-steroidal anti-
inflammatory drugs and disease-modifying antirheumatic drugs were started later after 
a median of 5 months (and generally within 2 years’ time).10 Patients included between 
1996 and 1998 were initially treated with chloroquine or sulfasalazine, and patients 
included after 1999 were promptly treated with methotrexate or sulfasalazine.10 In the 
analyses, the inclusion period was used as a proxy for the applied treatment strategy as 
described previously.11
The second dataset consisted of consecutive RA patients who underwent extremity MRI 
during the first visit in addition to the regular baseline visit. These patients were included 
between 2010 and 2012 (dataset B). In this cross-sectional study, radiographic erosions 
at baseline were related to MRI findings. 
All patients gave informed consent. The study was approved by the local Medical Ethics 
Committee. 
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Baseline erosions were defined similar to the 2010 criterion for RA-specific erosiveness.4,12 
Patients with ≥3 erosive small joints were considered ‘positive’ and patients with 0-2 
erosive joints were considered ‘baseline erosions negative’. 
All radiographs obtained during 7 years in dataset A were scored according to the Sharp-
van der Heijde (SHS) method by two readers with known time order and blinded to 
clinical data. Within-reader intraclass-observer correlation coefficients (ICC) were 0.91 
and 0.87 and the between-reader ICC was 0.89. The baseline radiographs of dataset B 
were SHS scored by one reader (ICC 0.86). In the analyses that were done on joint level, 
a joint was considered erosive in case of a SHS-erosion score ≥1.
MRI measurements
MRI examinations were performed on a MSK Extreme 1.5 T dedicated extremity 
scanner (GE, Wisconsin, USA). The recommended RAMRIS imaging set was acquired for 
the wrist, MCP and MTP joints. See the online supplementary methods for a detailed 
scanning protocol. Joints were scanned at the most painful, or if indifferent, dominant 
side. MRIs were scored according to RAMRIS by two readers independently, blinded to 
clinical data.13 The within-reader ICCs for the total RAMRIS score were 0.98 and 0.83; the 
between-reader ICC was 0.82. For all analyses, the synovitis and bone marrow oedema 
scores were assessed; the sum was called MRI inflammation. For analyses on joint 
level, MRI inflammation data on MCP(2-5) and MTP (1-5)-joints were extracted; MRI 
inflammation data on wrists were not used, as part of the carpal bones assessed with 
RAMRIS cannot be accurately evaluated on radiographs, prohibiting direct comparisons. 
For analyses on joint level, MRI inflammation data were categorized. MRI inflammation 
was considered to be present when both readers scored ≥ 1 for synovitis and/or bone 
marrow oedema at that joint or bone. An independent third reader was used in case of 
discordant scores, if 2/3 readers scored ≥1 MRI inflammation was considered present. 
For analyses on patient level the total MRI inflammation score, the sum of all scanned 
joints, was evaluated.
Analyses
For comparisons between groups, Student t test, Mann-Whitney test or χ2 - test 
were used when appropriate. Multivariate normal regression analysis for repeated 
measurements with radiological damage as response variable was used on log-
transformed radiological data as described elsewhere.11,14 This model takes advantage 
of within-patient correlations of serial radiographs and allows inclusion of patients 
with missing radiographs at certain time-points. All analyses were adjusted for age, 
gender and treatment strategy. First, the association between baseline erosions and 
joint damage over time was assessed. Then mediation analyses were performed to 
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investigate whether baseline erosions acted as a mediator between presumed predictors 
and structural damage over time. The presumed predictors for structural damage were: 
symptom duration (in weeks) as representative of the disease duration, presence of the 
autoantibodies ACPA and RF, the level of systemic inflammation as represented by the 
ESR and the extend of clinical local inflammation reflected by the SJC. A path diagram 
was used as described by Baron and Kenny to depict a causal chain (see figure 1).15 This 
illustrates the two causal paths that can lead to the outcome; a direct path from the 
independent to the outcome (c) and an indirect path form the mediator to the outcome 
(b). Finally, a path exists from the independent to the mediator (a). To test for mediation 
three regression analyses need to be performed.15 (1) Regress the mediator on the 
independent variable (a); the independent should significantly affect the mediator. (2) 
Regress the dependent (outcome) on the independent variable (c); the independent 
variable should significantly affect the outcome. (3) Regress the dependent on both 
the independent and the mediator. In case of mediation the mediator is significantly 
associated with the outcome and the effect of the independent variable on the outcome 
is less than in step 2 (partial mediation) or absent (full mediation). Baseline radiographic 




Of the 653 RA patients studied in dataset A, 53% had baseline erosions (≥3 erosive joints). 
Table 1 presents the baseline characteristics. Overall patients with baseline erosions 
were older, more often male (36.3% vs 26.1%), more often RF-positive (65.4% vs 55.9%) 
and had higher ESR (median 39.5 vs 27.0 mm/hr). The median symptom duration was 
similar in both groups. 
Baseline erosions are a predictor for future radiological damage
First baseline erosions were studied in relation to radiological damage over 7 years. This 
demonstrated that patients with baseline erosions had 3.45 times (95% CI 3.00 to 3.98, 
p<0.001) more radiological damage at any point in time than patients without baseline 
erosions. 
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Figure 1. Schematic overview of the causal paths that were studied using mediation models as 
described by Baron and Kenny. 
Legend Figure 1. The diagram illustrates the two causal paths that can lead to the outcome; a 
direct path from the independent to the outcome (c) and an indirect path form the mediator to 
the outcome (b). Finally a path exist from the independent to the mediator (a). According to the 
description of Baron and Kenny, to test for mediation the following three regression analyses need 
to be performed.15 (1) Regress the mediator on the independent variable (a); the independent 
should significantly affect the mediator. (2) Regress the dependent (outcome) on the independent 
variable (c); also here the independent variable should significantly affect the outcome. (3) 
Regress the dependent on both the independent and the mediator; in case of mediation the 
mediator is significantly associated with the outcome and the effect of the independent variable 
on the outcome is less than in step 2 (partial mediation) or there is no effect at all (full mediation). 
In this study we tested the following hypothesis; Do baseline erosions act as a mediator in the 
path of symptom duration, or in the path of autoantibodies (anticitrullinated-peptide antibodies 
(ACPA) and rheumatoid factor (RF)), or in the path of systemic inflammation (measured using the 
erythrocyte sedimentation rate), or  in the path of local clinical inflammation (measured using the 
swollen joint count). Suppose baseline erosions act in the path of symptom duration, symptom 
duration is associated with baseline erosions (a) and with structural damage over 7 years (c) but 
when baseline erosions and symptom duration are both included in the model, symptom duration 
is no longer associated with structural damage (full mediation) or the effect size of symptom 
duration in relation to structural damage over 7 years has diminished (partial mediation). The β 
for baseline erosions on structural damage over 7 years was 3.45 (95% CI 3.00 to 3.98 p<0.001). 
Thus patients with baseline erosions had 3.45 times more radiological damage at any point during 
follow-up than patients without baseline erosions. SHS, Sharp–van der Heijde score.
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Table 1. Baseline characteristics of RA patients with and without baseline erosions (dataset A) and 














Age, years, mean±SD 57.1±15.9 48.7±14.5 62.7±14.0* 56.7±13.3
Female, n (%) 449 (68.8) 218 (73.9) 219 (63.7)* 41(61.2)








<12 weeks symptom duration, n (%) 181 (27.7) 86 (29.2) 93 (27.0) 23 (34.3)
ACPA-positive, n (%) 358 (54.8) 150 (50.8) 198 (57.6) 40 (59.7)
RF-positive, n (%) 399 (61.1) 165 (55.9) 225 (65.4)* 42 (62.7)








Swollen joint count (66-SJC) 9 (5-15) 9 (5-14) 9 (4-15) 5 (3-10)
Data are presented as median (IQR) unless indicated otherwise.
Baseline erosions are present in case of ≥3 erosive joints.
Missing data in dataset A; Symptom duration n=31, ACPA n=23, ESR n=4, HAQ n=103, baseline 
radiographs n=14.
*p Value <0.05 for comparison with patients without erosions, analysed with χ2-test, Students t 
test or Mann-Whitney U test where appropriate. 
ACPA, anticitrullinated peptide antibodies; ESR, erythrocyte sedimentation rate; RA, rheumatoid 
arthritis; RF, rheumatoid factor; SJC, swollen joint count.
Baseline erosions are not a mediator of symptom duration 
We then hypothesized that patients who have baseline erosions are more advanced 
in their disease and that baseline erosions are a mediator between symptom duration 
at baseline and radiologic damage over time. Step 1 of the mediation analysis showed 
no significant association between symptom duration and baseline erosions (table 2). 
Patients with baseline erosions had symptoms for median 19.8 weeks and patients 
without erosion for median 19.0 weeks. Thus, baseline erosions did not act as a mediator 
in the path of  symptom duration. 
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Table 2. Results of the individual steps of the performed mediation analyses
Effect (OR) 95% CI P Value
Step 1: (a)  baseline erosions (as possible mediator)
Symptom duration, per week 1.00 1.00-1.01 0.21
ACPA positive 1.24 0.90-1.71 0.18
RF positive 1.49 1.08-2.05 0.015
Systemic inflammation, per mm/hour 1.01 1.01-1.02 <0.001
Local clinical inflammation, per SJ 1.00 0.98-1.02 0.79
Effect (β) 95% CI P Value
Step 2;(c) SHS over 7 years of FU (dependent)
Symptom duration, per week 1.0037 1.0016-1.0060 0.001
ACPA-positive 1.11 1.09-1.14 <0.001
RF-positive 1.08 1.05-1.10 <0.001
Systemic inflammation, per mm/h 1.0004 0.9999-1.0008 0.07
Local clinical inflammation, per SJ 0.9977 0.9963-0.9991 0.001
Effect (β) 95% CI p-value
Step 3: (b+c) SHS over 7 years of FU (dependent)
Each variable together with baseline erosions
Symptom duration, per week 1.0019 1.0002-1.0037 0.03
Baseline erosions 3.35 2.90-3.87 <0.001
ACPA-positive 1.14 1.12-1.16 <0.001
Baseline erosions 3.35 2.90-3.87 <0.001
RF-positive 1.10 1.07-1.12 <0.001
Baseline erosions 3.39 2.94-3.91 <0.001
Systemic inflammation, per mm/h 1.0005 1.0000-1.0009 0.01
Baseline erosions 3.45 6.40-3.98 <0.001
Local clinical inflammation, per SJ 0.9974 0.9961-0.9988 0.14
Baseline erosions 3.46 3.00-3.99 <0.001
Effects are given per unit increase, for example, per week increase in symptom duration , per unit 
increase in mm/h and per unit increase in swollen joints.
Steps 1, 2 and 3 are explained in figure 1. In step 1, a logistic regression analysis is performed 
and in steps 2 and 3 a multivariate normal regression analysis. ACPA, RF, ESR and SJC associated 
with radiological progression with interaction with time, indicating a more severe progression 
rate per year of follow-up. For instance, for ACPA the β is 1.11/year and this is equal to a 
1.11^7=2.08 times higher rate of joint destruction over 7 years, which is equal to a 108% increase 
in rate of joint destruction. Symptom duration and baseline erosions were significantly associated 
with radiological damage and that effect was constantly present during follow-up. For more 
methodological information see ref. 11 
ACPA, anticitrullinated-peptide antibodies; ESR, erythrocyte sedimentation rate; RF, rheumatoid 
factor; SHS, Sharp-van der Heijde score; SJ, swollen joint; SJC, swollen joint count.
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Baseline erosions are not a mediator of the presence of RA-related autoantibodies
Since ACPA and RF are associated with severe radiological joint damage, we then 
speculated that these autoantibodies are associated with baseline erosions and more 
subsequent joint damage. We therefore sought to determine whether baseline erosions 
acted as a mediator in the path of ACPA or RF. In step 1, ACPA had no significant effect 
on baseline erosions, whereas RF was significantly associated with baseline erosions (OR 
1.49, 95% CI 1.08 to 2.05, p=0.02, table 2). Step 2 showed that RF had a significant effect 
on radiological damage over 7 years (β 1.08, 95% CI 1.05 to 1.10, p<0.001). Finally, RF 
and baseline erosions both had a significant effect on radiological damage over time in 
step 3 (β 1.10, 95% CI 1.07 to 2.12, p<0.001 and β 3.39, 95% CI 2.94 to 3.91, p<0.001 
respectively). However, the conditions on mediation did not hold; namely the effect size 
of RF was not diminished in the analysis of step 3 (β=1.08 and β=1.10 respectively) and 
statistically significant. ACPA was not significantly associated with baseline erosions in 
step 1, and step 3 revealed that baseline erosions were independently associated with 
radiological damage when adjusted for ACPA (table 2). Therefore, baseline erosions 
were not a mediator between RA-related autoantibodies and radiological damage over 
7 years. 
Baseline erosions are not a mediator of systemic or local clinical inflammation 
The next hypothesis was that baseline erosions occurred in patients with high levels of 
inflammation and that this actually drives the association between baseline erosions 
and radiological joint damage over time. The ESR and SJCs were considered to reflect 
systemic and local inflammation. In step 1, only a significant effect was found for ESR (OR 
1.01 95% CI 1.01 to 1.02, p<0.001, table 2) However, in step 2, no significant effect was 
observed between ESR and long-term structural damage; therefore, the conditions on 
mediation were not met. Altogether baseline erosions had an effect on radiological joint 
damage independent of systemic or clinically measured local inflammation. 
Baseline erosions independent in multivariate model
Subsequently,  all potential predictors for severe joint damage (symptom duration, 
ACPA, RF, SJC and ESR) were included in a multivariate regression model with radiological 
damage over 7 years as outcome (table 3). Patients with baseline erosions had 3.23 
times more joint damage at any point during follow-up versus patients without baseline 
erosions (95% CI 2.79 to 3.74, p<0.001, figure 1, table 3). Thus presenting with baseline 
erosions was associated with a worse radiological outcome over time, and this could not 
be explained by the studied known predictors. 
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Table 3.The results of a multivariate analysis including nine variables and joint damage over 7 
years as outcome. 
Effect (β) 95% CI p Value
Baseline erosions 3.23 2.79-3.74 <0.001
Symptom duration, per week 1.0023 1.0004-1.0041 0.01
ACPA-positive 1.12 1.09-1.15 <0.001
RF-positive 1.03 1.01 -1.06 0.02
Systemic inflammation (ESR), per mm/h 1.0003 0.9999-1.0007 0.14
Local clinical inflammation (SJC), per SJ 0.9997 0.9983-1.0011 0.68
Age at inclusion 1.022 1.016-1.026 <0.001
Male sex 0.90 0.79-1.01 0.07
Treatment strategy 1 1.09 1.06-1.03 <0.001
Treatment strategy 2 1.06 1.03-1.08 <0.001
Effects are given per unit increase, for example, per week increase in symptom duration , per unit 
increase in mm/h and per unit increase in swollen joints.
Treatment strategy represents three different inclusion periods in which different treatment 
strategies were applied. Treatment strategy 1; patients included between 1993 and 1995 were 
initially treated with non-steroidal anti-inflammatory drugs. Treatment strategy 2; patients 
included between 1996 and 1998 were initially treated with chloroquine and sulfasalazine. 
Treatment strategy 3; patients included after 1999 were promptly treated with methotrexate 
or sulfasalazine, this was used as reference category and therefore not depicted in the table. 
ACPA, RF, ESR, SJC and treatment strategies 1 and 2 associated with radiological progression with 
an interaction with time, indicating a more severe progression rate per year of follow-up. For 
instance, for ACPA the β is 1.12/year and this is equal to a 1.12^7=2.21 times higher rate of joint 
destruction over 7 years, which is equal to a 121% increase in rate of joint destruction. Symptom 
duration, baseline erosions, age and sex were significantly associated with radiological damage 
and that effect was constantly present over time.
ACPA, anticitrullinated-peptide antibodies; ESR, erythrocyte sedimentation rate; RF, rheumatoid 
factor; SJ, swollen joint; SJC, swollen joint count.
Joints with baseline erosions often show subclinical inflammation on MRI 
To further explore mechanisms underlying baseline erosions as predictor for future joint 
damage, we evaluated whether they were associated with subclinical inflammation, 
which can be visualized by MRI in clinically non-swollen joints. Of the 603 MCP and MTP 
joints studied, 491 were clinically not swollen. Of these, MRI and radiographic data were 
available on 485 joints (for technical reasons 6/491 joints could not be evaluated on 
MRI). Joints with subclinical inflammation (MRI inflammation in clinically non-swollen 
joints) had radiographic erosions substantially more often compared with joints without 
subclinical inflammation (83% vs 25%, OR 15.2 95% CI 3.1 to 102.1, table 4).
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Table 4. Frequency of subclinical inflammation in 485 clinically non-swollen MCP and MTP joints 
in relation to the presence of baseline erosions on hand and foot radiographs in 67 RA patients
Baseline erosions No baseline erosions Total
MRI subclinical inflammation 10 (83%) 117 (25%) 127
No MRI subclinical inflammation 2 (17%) 356 (75%) 358
Total 12 (100%) 473(100%) 485
All joints that were assessed with MRI were also depicted on radiographs and scored accordingly. 
Joints with subclinical inflammation (MRI inflammation in clinically non-swollen joints) had more 
frequently baseline erosions compared to joints without subclinical inflammation (OR 15.2, 95% 
CI 3.1 to 102.1).
MCP, metacarpal phalangeal; MTP, metatarsophalangeal; RA, rheumatoid arthritis.
MRI inflammation is independently associated with baseline erosions
Finally, we studied, on patient level, whether MRI inflammation at disease presentation 
was associated with baseline radiographic erosions independent of other possible 
predictors for erosions. In a logistic regression analysis with the presence of baseline 
erosions as outcome, the MRI inflammation score was associated with an increased 
odds of erosions (OR 1.11 95% CI 1.02 to 1.20) independent of SJC, ESR, ACPA, RF or 
symptom duration (table 5). 
Table 5. Associations with radiographic baseline erosions (≥3 erosive joints) as outcome in 67 RA 
patients that had both radiographic and MRI data at baseline.
Univariable Multivariable
OR 95% CI p Value  OR 95% CI p Value
Age at inclusion, years 1.06 1.01 to -1.10 0.01 1.01 0.91 to 1.11 0.91
Male sex 0.78 0.29 to 2.10 0.63 0.33 0.05 to 2.48 0.28
Symptom duration, weeks 1.01 1.00 to 1.02 0.20 1.02 1.00 to 1.04 0.09
ACPA-positive 0.88 0.33 to 2.35 0.80 0.77 0.05 to 11.6 0.85
RF-positive 0.69 0.26 to 1.87 0.47 0.74 0.08 to 7.04 0.79
Systemic inflammation (ESR) 1.01 0.99 to 1.03 0.19 0.99 0.95 to 1.03 0.54
Local clinical inflammation (SJC) 1.11 1.01 to 1.23 0.03 1.05 0.87 to 1.26 0.63
MRI inflammation score 1.11 1.04 to 1.19 0.001 1.11 1.02 to 1.20 0.02
Both univariable and multivariable analyses were done on patient level. The MRI inflammation 
score was defined as the sum of the synovitis-score and bone-marrow-oedema score according 
to RAMRIS. This variable was associated with the presence of baseline erosions, defined as the 
presence of ≥3 erosive small hand or feet joints, as outcome. This association was independent of 
other predictors including markers of local clinical inflammation (SJC) and systemic inflammation 
(ESR).
ACPA, anticitrullinated-peptide antibodies; ESR, erythrocyte sedimentation rate; RA, rheumatoid 
arthritis; RF, rheumatoid factor; SJC, swollen joint count.
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Baseline erosions are used in classification criteria for RA1-3 and are one of the most potent 
predictors for future joint damage.16  Surprisingly, thus far no studies thoroughly explored 
potential mechanisms underlying this association. During the present study, we observed 
that baseline erosions are not located in the causal path of disease duration (symptom 
duration), autoantibodies (ACPA, RF) or commonly used markers of inflammation (SJC, 
ESR). Furthermore, we observed that the large majority of joints presenting with baseline 
erosions also showed subclinical inflammation. Combined together, these data suggest 
that subclinical inflammation is relevant for the development of baseline erosions. 
 
Association analyses as performed in the present study provide only an indication of 
causality. More conclusive evidence on causal relationships can be obtained from animal 
models where specific proteins can be knocked out or in relation to the current manuscript 
where inflammation can be induced and subsequent MRIs and radiographs of extremities 
can reveal the induced changes in joints and bone.17  In humans, however, such approaches 
cannot be adopted and mediation models were used as substitute. An advantage of 
mediation analysis is that known predictors were assessed separately. This yielded a higher 
certainty to conclude on causal paths than could be obtained from multivariable analysis.
 
No uniform definition of baseline erosions exist. Previous studies used different 
definitions, such as any radiological evidence of erosions, a cortical break of ≥2mm, 
presence of two or three erosions, or a certain Larsen or SHS score.7,18-22  In this study, 
erosive disease was defined as having ≥3 erosive joints, which is the same as the recently 
proposed definition of RA-specific erosiveness in light of the 2010 ACR/EULAR criteria.4 
Notably, when applying another cut-off for erosive disease (≥2 erosive joints) similar 
results were obtained (data not shown). A limitation of any definition of erosions 
visualized with radiographs is that these are depicted only two-dimensionally. 
 
The presence of baseline erosions was not a reflection of a longer symptom duration, 
suggesting that the duration of processes underlying the disease was similar in patients 
with and without erosions. Furthermore, differences in inflammation measured using 
ESR and SJC were insufficient to explain the association between baseline erosions and 
subsequent damage. No difference was found in the mediation analyses when CRP was 
used instead of ESR to reflect systemic inflammation (data not shown). In other words, 
these known risk factors for long-term joint damage (symptom duration, ESR and SJC) 
did not act via mechanisms that also promote baseline erosions. The biologic processes 
underlying the association between symptom duration and radiological outcome,23 which 
is also called the ‘window-of-opportunity’ are unknown. Apparently, these processes do 
not promote baseline erosions. Of note, there might be risk factors for baseline or long-
term structural damage that were not assessed in this study.
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Intriguingly we observed no significant difference in the percentage of ACPA positivity 
in patients with and without baseline erosions (58% vs 51%). Because a recent study 
showed that ACPA itself is capable of activating osteoclast activity, even in the preclinical 
phase,8 we assumed that ACPA-positive patients had more frequent erosions at baseline. 
The absence of this finding does not imply that ACPA does not activate osteoclasts. Still, 
radiological visible bone erosions at disease presentation cannot be explained by the 
effect of ACPA.
We observed that inflammation measured with MRI is associated with the presence 
of baseline erosions independently of ESR, SJC, ACPA and symptom duration. More 
importantly, 83% of the non-swollen-joints with baseline erosions had subclinical 
swelling. These data suggest that previous or still present subclinical inflammation is 
important to develop baseline erosions and further joint damage. This finding at disease 
onset is in line with observations of others, showing the relevance of MRI inflammation of 
RA patients in remission.24,25 There are however several limitations. The number of MCP 
and MTP joints that had baseline erosions in dataset B was small. Furthermore, no long-
term radiological outcome data were available of these joints. Thus, although a strong 
association was observed between subclinical inflammation and baseline erosions (step 
1 of the mediation analyses), step 3, revealing that baseline erosions are a mediator in 
the causal path between subclinical inflammation and future joint damage, could not be 
evaluated. Nonetheless, despite these limitations, the finding that all but two clinically 
non-swollen joints with baseline erosions also had subclinical inflammation at MRI is 
suggestive. Since the MRIs were made at the same time as the radiographs it cannot be 
excluded that the baseline erosions in the two non-swollen joints without subclinical 
inflammation were related to previous local inflammation that resolved at the time of 
disease presentation. 
In conclusion, this study is the first to explore mechanisms mediating the association 
between baseline erosions and future structural damage in early RA by taking advantage 
of both a large observational cohort and high-quality extremity MRI data. Present data 
suggest that local subclinical  inflammation is relevant.  Further studies on the long-term 
outcome of subclinical inflammation in the early clinical phase and presumably also in 
the preclinical phase of RA are warranted. 
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MR imaging of the hand (wrist and metacarpophalangeal joints) and forefoot 
(metatarsophalangeal joints) was performed within two weeks after inclusion, at the 
most painful side, or in case of completely symmetric symptoms at the dominant side. 
The presence of clinical arthritis at physical examination of the joints that were scanned 
was not a prerequisite. Patients with impaired renal function or known hypersensitivity 
or allergic reactions to contrast media were imaged without contrast administration 
(n=1).
MR imaging was performed on a MSK-extreme 1.5T extremity MR imaging system (GE, 
Wisconsin, USA) using a 145mm coil for the foot and a 100mm coil for the hand. The 
patient was positioned in a chair beside the scanner, with the hand or foot fixed in the 
coil with cushions.
The forefoot was scanned using a T1-weighted fast spin-echo (FSE) sequence in the 
axial plane with repetition time (TR) of 650 ms, echo time (TE) 17ms, acquisition matrix, 
388×288, echo train length (ETL) 2; and a T2-weighted FSE sequence with frequency 
selective fat saturation in the axial plane (TR/TE 3000/61.8; acquisition matrix 300x224, 
ETL7). Due to time constraints, imaging of the foot was limited to pre-contrast sequences 
only.
In the hand, the following sequences were acquired before contrast injection: T1-
weighted FSE sequence in the coronal plane (TR/TE 650/17ms; acquisition matrix 
388×88; ETL2); T2-weighted FSE sequence with frequency selective fat saturation 
in the coronal plane (TR/TE 3000/61.8ms; acquisition matrix, 300x224, ETL7). After 
intravenous injection of gadolinium contrast (gadoteric acid, Guerbet, Paris, France, 
standard dose of 0.1 mmol/kg) the following sequences were obtained: T1-weighted FSE 
sequence with frequency selective fat saturation in the coronal plane (TR/TE 650/17ms, 
acquisition matrix 364×224, ETL2), T1-weighted FSE sequence with frequency selective 
fat saturation in the axial plane (TR/TE 570/7 ms; acquisition matrix 320x192; ETL2).
Field-of-view was 100mm for the hand and 140mm for the foot. Coronal sequences had 
18 slices with a slice thickness of 2mm and a slice gap of 0.2mm. All axial sequences had 
a slice thickness of 3mm and a slice gap of 0.3mm, with 20 slices for the hand and 16 for 
the foot. Total imaging time was approximately 75 minutes.
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CHAPTER 9
Long-term outcome of Rheumatoid 
Arthritis defined according to the 
2010-classification criteria
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The 2010 American College of Rheumatology/European League Against Rheumatism 
(ACR/EULAR) criteria for rheumatoid arthritis (RA) have been thoroughly studied for 
the test characteristics but it is unclear whether ‘2010 RA’ has a different phenotype 
than ‘1987 RA’ when assessing the severity of the disease course. Therefore this study 
compared two long-term disease outcomes.
Methods
1502 early arthritis patients that had no other diagnoses than RA or undifferentiated 
arthritis (UA) were studied on fulfilling the 1987 ACR criteria, 2010 criteria or both. The 
severity of joint damage was studied with yearly radiographs over 7 years. Achieving 
disease-modifying antirheumatic drug (DMARD)-free sustained remission was assessed 
over 10-years follow-up. Multivariate normal regression and Cox-proportional hazard 
regression were used, adjusting for age, gender and treatment.
Results
550 patients fulfilled the 1987 criteria, 788 patients the 2010 criteria and 489 both 
criteria sets. Patients fulfilling the 2010 criteria developed less severe radiological 
joint damage (p=0.023) and achieved DMARD-free sustained remission more often 
(HR=1.18 (0.93–1.50)) than patients fulfilling the 1987 criteria, though the latter was not 
statistically significant. All 1987 +2010- patients were anti-citrullinated peptide antibody 
(ACPA)-negative. When also applying the radiologic criterion of the 2010-criteria, half 
of the 1987+2010− patients became 2010 criteria positive, but results on the long-term 
outcome remained similar. 
Conclusions 
‘2010 RA’ has a milder disease course than ‘1987 RA’. This may have important 
implications for basic scientific studies and clinical trials in RA.
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Presently rheumatoid arthritis (RA) can be classified according to either the 1987 ACR 
criteria or the 2010 American College of Rheumatology/European League against 
Rheumatism (ACR/EULAR) criteria. Both sets of criteria are being used and multiple 
studies have evaluated the performance of the 2010 criteria.1-5 A formal meta-analysis on 
the test characteristic is in progress (personal communication H Radner), but the current 
impression is that the 2010 criteria, compared to the 1987 criteria, are more sensitive 
and less specific in classifying RA.1 It is yet insufficiently clear whether the phenotype of 
RA is different when the disease is classified according to the 2010 criteria or the 1987 
criteria. Several studies observed that some disease characteristics at disease onset of 
2010 RA patients were milder than of 1987 RA patients.2-5 Some authors reported that 
erosions at baseline and after 2 years are more often present in 1987 RA compared to 
2010 RA.2,4-6 Together, these data lead to the presumption that RA defined according to 
the 2010 criteria is milder in nature than that defined according to the 1987 criteria, but 
there is insufficient data to draw definite conclusions on this matter. Particularly, there 
are no studies comparing the long-term outcome of RA patients when RA is classified 
either to the 1987 criteria or the 2010 criteria. The most characteristic hallmarks of RA 
are progression of joint damage and disease persistence. We aimed to compare these 
two long-term disease outcomes in relation to the classification of RA and performed the 
present longitudinal study to this end. 
METHODS
Patients
Early arthritis patients included in the Leiden Early Arthritis Clinic Cohort7 between 
1993 and May 2011 were studied. Inclusion took place when arthritis was confirmed 
at physical examination and symptom duration was <2 years. At the first visit, patients 
and rheumatologists completed questionnaires, physical examination was performed, 
and serum and radiographs were taken. Follow-up visits were performed yearly. For 
further description, see reference 7. The treatment differed for different inclusion 
periods. Patients included between 1993 and 1995 were initially treated with NSAIDs, 
patients included between 1996 and 1998 were initially treated with chloroquine or 
sulfasalazine and patients included after 1999 were promptly treated with methotrexate 
or sulfasalazine. The inclusion period was used as a proxy for the applied treatment 
strategy in the analyses. 
Of all 2748 included early arthritis patients, patients that at first visit had a clear 
diagnosis other than RA or undifferentiated arthritis were excluded (n=839), which is in 
line with the 2010 criteria. Patients that were treated in randomised clinical trials were 
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excluded (n=397) as the treatment of these patients was more tightly controlled and the 
medications used more potent, affecting the disease course. Patients with a follow-up 
<1 year were also excluded (n=10). Thus, 1502 patients were studied (figure 1A) and 
classified on fulfilling the 1987 ACR criteria and/or the 2010 ACR/EULAR criteria.
Figure 1. Flowchart of patient selection (A) and number of patients studied that fulfilled the 1987− 
and/or 2010 classification criteria at baseline (B)
Legend figure 1. (A) The 2010 American College of Rheumatology/European League against 
Rheumatism (ACR/EULAR) criteria state that these criteria should not be applied in patients 
that have other diagnoses. For this reason, patients that at the 2-week visit (when the results 
of laboratory and radiological evaluations were known) had clear rheumatologic diagnoses 
were excluded. Patients that were treated according to trial protocols were excluded as well, as 
treatment strategies of these patients differed from the other patients. However, the trial patients 
were included in a sensitivity analysis. (B) Of the 1502 patients studied, 489 fulfilled both criteria 
sets for rheumatoid arthritis (RA) at the 2-week visit. 299 patients fulfilled only the 2010-criteria 
and 61 patients fulfilled only the 1987-criteria. 714 patients fulfilled none of the criteria sets for 
RA.
501866-L-sub01-bw-vanNies




Two outcome measures were studied. The first was the severity of radiological damage 
during 7 years of follow-up. Hand and feet x-rays were taken at baseline and yearly 
thereafter and scored according to the Sharp-van der Heijde method by two readers with 
known time order, blinded to clinical data. Intraclass-observer correlation coefficients 
within the readers were 0.91 and 0.87 and between the two readers, it was 0.89.
The second outcome was achieving a disease-modifying antirheumatic drug (DMARD)-
free sustained remission during 10 years of follow-up. Remission was defined as the 
sustained absence of synovitis (by physical examination) after discontinuation of 
DMARD-therapy. Synovitis had to be absent for the entire period of follow-up and at 
least during 1 year8; in general, these patients were also discharged from the outpatient 
clinic. Patients that achieved such a remission but relapsed (n=13) were included in the 
non-remission group. This stringent definition of remission is the best possible outcome 
of RA as it approximates ‘cure’; it is the opposite of disease persistency. Medical files of 
all patients were studied on remission, and this was determined until the 5 April 2012.
Statistical analyses 
Analyses on remission were done using a Cox proportional hazard regression analysis.8 
Analyses on joint destruction were done using a multivariate normal regression analysis 
as described previously, including all radiographs in one analysis and taking advantage 
of serial measurements.9 Another advantage is that it allowed to study all patients, also 
in case of missing radiographs, preventing selection bias that would be induced by a 
completers-only analysis.10 All analyses were adjusted for age, gender, and treatment 
strategy. First the long-term outcomes of patients with RA according to the 1987 
criteria and RA according to the 2010 criteria were compared. In this analysis, patients 
that fulfilled both criteria sets were included in both groups. Subsequently all patients 
were split in three groups (1987+2010−, 1987−2010+ and 1987+2010+) and analyses 
repeated. SPSS V.20.0 was used. p Values <0.05 were considered significant.
RESULTS
Baseline characteristics
Of the 1502 patients studied, 550 patients fulfilled the 1987 criteria, 788 patients the 
2010 criteria by having ≥6 points and 489 patients fulfilled both criteria (figure 1B). Table 
1 presents the baseline characteristics. Overall, no large differences were seen between 
1987 RA and 2010 RA, but 2010+ patients experienced less morning stiffness than 1987+ 
patients (median 60 vs 90 min) and had slightly lower C-reactive protein (CRP) levels. 
When comparing the three subgroups, it was observed that all 1987+2010− patients 
were anti-citrullinated peptide antibody (ACPA)-negative. 
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Comparison of 1987 and 2010 RA
RA patients according to the 2010 criteria had less severe radiological joint destruction 
over 7 years of disease than RA patients classified using the 1987 criteria (p=0.023, figure 
2A). When evaluating DMARD-free sustained remission, more remission was achieved in 
2010+ RA-patients than in 1987+ RA-patients,though this difference was not statistically 
significant (HR=1.18(0.93-1.50) p=0.17, figure 2B). 
Subanalyses
Subsequently, the RA patients were stratified in three groups (1987+2010−, 1987−2010+, 
1987+2010+) and the analyses were repeated. As presented in figure 2 C,D, 1987+2010+ 
RA patients developed more severe joint destruction and achieved DMARD-free 
sustained remission less often than patients fulfilling one criteria set for RA (p<0.001 
for both outcomes and comparison of three groups). Moreover, when analysing these 
subgroups in more detail, the severity of joint damage was not different between the 
1987+2010+ and 1987+2010− patients (p=0.35) but differed between the 1987+2010+ 
and 1987 −2010+ patients, p<0.001, figures 2C,D). Interestingly, 1987 +2010− RA 
patients achieved DMARD-free sustained remission most frequently. However, this small 
subgroup contained only ACPA-negative patients. When the analysis was also adjusted 
for ACPA, this effect was no longer present (figure 2F). 
Thus far, the 2010 criteria were applied using the point system. When applying the 
radiological criterion for RA-specific erosiveness (≥3 erosive joints)(11;12) in addition 
to the point system, 30 of the 61 1987+2010− RA were now 2010-criteria positive. All 
analyses on joint damage and remission were repeated; this did not influence the results 
(see online supplementary figures 1 and 2).
Finally, all analyses were repeated including the 397 patients that were treated in clinical 
trials, yielding similar results as described above (data not shown).
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Figure 2. Comparison of long-term outcomes of rheumatoid arthritis (RA) according to fulfilment 
of the 1987− and/or 2010 classification criteria for RA. 
Legend figure 2. All analyses were adjusted for age, gender and treatment. Depicted in (A, C and 
E) are the predicted (by the multivariate normal regression model) Sharp-van der Heijde scores 
during 7-years of follow-up. Depicted in (B, D and F) are the percentage of patients achieving 
disease-modifying anti-rheumatic drug (DMARD)-free sustained remission (A and B) Comparison 
of patients fulfilling the 1987 criteria and patients fulfilling the 2010 criteria. (C and D) Comparison 
of patients fulfilling either one or both criteria sets for RA. (E and F) Comparison of patients fulfilling 
either one or both criteria sets for RA, after also adjusting for the presence of ACPA. (C–F) Presented 
are the overall p values when comparing three groups. For comparisons of subgroups with the 
1987+2010+ patients as reference the results were for C: 1987+/2010+ vs 1987+/2010− p=0.35, 
1987+/2010+ vs 1987−/2010+ p<0.001. D:1987+/2010+ vs 1987+/2010− p<0.001, 1987+/2010+ 
vs 1987−/2010+ p<0.001: E: 1987+/2010+ vs 1987+/2010− p=0.14, 1987+/2010+ vs 1987−/2010+ 
p<0.001. F:1987+/2010+ vs 1987+/2010− p=0.21, 1987+/2010+ vs 1987−/2010+ p<0.001.
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The present study evaluated the long-term outcome of patients classified to the 
1987 criteria or the 2010 criteria and observed a statistically significant difference in 
the severity of joint damage and a non-significant difference with regard to disease 
persistency. For both outcomes, patients classified as RA using the 2010 criteria had a 
less severe disease course. Thereby the present data suggest that RA, when using the 
most recent classification criteria, has become a milder disease. 
This observation might fit within the observations that the 2010 classification criteria 
have a lower specificity than the 1987 criteria and can be positive in patients that later 
on have other diagnoses (associated with a less destructive course).1,5,6,13-15  Alternatively, 
patients fulfilling the 2010 criteria, in particular, the 1987−2010+ patients, may simply 
represent a milder set of patients. The milder outcome observed was not due to an 
earlier diagnosis and earlier treatment initiation, as the 2010 criteria were applied after 
the follow-up data were obtained.
In our study, we did not observe large differences in baseline characteristics, though the 
1987 RA patients experienced more morning stiffness than the 2010 RA patients. This may 
be a consequence of morning stiffness being part of the 1987 criteria. Adding morning 
stiffness as an additional adjustment factor to the analyses did not give different results 
(data not shown); hence the findings done were not driven by this baseline difference.
The 2010 criteria were derived with MTX-usage as outcome; by using this outcome, 
some level of circularity could not be prevented. Advantages of the two outcomes used 
here is that they are independent of any set of classification criteria, and therefore, do 
not suffer from circle reasoning.
A limitation is that patients were treated. Ideally, the present study question was evaluated 
in patients that were not treated over many years, as this completely represents the 
natural disease course. We excluded patients that were treated in clinical trials and studied 
only patients treated according to routine care. Nonetheless, the treatment strategies 
used in these patients had changed over time; therefore analyses were adjusted for these 
differences in treatment. Importantly, the proportion of 1987+ and 2010+ patients was 
similar for the different inclusion periods (data not shown). Moreover, including patients 
who were treated in clinical trials did not influence the findings.
All 1987+2010− patients were ACPA-negative, which is in line with another recent 
report.16 When the radiological criterion of the 2010 criteria was also applied, half of 
this group of patients became 2010-criteria positive. This supports the relevance of the 
radiological criterion as the frequency of this misclassification reduced. 
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In conclusion, the present longitudinal study showed that RA classified according to 
the 2010 criteria has less severe joint destruction and is less often persistent than RA 
classified according to the 1987 criteria. This may have important implications, both for 
basic scientific studies and randomised clinical trials in RA.
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Supplementary figure 1. Fulfillment of the 1987- and 2010 classification criteria at baseline after 
application of the radiological criterion of the 2010 criteria in addition to the point system.
Of the 1502 included patients, 519 fulfilled both criteria sets for RA. 299 patients fulfilled only 
the 2010-criteria and 31 patients fulfilled only the 1987-criteria. 714 patients fulfilled none of the 
criteria sets for RA 
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Supplemental figure 2. Comparison of long-term outcomes of RA according to fulfillment of the 
1987- and/or 2010 classification criteria for RA after applying the erosion criterion.
Legend supplemental figure 2.
All analyses were adjusted for age, gender and treatment. Depicted in A, C and E are the predicted 
(by the multivariate normal regression model) Sharp-van der Heijde scores  during 7-years of follow-
up. Depicted in B,D,F are the percentage of patients achieving DMARD-free sustained remission 
A-B: Comparison of patients fulfilling the 1987-criteria and patients fulfilling the 2010-criteria. 
C-D: Comparison of patients fulfilling either one or both criteria sets for RA. 
E-F Comparison of patients fulfilling either one or both criteria sets for RA, after  also adjusting for 
the presence of ACPA. 
C,D,E,F; Presented are the overall p-values when comparing three groups. For comparisons of 
subgroups with the 1987+2010+ patients as reference the results were for;
C: 1987+/2010+ versus 1987+/2010- p=0.001, 1987+/2010+ versus 1987-/2010+ p<0.001. 
D:1987+/2010+ versus 1987+/2010- p<0.001, 1987+/2010+ versus 1987-/2010+ p<0.001: 
E: 1987+/2010+ versus 1987+/2010- p=0.08, 1987+/2010+ versus 1987-/2010+ p<0.001. 
F:1987+/2010+ versus 1987+/2010- p=0.01, 1987+/2010+ versus 1987-/2010+ p<0.001. 
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CHAPTER 10
TRAF1/C5 polymorphism is not 
associated with increased mortality 
in rheumatoid arthritis: two large 
longitudinal studies
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Recently an association between a genetic variation in TRAF1/C5 and mortality from 
sepsis or cancer was found in rheumatoid arthritis (RA). The most prevalent cause of 
death, cardiovascular disease, may have been missed in that study, since patients were 
enrolled at an advanced disease stage. Therefore, we used an inception cohort of RA 
patients to investigate the association between TRAF1/C5 and cardiovascular mortality, 
and replicate the findings on all-cause mortality. As TRAF1/C5 associated mortality may 
not be restricted to RA, we also studied a large cohort of non-RA patients.
Methods
615 RA patients from the Leiden Early Arthritis Clinic (EAC) (mean follow-up 7.6 years) 
were genotyped for rs10818488. In addition 5634 persons enrolled in the PROspective 
Study of Pravastatin in the Elderly at Risk (mean follow-up 3.2 years) were genotyped for 
rs2416808 (R2 >0.99 with rs10818488). The life/death status was determined and for 
the deceased persons the cause of death was ascertained. Cox proportional hazards and 
regression models were used to assess hazard ratios (HR) and 95% confidence intervals 
(CI).
Results
 Seventy-seven RA patients died. The main death causes in RA patients were cardiovascular 
diseases (37.7%), cancer (28.6%) and death due to infections (9.1%). No association 
was observed between the rs10818488 susceptible genotype AA and cardiovascular 
mortality (HR 1.08 95%CI 0.54 to 2.15) and all-cause mortality (HR 0.81 95%CI 0.27 to 
2.43). Similar findings were observed for rs2416808 susceptible genotype GG in the non-
RA cohort (HR 0.99; 95%CI 0.79 to 1.25 and HR 0.89; 95%CI 0.64 to 1.25, respectively).
Conclusions
The TRAF1/C5 region is not associated with an increased mortality risk.
501866-L-sub01-bw-vanNies




Patients with rheumatoid arthritis (RA) have an increased mortality risk. A recent review, 
studying data from 84 unique cohorts, showed that mortality rates in RA patients were 
1.5 to 1.6 fold higher than in the general population.1 The attributed causes of death in 
RA patients are identical to those in the general population, 1  cardiovascular disease 
being the primary cause of death followed by cancer and infection. Age, sex and most 
clinical markers that are related to a more severe destructive disease course (among 
others number of inflamed joints, C reactive protein (CRP) and presence of erosions) are 
also associated with higher mortality risks. 1
Genetic risk factors for mortality in RA are scarcely investigated. Presence of the human 
leukocyte antigen (HLA)-DRB1 shared epitope alleles are reported to be associated with 
an increased mortality and, in particular, mortality related to cardiovascular disease 
(CVD).2-4 Although a lot of progress has been made in the field of genetics of RA-
susceptibility, the HLA-shared epitope alleles still constitute the most powerful genetic 
risk factor to developing RA. Well-replicated non-HLA risk factors are PTPN22, TNFAIP3, 
and TRAF1/C5.5-7 TRAF1/C5 associated with several autoimmune diseases other than RA 
such as juvenile idiopathic arthritis (JIA) and systemic lupus erythomatodes.8,9
A recent study analyzed the TRAF1/C5 variant, rs3761847, in relation to mortality in RA 
and observed an increased mortality risk for the susceptible genotype GG compared 
with the non-susceptible AA genotype (hazard ratio (HR) = 3.96, 95% confidence interval 
(CI) = 1.24 to 12.6).10 Such an observation is relevant because it indicates that genetic 
factors, such as TRAF1/C5, contribute to the increased mortality in RA. The causes of 
death were also investigated. Intriguingly, no increased death rate for CVD was found 
among GG homozygotes, whereas increased death rates were found for cancer and 
infections. As this study enrolled patients with a median disease duration of 10 (range 
4 to 18) years, which were subsequently followed up for two to four years, CVD related 
deaths occurring earlier in the disease course may have been missed. To further explore 
the association between the TRAF1/C5 locus and CVD-related mortality in RA, we studied 
a cohort of 615 early RA patients that were followed from disease onset to 14 years 
onwards. In addition, we investigated whether the association with all-cause, infectious 
and cancer-related mortality Panoulas and colleagues observed could be replicated.10 
Finally, as an association between TRAF1/C5 and mortality may not be restricted to RA 
patients, we also analysed a large cohort of non-RA patients.
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MATERIAL AND METHODS
Early arthritis clinic cohort
The Leiden early arthritis cohort (EAC) is an inception cohort consisting of patients 
with recent-onset arthritis referred to the Department of Rheumatology of the Leiden 
University Medical Center from 1993 onwards.11 Patients were included when arthritis 
was observed by a rheumatologist. For the present study, patients were selected who 
fulfilled the American College of Rheumatology 1987 revised criteria for RA within the 
first year of follow up and had DNA samples available (n = 615).12 Written informed 
consent was obtained from all participants. The study was approved by the appropriate 
local institutional review board. At inclusion, a physical examination was performed and 
blood samples were taken to determine CRP, immunoglobulin (Ig) M rheumatoid factor 
(RF; by ELISA) and anti-cyclic citrullinated peptide (CCP) 2 antibodies (Immunoscan RA 
Mark 2; Euro-Diagnostica, Arnhem, the Netherlands). Anti-CCP2 positivity had a cut-
off level of 25 arbitrary units, according to manufacturer’s instructions. Patients also 
filled in a Health Assessment Questionnaire (HAQ) 13 and radiographs of hands and feet 
were taken and scored by one experienced reader (the intraclass-observer correlation 
coefficients was 0.91), using the Sharp van der Heijde method.14
Cohort of non-RA patients
As well as the RA patients, 5634 participants with available DNA from the PROspective 
Study of Pravastatin in the Elderly at Risk (PROSPER) were studied. In short, PROSPER is 
a randomized double-blind placebo-controlled trial that assessed whether pravastatin 
treatment in elderly men and women diminished the risk of major vascular events.15 
Participants were screened and enrolled in Scotland (Glasgow), Ireland (Cork), and 
the Netherlands (Leiden) between December 1997 and May 1999. Written informed 
consent was obtained from all participants. The study was approved by the appropriate 
local institutional review boards of all centers. The primary endpoint in the study was a 
combination of death from coronary heart disease (CHD), non-fatal myocardial infarction 
(MI), and fatal or non-fatal stroke. After three years of follow up, CVD and transient 
ischemic attacks (TIAs) were less prevalent in the group treated with pravastatin.16
SNP genotyping
rs10818488 was genotyped in the RA cohort and rs2416808, which is in complete 
linkage disequilibrium with rs10818488 (r2>0.99), was genotyped in the non-RA cohort. 
Genotypings were performed using the MassArray matrix-assisted laser desorption 
ionisation time-of-flight mass spectrometry, according to the protocols recommended 
by the manufacturer (Sequenom, San Diego, CA, USA). Each 384-well plate contained at 
least 4 positive (CEPH DNA) and 4 negative controls, to check for assay performance and 
contaminations, respectively. Spectro- Caller software (Sequenom, San Diego, CA, USA) 
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supplied by the manufacturer was used to automatically identify the genotypes. Clusters 
were checked and all doubtful calls were manually evaluated. Ten percent of the genotypes 
were performed in duplicate and the error rate was below 1%. Allele frequencies and 
Hardy-Weinberg equilibrium consistency were determined with Haploview.17 Both SNPs 
were in agreement with Hardy-Weinberg equilibrium. Both rs10818488 and rs2416808 
are in complete linkage-disequilibrium with rs3761847 genotyped by Panoulas and 
colleagues (r2>0.99 data from Hapmap, and Kurreeman and colleagues).5,6,10
Notification of death
In the EAC, patients were followed longitudinally from the moment of their inclusion until 
1 April, 2008, or death. All RA patients were tracked nationally using the civic registries 
(Gemeentelijke Basis Administratie) to ascertain life or death status. Causes of death 
for RA patients were obtained from Statistics Netherland18 and coded according to the 
International Classification of Diseases 10th revision of the World Health Organization 
.19 In the non-RA cohort, patients were followed for 3.2 years and the causes of death in 
this period were obtained from post-mortem reports and/or certification of death. All 
endpoints were adjudicated by a study endpoint committee.
Analysis of data
Data are expressed as mean (± standard deviation (SD)) with a 95% CI for continuous 
variables and as proportions for categorical variables. Differences in baseline patient 
characteristics between the single nucleotide protocol (SNP) genotypes were compared 
using a oneway analysis of variance test or Kruskal Wallis test for continuous variables 
and the chi-squared test for nominal variables. Associations between genotype and 
mortality were tested with univariate cox regression analyses and log rank tests. 
In a study in RA patients (unpublished) we observed that age, CRP level and Sharp-van 
der Heijde score were independently associated with mortality. In order to investigate 
whether TRAF1/C5 is associated with mortality after adjusting for gender, HAQ-score and 
other previously found risk factors, a multivariate cox regression analysis was performed. 
Subjects from the cohort of non-RA patients who withdrew consent or died during the 
study were censored at the date of death or at the last date of follow up. Cox regression 
analyses in the cohort of non-RA patients were adjusted for gender, age, pravastatin or 
placebo use, and country. 
Panoulas and colleagues observed a HR of 3.96. The RA cohort has a power of 99.6% to 
identify such an association with C5/TRAF1 based on the observed genotype frequencies 
and an alpha of 0.05. In the non-RA cohort this power was 100%. Assuming that the 
finding by Panoulas and colleagues was affected by the winners curse and the true HR 
would be lower, for example a HR of 1.5, then the power of the RA cohort and non-RA 
cohort to observe an association was 28% and 97.5%, respectively. 
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All statistical analyses were performed using Statistical Package for Social Sciences 




The 615 RA patients had mean (± SD) age of 56.4 ± 15.6 years and 68.5% were female. 
The mean CRP concentration was 29.5 ± 33.1 mg/L, 57% were RF positive, 43.4% were 
anti-CCP2 positive, the mean HAQ score was 1.07 ± 0.72 and the median Sharp-van der 
Heijde score at baseline was 6 (range 2 to 12). The genotype frequencies for rs10818488 
were: 29% GG (n = 180), 53% AG (n = 324) and 18% AA (n = 111). No differences in 
baseline characteristics between genotypes were observed (Table 1). The mean follow 
up was 7.6 ± 3.6 years (range 4.7 to 10.5 years). 
In the cohort of non-RA patients 51.6% were female and the mean age was 75.3 ± 3.4 
years. For baseline characteristics see Table 2. The slight difference in history of stroke 
was considered to be a spurious finding due to multiple comparisons. The genotype 
frequencies for rs2416808 were: 30.9% AA (n = 1743), 48.4% AG (n = 2725) and 19.9% 
GG (n = 1123). The mean follow up in these patients was 3.2 ± 0.6 years. 
Mortality in RA cohort
Seventy-seven RA patients died during follow up; 46 (11%) women and 31 (16%) men. 
Twenty-five percent of these patients carried the GG genotype, 57% the AG genotype 
and 18% the AA genotype. The survival probability of rs10818488 genotypes and all-
cause mortality is presented in Figure 1a. No significant difference in all-cause mortality 
was found across the genotypes (HR = 1.06, 95% CI = 0.76 to 1.46, P = 0.752). The major 
cause of death in RA patients was attributed to CVD (37.7%). This was most frequently 
caused by acute MI and the second most frequent cause of CVD-related mortality was 
heart failure. Besides CVD, two other major causes of death in RA patients were cancer 
(28.6%; n = 22), most frequently of the bronchus and lungs, and infection (9.1%; n = 7).
The 29 patients who died due to CVD had the following genotypes for rs10818488: 31% 
GG homozygotes, 52% AG heterozygotes and 17% AA homozygotes. Survival probability 
of CVD-related mortality is presented in Figure 1b. Also, here no significant difference 
was found between the three genotypes (HR = 0.91, 95% CI = 0.53-1.54, P = 0.713; Table 
3). 
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Table 1. Baseline characteristics of the RA patients per genotype of rs10818488
GG AG AA
n = 180 (29%) n = 324 (53%) n = 111 (18%)
Age (years)  56.2 ± 15.2  56.3 ± 15.5  57.3 ± 16.5
Females, n (%)  132 (73.3)  218 (67.3)  71 (64.0)
Past or current smoker, n (%)  83 (51.2)  139 (48.1)  53 (54.1)
Swollen joint count  9.0 ± 6.6  9.4 ± 7.3  8.0 ± 6.0
BMI (kg/m2)  25.5 ± 3.7  25.7 ± 3.8  25.7 ± 4.0
RF positive, n (%)  101 (57.1)  181 (57.3)  70 (63.6)
Anti-CCP positive, n (%)  75 (56.4)  146 (57.5)  46 (51.7)
CRP (mg/L)  28.1 ± 29.0  31.6 ± 36.1  25.8 ± 30.1
HAQ (0-3)  1.05 ± 0.70  1.10 ± 0.72  1.03 ± 0.77
Total Sharp- van der Heijde score, median (IQR 
25-75)
 6 (2-13)  6 (2-12)  5 (1.5-11)
Except if stated otherwise values are mean (standard deviation).
#Data not available for all cases (smoking status n = 66, swollen joint count n = 111, BMI n = 156, 
rheumatoid factor in n = 12, anti CCP n = 139, CRP n = 46, HAQ n = 113, Total Sharp- van der Heijde 
score n = 27).
BMI, body mass index; CCP, cyclic citrullinated peptide; CRP, C-reactive protein; IQR, interquartile 
range; HAQ, Health Assessment Questionnaire; RA, rheumatoid arthritis; RF, rheumatoid factor.
Table 2. Baseline characteristics of the non-RA patients per genotype of rs2416808
AA AG GG
n = 1783 (32%) n = 2725 (48%) n = 1123 (20%)
Age (years)  75.24 (3.35)  75.39 (3.31)  75.35 (3.45)
Females, n (%)  898 (50)  1427 (52)  582 (52)
Current smoker, n (%)  459 (26)  738 (27)  311 (28)
BMI (kg/m2)  26.85 (4.13)  26.85 (4.19)  26.76 (4.28)
Systolic blood pressure (mmHg)  154.36 (21.18)  154.78 (22.23)  154.89 (21.59)
Diastolic blood pressure (mmHg)  83.65 (11.34)  83.97 (11.45)  83.50 (11.67)
CRP (mg/L)  5.67 (8.65)  5.97 (11.58)  6.13 (13.32)
Total cholesterol (mmol/L)  5.68 (0.90)  5.66 (0.90)  5.74 (0.92)
History of diabetes, n (%)  203 (11)  281 (10)  113 (10)
History of hypertension, n (%)  1093 (61)  1721 (63)  678 (60)
History of myocardial infarction, n (%)  239 (13)  375 (14)  146 (13)
History of stroke or TIA, n (%)  174 (10)  321 (12)  137 (12)*
History of vascular disease, n (%)  770 (43)  1220 (45)  502 (45)
History of angina, n (%)  484 (27)  740 (27)  290 (26)
History of claudication, n (%)  124 (7)  180 (7)  75 (7)
Except if stated otherwise values are mean (standard deviation).
* History of TIA: P value 0.027.
BMI, body mass index; CRP, C-reactive protein; RA, rheumatoid arthritis; TIA, transient ischemic 
attack.
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Multivariate cox regression analyses were performed to assess whether the TRAF1/C5 
susceptible genotype was associated with mortality after adjustments for other known 
risk factors for mortality. Also after adjustments, no significant association between 
rs10818488 genotype and all-cause (HR = 0.91, 95% CI = 0.61 to 1.37), cardiovascular 
(HR = 0.97, 95% CI = 0.54 to 1.76), cancer (HR = 0.66, 95% CI = 0.28 to 1.56) or infectious-
related mortality (HR = 0.54, 95% CI = 0.09 to 3.13) was observed. 
Figure 1.  Survival curves for all-cause and cardiovascular mortality in RA patients per genotype 
of rs10818488. 
Legend figure 1. The log rank tests showed P values for all-cause mortality and cardiovascular 
mortality of 0.69 and 0.93, respectively. (a) All-cause mortality. (b) Cardiovascular mortality. Blue 
line: GG n = 180. Red line: AG n = 324. Green line: AA n = 111.
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Mortality in non-RA cohort
In the non-RA cohort, 586 participants died, 32% were AA homozygote, 48% AG 
heterozygote and 20% GG homozygote for rs2416808. Also, no significant association was 
found between the TRAF1/C5 variants and allcause mortality (HR = 0.99, 95% CI = 0.89 
to 1.11), CVD-related (HR = 0.95, 95% CI = 0.80 to 1.12) and cancer-related mortality (HR 
= 1.00, 95% CI = 0.82 to 1.21; Table 3). Analyzing only the placebo-treated group did not 
change the results (data not shown). Similarly, also in the non-RA cohort after adjustments, 
no significant association was found between rs2416808 and allcause (HR = 0.99, 95% 
CI = 0.88 to 1.11), cardiovascular (HR = 0.94, 95% CI = 0.80 to 1.11) or cancer-related 
mortalities (HR = 1.00, 95% CI = 0.82 to 1.22) in a multivariate cox regression analysis.
Table 3. Hazard ratios for genotypes rs10818488 and rs2416808 in the RA-cohort and Non-RA 
cohort in univariate cox regression analysis
Hazard ratios RA cohort
Trend  AA vs GG
Mortality  HR(95% CI)  P value HR  (95% CI)  P value
All-cause  1.06 (0.76-1.46)  0.752  1.08 (0.54-2.15)  0.830
CVD  0.91 (0.53-1.54)  0.713  0.81 (0.27-2.43)  0.712
Cancer  0.90 (0.49-1.67)  0.741  0.73 (0.18-2.92)  0.657
Infectious  1.19 (0.41-3.51)  0.748  1.42 (0.09-22.7)  0.803
Hazards ratios non-RA cohort
Trend  GG vs AA
Mortality  HR (95% CI)  P value  HR (95% CI)  P value
All-cause  0.99 (0.89-1.11)  0.890  0.99 (0.79-1.25)  0.924
CVD  0.95 (0.80-1.12)  0.512  0.89 (0.64-1.25)  0.515
Cancer  1.00 (0.82-1.21)  0.980  1.02 (0.70-1.50)  0.919
CI, confidence interval; HR, hazard ratio; CVD, cardiovascular disease; RA, rheumatoid arthritis.
DISCUSSION
The present study was performed to investigate the relation between a well-replicated 
genetic RA susceptibility factor, TRAF1/C5, and the mortality risk in a cohort of RA 
patients. No evidence for an association of this risk factor with mortality was observed. 
Panoulas and colleagues recently observed an increased mortality risk for carriers of the 
TRAF1/C5 susceptibility risk genotype in RA patients.10 Both polymorphisms analyzed in 
the present study, rs10818488 and rs2416808, are in complete linkage-disequilibrium 
with the rs3761847 SNP genotyped by Panoulas and colleagues (r2>0.99 data from 
Hapmap, and Kurreeman and colleagues).5,6 However, we could not replicate their 
finding, despite having a larger cohort (615 vs 400 RA patients), a longer follow-up 
duration (mean 7.6 vs 2.6 years) and a higher number of events (77 vs 23 deaths). In 
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addition, Panoulas and colleagues reported an increased risk of death due to cancer and 
sepsis, but not CVD. It is possible that the cohort design from Panoulas and colleagues 
was less suitable to study association with CVD-related mortality, because patients were 
enrolled at an advanced disease stage. In this setting, a possible relation between TRAF1/
C5 and cardiovascular mortality may be missed, because patients dying of CVD earlier 
in the disease course are not part of their cohort. This hypothesis was corroborated by 
our results in the RA cohort, which showed that most of the CVD-related deaths were 
concentrated in the first 10 years of disease. However, also in our EAC, no association 
was found between TRAF1/C5 locus and cardiovascular mortality in RA.
In order to further unravel the eventual association between TRAF1/C5 locus and 
mortality, we hypothesized that this risk would not be restricted to RA. Therefore, we 
also genotyped TRAF1/C5 in a large cohort of elderly people that were prospectively 
followed in PROSPER. This large cohort was well-powered to detect also small HR (e.g. 
1.5). Nonetheless, TRAF1/C5 did not confer an increased mortality risk. This strengthened 
our findings of an absent association between TRAF1/C5 and risk of death. 
In the end, one might argue that any cohort that enrolls older participants is inappropriate 
to study mortality, because the risk genotype may cause an early death. In this sense, 
prospective studies that follow the participants over a period of decades may be more 
suitable to answer this question. Nevertheless, the rs10818488 genotype frequencies in 
our JIA cohort (GG = 30%, AG = 53%, AA = 17%), which has a mean age of 6.4 years at 
inclusion, did not differ from the frequencies in the adult EAC cohort.8 Also the minor 
allele frequency in the non-RA cohort is similar to those in the general population.20 
In addition, both cohorts were in agreement with Hardy-Weinberg equilibrium. This 
indicates that there was no selection of the protective genotype in the RA or non-RA 
cohort. This makes an early death in the risk genotype carriers unlikely and further 
supports the lack of association of these TRAF1/ C5 variants with mortality. 
In the RA-cohort, mortality due to infections were relatively infrequent, the number 
of deaths attributed to infections is insufficient to make definite conclusions on the 
association between TRAF1/C5 and this specific cause of mortality.
The important causes of death observed in RA patients in the present study are similar 
to the main causes of death in the general Dutch population.18 The frequency of CVD-
related mortality itself is reported to be higher in RA patients than in healthy individuals.1 
Results from the Nurses Health Study revealed that women with RA had a relative risk 
of 1.8 for fatal MI.21 Unfortunately, we were unable to test whether the frequency of 
cardiovascular death was also increased in our EAC RA cohort, because we do not have 
mortality information on an age- and gender-matched Dutch control population. 
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In conclusion, TRAF1/C5 polymorphisms predisposing to RA susceptibility are not 
associated with all-cause mortality or cardiovascular- or cancer-related mortality in RA 
and in an elderly cohort of persons without RA. 
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CHAPTER 11
Rheumatoid factor and anti-citrullinated 
protein antibody positivity, but not level, 
are associated with increased mortality in 
patients with rheumatoid arthritis: results 
from two large independent cohorts
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This study aimed to investigate rheumatoid factor (RF) and anti-citrullinated protein 
antibody (ACPA) status and levels as predictors of mortality in two large cohorts of 
patients with early inflammatory arthritis (EIA).
Methods
Data from the Norfolk Arthritis Register (NOAR) and Leiden Early Arthritis Clinic (EAC) 
cohorts were used. At baseline, patients had demographic data and smoking status 
recorded; RF, ACPA and inflammatory markers were measured in the local laboratories. 
Patients were flagged with national death registers until death or censor date. Antibody 
status was stratified as negative, low or high positive by RF and ACPA levels individually. 
In addition, patients were grouped as seronegative, RF positive, ACPA positive or double 
antibody (RF and ACPA) positive. Cox regression models explored associations between 
antibody status and mortality adjusting for age, sex, smoking status, inflammatory 
markers and year of enrolment.
Results
A total of 4962 patients were included, 64% were female. Median age at onset was 56 
(NOAR) and 54 (EAC) years. In NOAR and EAC respectively, 35% and 42% of patients were 
ACPA/RF positive. When antibody status was stratified as negative, low or high positive, 
there were no consistent findings between the two cohorts. Double antibody positivity 
was associated with excess mortality in both cohorts compared to seronegative patients: 
NOAR and EAC respective adjusted HR (95% confidence interval) 1.35 (1.09 to 1.68) and 
1.58 (1.16 to 2.15).
Conclusions
Patients with EIA who are seropositive for both RF and ACPA have increased mortality 
compared to those who are single positive or seronegative. Antibody level in seropositive 
patients was not consistently associated with excess mortality.
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In patients with inflammatory arthritis, the autoantibodies rheumatoid factor (RF) and 
anti-citrullinated protein antibody (ACPA) have been associated with poor outcomes, 
such as increased disease activity, radiographic progression and disability.1-5 However, the 
utility of antibody level in predicting the prognosis of inflammatory arthritis, in particular 
rheumatoid arthritis (RA), has not been clearly established. In a recent multicenter 
prospective study of patients with early inflammatory arthritis (EIA), the presence of RF 
and/or ACPA was a significant predictor of RA diagnosis within two years, but level did 
not appear to be important.6 In contrast, in a study of patients with EIA from Norway in 
2010, Mjaavatten et al. found that increasing levels of RF and ACPA were associated with 
persistent joint inflammation.7 Other studies have failed to show consistently that either 
RF or ACPA antibody level is important in predicting poor outcome in patients with EIA 
and RA [8-10]. In addition, recent data from a subset of the Leiden Early Arthritis Clinic 
have shown that the avidity of ACPA may be prognostically more important than the 
level itself .11
Nevertheless, antibody level is included in the 2010 American College of Rheumatology 
(ACR)/European League Against Rheumatism (EULAR) classification criteria for RA,12 
which aim to identify those patients with EIA with poor prognosis sufficient to require 
intervention with disease modifying therapy. The presence of RF and ACPA are weighted 
as part of the total score according to their level; patients are said to be low positive if 
their level is greater than the upper limit of normal (ULN) but less than three times the 
ULN, and high positive if their level is at least three times the ULN. Thus, patients with 
high antibody levels are more likely to fulfil the criteria, and it would be interesting to 
investigate whether these cut-offs are appropriate in predicting other adverse outcomes, 
such as mortality. 
The increased mortality in patients with RA has been long established.13 It is also well 
recognised that the presence of RF in sera of patients with inflammatory arthritis 
(whether or not they meet formal classification criteria for RA) is associated with an 
increased risk of premature death.14-16 In fact, this association has been demonstrated 
even in subjects without symptoms of arthritis.17 ACPA positivity has also been shown to 
predict premature mortality in the Norfolk Arthritis Register18; however this association 
has yet to be confirmed in other cohorts. 
The aims of this study were to investigate the association between mortality and RF 
and/or ACPA positivity and level in patients with EIA. The term EIA includes all patients 
with RA early in the disease process, and studying these patients allows additional 
inclusion of those patients who may later go on to meet formal classification criteria 
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for RA. It has been recognised that significant variability in antibody testing can occur 
between laboratories.19 Thus, to strengthen the external validity of the study results, we 
investigated these questions in two large prospective cohorts of patients with EIA: the 




Patients in Norfolk, UK, were recruited to NOAR between 1990 and 2009 from primary 
and secondary care if they were adults (≥16 years) and had ≥2 swollen joints for ≥4 
weeks; NOAR has been described in detail elsewhere. 20 Leiden EAC has also been 
described previously21; briefly patients in the region of Leiden, the Netherlands, with 
synovitis confirmed by a rheumatologist were recruited to the Leiden EAC from 1993 
onwards if their symptom duration was less than two years at presentation. In order to 
make the two cohorts as comparable as possible, patients in NOAR were only included in 
this study if they had symptom duration of less than two years at presentation.
Assessment and follow up
Patients in NOAR are assessed at baseline by a research nurse who administers a 
structured questionnaire, including demographic details as well as disease and smoking 
history (never, past, current), performs a 51 tender and swollen joint count and obtains a 
blood sample. Sera are stored frozen and tested for C-reactive protein (CRP) and RF (latex 
test, low positive cut-off 40 units/ml, high positive cut-off 120 units/ml); subsequently 
ACPA, as defined by anti-CCP2 antibodies, are tested for using the Axis- Shield, Dundee, 
UK Diastat Anti-CCP kit (low positive cutoff 5 units/ml, high positive cut-off 15 units/ml). 
The Leiden EAC initial assessment includes medical history, clinical examination and joint 
counts. Blood samples are taken and tested for erythrocyte sedimentation rate (ESR), RF 
(IgM-RF in-house ELISA, low positive cut-off 5 units/ ml, high positive cut-off 15 unit/ml) 
and ACPA (AntiCCP-2, Euro-Diagnostica, Malmo, Sweden ImmunoscanRA Mark 2, low 
positive cut-off 25 units/ml, high positive cut-off 75 units/ml). All cut-offs used are those 
recommended by the relevant manufacturers. Patients in NOAR are flagged with the NHS 
Information Centre (NHS IC) from baseline. NHS IC provide copies of death certificates 
to NOAR with approximately six months lag in reporting. They also provide a date of 
‘embarkation’ for patients who leave the UK. Mortality data on patients recruited to the 
EAC are tracked nationally using the civic registries (Gemeentelijke Basis Administratie) 
in the Netherlands. NOAR is approved by Norfolk and Norwich University Hospital 
Local Research Ethics Committee UK, and EAC was approved by the local medical ethics 
committee LUMC The Netherlands.
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Antibody levels were divided into negative, low positive and high positive as defined by 
the 2010 classification criteria.12 These cut-offs were selected to investigate the ability of 
this aspect of the criteria to predict mortality. NOAR patients were censored for analysis 
at date of death, date of embarkation or 30 June 2012, whichever came first. Leiden 
EAC patients were censored at date of death or 1 May 2012. Analyses were conducted 
separately in each cohort. Kaplan-Meier survival curves were used to compare survival 
univariately in patients grouped according to their antibody status. Cox proportional 
hazard models were used to investigate the association between antibody status, antibody 
level and subsequent mortality. A number of different models were developed. Firstly, 
patients were categorised according to antibody status as negative, low positive or high 
positive, and two models were then developed considering RF and ACPA status separately. 
A third model investigated whether the presence (above the ULN) of both antibodies, 
rather than antibody level, was important in predicting mortality by categorising patients 
as seronegative, RF single antibody positive, ACPA single antibody positive and double 
antibody positive (that is, both RF and ACPA positive). Univariate models were constructed 
initially, then age and sex adjusted; finally a multivariate model was developed adjusting 
for age, gender, baseline smoking status (categorized as current, ever or never smokers), 
inflammatory marker (ESR in EAC or CRP in NOAR) level, and year of enrolment to the 
cohort as a proxy for changing treatment strategies over time. All analyses were repeated 
in the population of patients fulfilling the 2010 ACR/EULAR criteria for RA. We aimed to 
focus on the predictive properties of the antibodies specifically and were deliberately 
parsimonious with our variable selection in the multivariate model. Thus, if a variable 
was not considered a confounder a priori, that is, would not have associations with both 
antibody status and mortality, it was not included. Similarly, variables that might be on the 
causal pathway between antibody status and mortality (such as disease activity over time) 
were also not included, as the relationship between antibody status and disease activity 
can only occur in one direction. 
In the model in which the presence of both antibodies was compared to single antibody 
positivity and seronegativity, only patients who had been tested for both antibodies 
were included. In NOAR, 2,195 (72%) patients had data on both antibodies; data were 
more complete for the EAC, where 1,663 (87%) had both antibodies measured. In NOAR, 
therefore, baseline characteristics of patients with and without complete antibody data 
were assessed for differences. In addition, in order to ensure that the reported results 
were representative, multiple imputation using chained equations was performed to 
impute the antibody status of those patients with missing data. A subsequent sensitivity 
analysis was performed using the imputed dataset and these results were compared 
with those from the complete case analysis. Data from NOAR were analysed using the 
Stata 11 software package (Stata, College Station, TX, USA), data from EAC were analysed 
using SPSS for Windows version 20.0 (SPSS, Chicago, IL, USA).
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Table 1. Demographic and baseline disease characteristics
Demographic/characteristic  NOAR  Leiden EAC
number = 3,053 number = 1,909
Female number (%)  1970 (65)  1205 (63)
Age at symptom onset (years) median (IQR) 56 (44 to 68)  54 (42 to 67)
Symptom duration (weeks) median (IQR) 26 (14 to 47)  17 (8 to 33)
RF/ACPA positive number (%)  1079 (35)  810 (42)
RF positive  912 (34)  704 (37)
RF low positive  315 (12)  256 (13)
RF high positive  594 (22)  445 (23)
ACPA positive  598 (27)  591 (31)
ACPA low positive  91 (4)  66 (3.5)
ACPA high positive  507 (23)  532 (27.9)
Inflammatory marker (CRP, mg/L) 9 (2 to 20)  -
Inflammatory marker (ESR, mm/hr) -  25 (11 to 44)
Smoking status
Never  998 (33)  740 (45)
Previous  1189 (39)  445 (27)
Current  748 (26)  450 (28)
2010 ACR/EULAR RA criteria positive number (%) 1701 (63)  1073 (57)
1987 ACR RA criteria positive number (%) 1303 (43)  736 (39)
Categorical variables are presented as number (% non-missing data). % percentage missing 
values for NOAR and Leiden EAC, respectively, were as follows; RF/ACPA10% and 0.5%, RF 11 % 
and 1%, ACPA 27% and 12%, CRP 18%, ESR 1%, smoking status 4% and 14%, 2010 RA 11% and 
1%, 1987 RA 0.5% and 0%. ACPA, anti-citrullinated protein antibodies; ACR, American College of 
Rheumatology; CRP, C-reactive protein; EAC, Early Arthritis Clinic; ESR, erythrocyte sedimentation 
rate; EULAR European League Against Rheumatism; IQR, inter-quartile range; NOAR, Norfolk 
Arthritis Register; RF, rheumatoid factor; RA, rheumatoid arthritis. The italicised words describe 
how each characteristic is being presented numerically rather than the name of the characteristic 
itself, and are therefore italicised for clarity to make that distinction.
RESULTS
A total of 4,962 patients with EIA were included in the study (3,053 from NOAR, 1,909 
from Leiden EAC). The cohorts had similar age and gender distributions, 65% (1,970) 
female in NOAR, 63% (1,205) female in the EAC, respective median (interquartile range) 
age at symptom onset 56 (44 to 68) and age at inclusion 54 (42 to 67) years. In NOAR, 
63% of patients fulfilled the 2010 ACR/EULAR classification criteria for RA, in the EAC 
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this proportion was 57% of patients. Baseline characteristics of patients from the two 
cohorts are shown in Table 1. The mean (standard deviation) follow up in each study 
was 11.8 (5.8) years in NOAR and 8.5 (5.2) years in EAC. There were 787 deaths during 
36,109 person years follow up in NOAR, and 275 deaths during 16,187 person years 
follow up in the EAC; this resulted in crude death rates of 21.8 and 17.0 deaths per 1,000 
person years in each cohort, respectively. The number of deaths in each of the antibody 
subgroups are shown in Table 2.
Table 2. Number of deaths in each antibody group
Antibody group NOAR Leiden EAC
RF/ACPA negative 401 28
RF/ACPA low positive 39 40
RF/ACPA high positive 264 106
RF negative 444 137
RF low positive 52 54
RF high positive 202 82
ACPA negative 394 154
ACPA low positive 21 17
ACPA high positive 156 86
Both antibodies negative 339 119
RF positivea 47 35
ACPA positivea 51 9
Both antibodies positive 128 93
aWhere patients had both antibodies tested. ACPA, anti-citrullinated peptide antibodies; EAC, 
Early Arthritis Clinic; NOAR, Norfolk Arthritis Register; RF, rheumatoid factor.
Antibody levels
The first Cox proportional hazards models (univariate and adjusted) examined RF and 
ACPA levels separately (Table 3). There appeared to be a marked difference in RF high 
and low positivity in the NOAR cohort: low positive RF adjusted hazard ratio (HR) (95% 
confidence interval (CI)) 0.80 (0.59 to 1.08), high positive RF adjusted HR (95% CI) 1.49 
(1.25 to 1.77). However, this was not replicated in the EAC cohort: low positive RF 
adjusted HR (95% CI) 1.62 (1.16 to 2.26), high positive RF adjusted HR (95% CI) 1.63 
(1.19 to 2.24). Differences between the two cohorts were also seen with ACPA (Table 3). 
In the EAC, low positive ACPA status was associated with increased mortality, but high 
positive ACPA was not, respective adjusted HR (95% CI) 2.21 (1.31 to 3.72) and 1.25 (0.93 
to 1.69). Conversely, in NOAR there was a trend towards increased mortality in the low 
positive ACPA group, and high positive ACPA status was significantly associated, adjusted 
HR (95% CI) 1.32 (1.08 to 1.61). Of note, there were only a small number of patients and, 
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therefore, deaths in the ACPA low positive group in either cohort: 21 deaths in NOAR and 
17 in the EAC. Similar findings were observed in the population of patients fulfilling the 
2010 ACR/EULAR criteria for RA, although not always reaching statistical significance, 
probably due to smaller group sizes. Data on the full multivariate models are available as 
part of Additional file 1. The Additional file 1 also includes a model comparing patients 
negative for both antibodies to those with low and high levels of either antibody and 
models dividing RF and ACPA levels into tertiles rather than using the predefined cut-
offs of the 2010 criteria. These additional models demonstrated similar results to those 
reported here.
Number of antibodies
This Cox model stratified patients by the number of antibodies present (negative, RF 
positive, ACPA positive, and double antibody positive if both RF and ACPA were positive). 
The results were more consistent between the two cohorts (Table 4 and Figure 1) and 
between the total EIA population and the 2010 ACR/EULAR RA population. In both NOAR 
and the EAC there was a trend towards increased mortality in patients who had a single 
positive antibody compared to no positive antibodies, other than single ACPA positivity 
in the Leiden EAC, where the number of deaths was small. In both cohorts the presence 
of two positive antibodies was significantly associated with increased mortality, adjusted 
HRs (95% CI) NOAR: 1.35 (1.09 to 1.68), EAC: 1.57 (1.15 to 2.14). No differences were 
identified in the baseline characteristics of patients with missing data in NOAR for this 
model, and the sensitivity analysis using imputed data produced similar results to the 
complete case analysis [see Additional file 1].
Figure 1. Unadjusted survival curves stratified by number of antibodies.
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Table 3. Comparison of patients RF or ACPA negative to those with low and high RF or ACPA levels 
NOAR
NOAR  Leiden EAC
Total EIA 
population
 2010 ACR/EULAR 
positive cohort
 Total EIA 
population
 2010 ACR/EULAR 
positive cohort
Model/predictor  HR  95% CI  HR  95% CI  HR  95% CI  HR  95% CI
RF:
Unadjusteda
RF low positive  0.90  0.68 to 1.20  0.90  0.66 to 1.24  2.13  1.55 to 2.91  1.75  1.21 to 2.54
RF high positive  1.67  1.41 to 1.97  1.43  1.18 to 1.74  1.75  1.33 to 2.31  1.39  0.99 to 1.93
Age and sex 
adjusteda
RF low positive  0.81  0.61 to 1.08  0.80  0.58 to 1.10  1.67  1.21 to 2.29  1.67  1.15 to 2.42
RF high positive  1.54  1.30 to 1.82  1.33  1.09 to 1.62  1.92  1.46 to 2.53  2.00  1.42 to 2.81
Multivariateab
RF low positive  0.80  0.59 to 1.08  0.85  0.61 to 1.18  1.62  1.16 to 2.26  1.57  1.07 to 2.32
RF high positive  1.49  1.25 to 1.77  1.40  1.14 to 1.71  1.63  1.19 to 2.24  1.68  1.16 to 2.44
ACPA:
Unadjustedc
ACPA low positive  1.05  0.68 to 1.63  0.98  0.61 to 1.59  1.65  1.00 to 2.72  0.97  0.54 to 1.73
ACPA high positive  1.49  1.24 to 1.79  1.27  1.03 to 1.57  1.17  0.90 to 1.52  0.79  0.58 to 1.06
Age and sex 
adjustedc
ACPA low positive  1.16  0.75 to 1.81  1.19  0.73 to 1.93  2.52  1.52 to 4.18  1.99  1.10 to 3.61
ACPA high positive  1.41  1.17 to 1.69  1.29  1.04 to 1.59  1.45  1.11 to 1.90  1.37  1.00 to 1.89
Multivariatecb
ACPA low positive  1.39  0.89 to 2.16  1.44  0.89 to 2.36  2.21  1.31 to 3.72  1.78  0.96 to 3.28
ACPA high positive  1.32  1.08 to 1.61  1.24  0.99 to 1.57  1.25  0.93 to 1.69  1.22  0.86 to 1.73
aRF negative was used as a reference group; badjusted for age at symptom onset, sex, baseline 
smoking status, year of inclusion in cohort and inflammatory marker; cACPA negative was used 
as a reference group. Inflammatory marker = C-reactive protein in NOAR, = erythrocyte sedimen-
tation rate in EAC. ACPA, anti-citrullinated protein antibodies; CI, confidence interval; HR, hazard 
ratio; RF, rheumatoid factor. The bold and italic text indicates subtitles, hence why there are no 
values in the table next to them. It is therefore essential that they look different to the predictor 
variables and the result values themselves. 
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Table 4. RF and ACPA positive versus single positive and both antibodies negative
NOAR  Leiden EAC
Total EIA 
population
 2010 ACR/EULAR 
positive cohort
 Total EIA 
population
 2010 ACR/EULAR 
positive cohort
Model/predictor  HR  95% CI  HR  95% CI  HR  95% CI  HR  95% CI
Unadjusted 
RF positive 1.11  0.83 to 1.49 1.10  0.79 to 1.53  1.88  1.29 to 2.74 1.53  0.99 to 2.36 
ACPA positive 1.27  0.94 to 1.73 1.14  0.82 to 1.59  0.63  0.32 to 1.23 0.31  0.13 to 0.73 
Both antibodies 
positive
1.51  1.23 to 1.85 1.29  1.02 to 1.64  1.59  1.21 to 2.09 1.12  0.80 to 1.57 
Age and sex adjusted 
RF positive 1.05  0.78 to 1.41 1.10  0.79 to 1.54  1.45  0.99 to 2.13 1.54  0.99 to 2.37 
ACPA positive 1.40  1.03 to 1.91 1.42  1.02 to 1.99  0.96  0.48 to 1.90 0.71  0.30 to 1.68 
Both antibodies 
positive
1.38  1.12 to 1.69 1.25  0.99 to 1.59  1.82  1.38 to 2.40 1.83  1.29 to 2.60 
Multivariatea 
RF positive 1.11  0.82 to 1.51 1.22  0.87 to 1.72  1.48  0.99 to 2.21 1.47  0.94 to 2.30 
ACPA positive 1.35  0.98 to 1.88 1.39  0.97 to 1.99  1.05  0.53 to 2.09 0.79  0.33 to 1.89 
Both antibodies 
positive
1.35  1.09 to 1.68 1.31  1.01 to 1.69  1.57  1.15 to 2.14 1.59  1.08 to 2.32 
aAdjusted for age at symptom onset, sex, baseline smoking status, year of inclusion in cohort 
and inflammatory marker; both antibodies negative was used as reference group; inflammatory 
marker=C-reactive protein in NOAR, = erythrocyte sedimentation rate in EAC. ACPA, anti-
citrullinated protein antibodies; CI, confidence interval; HR, hazard ratio; RF, rheumatoid factor. 
The bold and italic text indicates subtitles, hence why there are no values in the table next to 
them. It is therefore essential that they look different to the predictor variables and the result 
values themselves.
DISCUSSION
In two well established observational cohorts of EIA and its sub-population of patients 
with RA, we have shown that RF and ACPA positivity are predictors of excess mortality, 
and that the presence of both antibodies was a stronger predictor of mortality than 
single antibody positivity. However, in this first large study to investigate the association 
between antibody levels and mortality, the influence of increasing antibody level was 
not consistent between the two cohorts. 
Our data have once again demonstrated the known relationship between RF positivity 
and early mortality,14 and confirmed that a similar association exists in patients who 
are ACPA positive. This has previously been described in NOAR18 but only reported 
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elsewhere by two other groups of investigators. The first study was in a subset of 299 
patients in the Rochester epidemiology project,22 half of whom had RA. The second small 
study, by Sihvonen et al.23 used logistic regression (which does not allow for censoring) 
rather than Cox models to analyse the data. It was, therefore, important to corroborate 
this association in another large EIA cohort, such as the Leiden EAC.
The results of our study are concordant with the findings of Ursum et al., who studied 
545 patients with early arthritis in the Netherlands.10 They found no association after 
two years between antibody levels and early disease outcomes, including disease 
activity measured by DAS28, functional status measured by the Health Assessment 
Questionnaire (HAQ) and radiographic progression. Similarly, a number of other 
small studies have reinforced the association between ACPA positivity and other poor 
outcomes, such as increased disease activity and radiographic damage, but have failed 
to identify an association with increasing ACPA levels.8,24 By contrast, Syversen et al. 
conducted a study of 125 patients who met the 1987 ACR classification criteria for 
RA25 in a subpopulation of the European Research on Incapacitating Disease and Social 
Support (EURODISS) project.26 They found that 10 year radiographic progression was 
increased in patients with low-moderate ACPA levels (>ULN and ≤8 times ULN), but this 
appeared to be further increased in patients with very high levels of ACPA (>8 times 
the ULN). However, they also demonstrated that the highest probability of radiographic 
progression occurred in patients who were positive for both RF and ACPA. A recent study 
in Italy examined progression from EIA to RA in 192 patients6. In accordance with our 
findings, they demonstrated the presence of both antibodies predicted RA, but antibody 
high or low positivity had no influence. In the Norwegian Very Early Arthritis Clinic (NOR-
VEAC) study, Mjaavatten et al. showed additive value in testing for both antibodies in 
order to predict disease persistence.7 They also demonstrated an association between 
antibody level and persistent arthritis, however the number of patients per group was 
small (<30). In addition, their analysis employed last observation carried forward to 
account for patients who did not have complete follow up. It is possible, therefore, that 
their results were influenced by attrition bias; that is, patients whose arthritis resolved 
may not have attended further follow up, and at their last recorded visit, their arthritis 
appeared to be persistent even though it subsequently resolved. It is possible that 
the different characteristics and follow up of these cohorts account for the different 
findings; in addition the different cut-offs of the commercially available assays may not 
correspond. Nevertheless, this emphasises that the role of antibody levels in predicting 
outcomes for patients with inflammatory arthritis has not been robustly established.
There are limitations to our study. We decided not to perform a pooled analysis of data 
from both cohorts because the different inclusion criteria of the two cohorts could 
potentially produce misleading conclusions. We did not aim to develop a full predictive 
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model for mortality in RA, but focussed specifically on the association between antibody 
status and level, and mortality. Therefore, the number of confounders included in the 
multivariate model was small, and the final model does not account for all predictors 
of mortality in RA. As in all observational studies, there remains potential for residual 
confounding for which we have not adjusted. Further, in our analyses we did make the 
assumption that antibody status is fixed. This assumption seemed reasonable as the 
majority of studies have shown for both RF and, particularly, ACPA, that few patients 
convert from seropositive to negative over time ,27-29 and when this does occur, risk of 
poor outcome may be maintained.30
CONCLUSIONS
In conclusion, in this large study investigating the relationship between antibody levels 
and mortality in EIA, we have shown that patients with both RF and ACPA, rather than 
the higher levels of the antibodies, had increased rates of early death. We have also 
confirmed the association between ACPA positivity and excess mortality in a second 
large EIA cohort. Therefore, in patients presenting with early rheumatoid arthritis, 
the number of positive antibodies may be more important than the antibody levels in 
assessing the mortality risk in clinical practice. 
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Table S2. Univariate and multivariate Cox proportional hazard models comparing RF and ACPA 
high/low positive vs negative
NOAR
Unadjusted Age & sex adjusted Multivariate*
HR 95% CI HR 95% CI HR 95% CI
RF negative ref ref ref
RF low positive 0.90 0.68-1.20 0.81 0.62-1.06 0.80 0.59-1.07
RF RF high positive 1.67 1.41-1.97 1.54 1.29-1.83 1.49 1.23-1.80
Female gender - - 0.71 0.62-0.83 0.78 0.66-0.92










Inclusion year - - - - 0.96 0.94-0.98
Inflammatory marker - - - - 1,003 1.002-1.005
ACPA negative ref ref ref
ACPA low positive 1.05 0.69-1.60 1.16 0.80-1.68 1.38 0.98-1.97
ACPA ACPA high positive 1.49 1.24-1.79 1.41 1.15-1.72 1.38 1.11-1.71
Female gender - - 0.71 0.60-0.84 0.81 0.67-0.98










Inclusion year - - - - 0.96 0.94-0.98
Inflammatory marker - - - - 1,003 1.001-1.005
HR, hazard ratio; CI, confidence interval; RF, rheumatoid factor; ACPA, anti-citrullinated peptide 
antibodies; inflammatory marker = C-reactive protein in NOAR, = erythrocyte sedimentation rate 
in EAC
*adjusted for age at symptom onset, sex, baseline smoking status, year of inclusion in cohort & 
inflammatory marker 
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Unadjusted Age & sex adjusted Multivariate*
HR 95% CI HR 95% CI HR 95% CI
ref ref ref
2.13 1.55-2.91 1.67 1.21-2.29 1.62 1.16-2.26
1.75 1.33-2.31 1.92 1.46-2.53 1.63 1.19-2.24
- - 0.75 0.59-0.95 0.73 0.56-0.97
- - 1.10 1.09-1.11 1.11 1.09-1.12






- - - - 0.95 0.92-0.99
- - - - 1,006 1.001-1.010
ref ref ref
1.65 1.00-2.72 2.52 1.52-4.18 2.21 1.31-3.72
1.17 0.90-1.52 1.45 1.11-1.90 1.25 0.93-1.69
- - 0.71 0.55-0.91 0.73 0.55-0.97
- - 1.10 1.09-1.11 1.10 1.09-1.12






- - - - 0.97 0.93-1.01
- - - - 1,006 1.001-1.011
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Table S5 Sensitivity analysis with imputed data
NOAR
Multivariate*
HR 95% CI FMI
Both antibodies negative ref - -
RF positive 1.12 0.83-1.52 0.153
ACPA positive 1.31 0.95-1.83 0.198
Both antibodies positive 1.38 1.13-1.68 0.101
Female gender 0.76 0.65-0.90 0.002













Inclusion year 0.96 0.94-0.98 0.002
Inflammatory marker 1,003 1.002-1.005 0.004
HR, hazard ratio; CI, confidence interval; FMI, fraction of missing information; 
inflammatory marker = C-reactive protein in NOAR
*adjusted for age at symptom onset, sex, baseline smoking status, year of inclusion in cohort & 
inflammatory marker
Abbreviations
ACPA: anti-citrullinated protein antibody; ACR: American College of Rheumatology; 
DAS28: Disease Activity Score based on 28 joint count; CRP: C-reactive protein; EAC: 
Leiden Early Arthritis Clinic; EIA: early inflammatory arthritis; ELISA: enzyme-linked 
immunosorbent assay; ESR: erythrocyte sedimentation rate; EULAR: European League 
Against Rheumatism; EURODISS: European Research on Incapacitating Disease and 
Social Support; HR: hazards ratio; NHS-IC: NHS Information Centre; IQR: interquartile 
range; NOAR: Norfolk Arthritis Register; RA: rheumatoid arthritis; RF: rheumatoid factor; 
ULN: upper limit of normal; 95% CI: 95% confidence interval.
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Improved treatment strategies reduce 
the increased mortality risk in early 
RA patients
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A higher mortality rate in patients with RA than in the general population has been 
reported in most series. Treatment strategies for RA have improved dramatically over the 
last decades, resulting in less inflammation and joint damage. We investigated whether 
this change in treatment corresponds to reversal of excess mortality by studying a large 
inception cohort of early RA patients exposed to different treatment strategies.
Methods
Six hundred and eighty-four RA patients included in the Leiden Early Arthritis Clinic 
between 1993 and 2008 were studied. Treatment was different for three inclusion 
periods. From 1993 to 1995 patients were treated with NSAIDs and only late in their 
disease with DMARDs. From 1996 to 1998 patients were promptly treated with HCQ 
or SSZ. From 1999 to 2008 patients were immediately treated with MTX monotherapy 
or in combination with other disease-modifying drugs. Life/death status was tracked 
nationally using the civic registries. Mortality rates were compared with the general 
Dutch population.
Results
In Periods 1 and 2, increased standardized mortality rates were found, 1.35 (95% CI 
0.94, 1.93) and 1.23 (95% CI 0.91, 1.67), respectively, while a decreased standardized 
mortality rate was found for patients included in 1999–2006 [0.49 (95% CI 0.31, 0.77)]. 
Age of onset [hazard ratio (HR) 1.10 (95% CI 1.07, 1.13)], erosive disease [HR 2.03 (95% 
CI 1.22, 3.37)], high CRP level [HR 1.09 (95% CI 1.01, 1.18)], smoking [HR 2.39 (95% CI 
1.31, 4.38)] and higher baseline HAQ score [HR 1.53 (95% CI 1.06, 2.20)] associated with 
mortality.
Conclusion
Current treatment strategies for early RA, such as that given in inclusion Period 3, might 
contribute to the reversal of excess mortality in RA. 
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RA is a chronic inflammatory disease that is characterized by polyarthritis joint damage, 
disability and decreased work participation.1 A recent review showed that mortality 
rates in RA are 1.5- to 1.6-fold higher than in the general population; this was based on 
84 unique cohorts.2 The attributed causes of death are similar to the general population 
with cardiovascular diseases being the primary cause of death.2,3 Patient or disease 
characteristics that are associated with a severe course of RA were found associated 
with higher risks of death.2
In the past 20 years, treatment strategies for RA have dramatically changed. Prompt 
start of DMARDs, combination therapy and tight control of disease activity are currently 
proved to be essential for beneficial disease outcome.4-6 Treatment strategies composed 
of these three components are more effective in achieving remission and preventing 
joint damage.7 Since the increased mortality risk is associated with other severity 
outcomes such as joint damage and since levels of joint destruction are reduced by the 
improved treatment strategies, we hypothesized that mortality rates benefit from these 
treatment strategies as well. This hypothesis is supported by observational studies on RA 
patients treated with MTX and anti-TNF, which showed improved survival.8-10 However, 
whether nowadays treatment strategies indeed reduce the increased mortality risk is 
thus far unknown.
Therefore, the present study aimed to investigate whether changes in treatment 
strategies are also reflected by changes in mortality rates. For this we took advantage 
of a unique longitudinal cohort of early RA patients that includes patients since 1993 
and in which treatment strategies have changed dramatically over time. From 1993 
till 1995 a wait-and-see policy applied and initial MTX was almost never used. From 
1996 till 1998 treatment with HCQ or SSZ was initiated immediately but initial MTX was 
infrequently prescribed. From 1999 onwards, however, immediate treatment with MTX 
or combination therapy was initiated.
METHODS
Study design
The Leiden Early Arthritis Clinic (EAC) is a clinical inception cohort consisting of patients 
with recent-onset arthritis referred to the Department of Rheumatology of the Leiden 
University Medical Center (LUMC) from 1993 and onwards.11 Patients were included 
when arthritis was observed by a rheumatologist. At the time of analysis, April 2008, 
the EAC consisted of 2079 patients with recent-onset arthritis (no longer than 2 years) 
of any origin. Written informed consent was obtained from all participants. The study 
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was approved by the appropriate local institutional review board (Ethische Commissie 
van het LUMC). For this study we selected the patients who fulfilled, within 1 year 
of follow-up, the ACR 1987 revised criteria for RA (n = 684).12 In order to investigate 
whether treatment influenced the survival of RA patients, patients were divided into 
three separate inclusion periods in which different treatment strategies were applied. 
The first inclusion period concerns 1993–95. The 108 RA patients included in this period 
were treated initially with NSAIDs and subsequently with chloroquine or SSZ if they had 
persistent active disease. The decision to start with, the dosage and the choice of DMARD 
were left to the treating rheumatologist’s discretion. In the second inclusion period, 
1996–98, 174 RA patients were routinely treated with NSAIDs and promptly treated with 
either chloroquine or SSZ.13 In the third period (inclusion between 1999 and 2006), the 
majority of the 402 RA patients were promptly treated with MTX monotherapy and a 
minority with monotherapy of other DMARDs or initial combination therapy (Table 1). 
In all three inclusion periods, an equal number of patients received biological agents 
somewhere during the follow-up period. Moreover, in 2000, treatment adjustments 
based on DASs were introduced.








HCQ 50  29.5  15.2
SSZ 40  61.0  14.5
MTX 5  9.5  70.3
Other 5
Initial combination therapy, %
MTX + SSZ  1.5  2.5 5
MTX + SSZ + HCQ  1.5 6 7
Initial combination therapy with oral 
prednisone
 13.9  19.5  16.2
Delay in treatment initiation, median 
(interquartile range 25–75)
Time between symptom onset and 
inclusion, months
 5.1 (2.6–10.7)  4.2 (2.2–6.9)  4.2 (2.4–8.6)
Time between symptom onset and start 
of DMARD therapy, months
 9.9 (6.3–18.5)  6.1 (3.0–10.8)  6.0* (2.8–10.0)
Time between inclusion in EAC and start 
of DMARD therapy, days
 107 (48.5–227.5)  20 (14–56)  27* (9–60)
None of the patients was initially treated with anti-TNF. During the available follow-up the 
frequency of anti-TNF use was notdifferent between the three groups (2.8, 4.6 and 4.2%, 
respectively). *P<0.0001.
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At inclusion, a physical examination was performed and smoking history was taken. 
Patients filled in a HAQ, modified for use in Dutch patients.14 Radiographs of hands and 
feet were made and scored by experienced readers, using the Sharp–van der Heijde 
method.15 Blood samples were taken to determine ESR, CRP and IgM RF (ELISA) and CCP 
status (ELISA) (Immunoscan RA, MARK 2; Euro-Diagnostica, Arnhem, The Netherlands). 
Anti-CCP positivity had a cut-off level of 25 arbitrary units. 
Notification of death
Patients were followed longitudinally from the moment of their inclusion in the EAC 
cohort until 1 April 2008 or until their death. All patients were tracked nationally using 
the civic registries (Gemeentelijke Basis Administratie, GBA) to ascertain life/death 
status. Mortality data of the general Dutch population were obtained from Statistics 
Netherlands.16
Analysis of data
Differences in characteristics at inclusion were compared with the t-test and one-way 
ANOVA for continuous variables and the chi-square test for nominal variables. Data are 
expressed as mean (S.D.) with a 95% CI, unless otherwise stated. The mortality of RA 
patients is compared with the general population using standardized mortality ratios 
(SMRs). SMR is the ratio between the observed number of deaths of RA patients and the 
expected number of deaths in the general Dutch population adjusted for age, sex and 
inclusion period. Analyses were done stratified by inclusion period and for each inclusion 
year compared with the general Dutch population. Survival curves were calculated using 
Kaplan–Meier survival curves. Expected survival curves of the Dutch population were 
calculated using the methods of Hakulinen.17 This method is based on the concept of an 
expected life table and takes differences in patient withdrawal of subgroups of patients 
with equal relative survival rates into account.
Associations between risk factors for RA severity and survival were studied using 
univariate and multivariate Cox proportional hazards and regression models. All studied 
variables were entered in the multivariate model because the P-value in the univariate 
model can be falsely high or low if there are confounding effects. A number of patients 
had missing values for some of the variables [BMI (n = 253), RF (n = 22), anti-CCP (n = 
168), erosions (n = 197), ESR (n = 28), CRP (n = 59), smoking (n = 79), HAQ (n = 131)], 
which would have resulted in their exclusion from the multivariate model. For these 
patients we used multivariate imputation by chained equations to obtain five imputed 
data sets [18] and the results of the analyses of the five imputed data sets were pooled 
to obtain the correct S.E.s of the estimates.19 Cox regression analyses were done with 
and without the imputed data.
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All statistical analyses were performed by using Statistical Package for Social Sciences 
version 14.0 (SPSS, Chicago, IL, USA), STATA 11 was used to calculate the SMRs and 
expected survival curves and R was used to perform the multiple imputations.20 In all 
tests, P<0.05 was considered to be statistically significant.
RESULTS
Baseline characteristics
In total, 684 RA patients were included between 1 January 1993 and April 2006. Baseline 
characteristics of all RA patients as well as for the patients in the three inclusion periods 
are presented in Table 2. The delay between the first onset of symptoms and assessment 
by the rheumatologist was not significantly different in all three time periods, indicating 
a comparable referral strategy by the general practitioner in all treatment periods. In 
contrast, the patients included in the second and third inclusion periods had less delay 
in initiation of DMARDs after assessment by the rheumatologist compared with patients 
included in the first period.






n = 402  Total
Age, years  56.9 (14.4)  55.5 (17.2)  57.1 (15.3)  56.7 (15.7)
BMI  25.5 (3.1)  25.2 (3.1)  26.0 (4.1)  25.8 (3.8)
RF positive, n (%)  65 (60.2)  92 (52.9)  228 (60.0)  385 (58.2)
Anti-CCP positive, n (%)  65 (60.2)  90 (55.2)  125 (53.4)  286 (55.4)
ESR, first hour, mm  51 (34)  40 (26)  37 (25)*  40 (27)
CRP, mg/l  30 (25)  33 (34)  29 (37)  30 (35)
Past or current smoker, n (%)  51 (53)  75 (47)  180 (52)  306 (51)
HAQ (0–3)  1.03 (0.67)  1.07 (0.74)  1.12 (0.74)  1.1 (0.73)
Unless otherwise stated values are mean (S.D.). Age: age at inclusion in EAC cohort
follow-up: duration between inclusion date in EAC cohort and endpoint 1 April 2008 or death
smoking status: never smoked vs ever smoked (smoking in past and current). Data not available 
for all cases [BMI n = 253), RF (n = 22), ESR (n = 28), CRP (n = 59), smoking status (n = 79), HAQ (n 




During follow-up 90 RA patients died, while 85 deaths were expected within the general 
population. Mean age at death was 75.8 (S.D. 9.6) years. No difference in mortality 
was observed between all included RA patients [SMR 0.95 (95% CI 0.78, 1.17)] and the 
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matched general Dutch population. Male RA patients had an SMR of 0.87 (95% CI 0.63, 
1.21) and female RA patients an SMR of 1.02 (95% CI 0.78, 1.33). Subsequently the SMRs 
for the three inclusion periods were determined (Fig. 1A–C). An increased mortality rate 
was found in Period 1 as well as in Period 2 [SMR 1.35 (95% CI 0.95, 1.93) and SMR 1.23 
(95% CI 0.91, 1.67), respectively]. In contrast, a decrease in mortality rate was found in 
patients included from 1999 until 2006 [SMR 0.49 (95% CI 0.31, 0.77)]. The SMRs in the 
three inclusion periods were statistically significantly different (P = 0.0002), and together 
these data reveal a nullification of the increased mortality risk. The log rank test of the 
three inclusion periods had a P = 0.008. 
Risk factors associated with mortality
In the univariate analysis, all analysed factors were associated with increased risk of 
mortality in our RA population except for BMI, RF, anti-CCP and smoking status (Table 
3). The multivariate analysis revealed that a higher age [hazard ratio (HR) 1.10 (95% CI 
1.07, 1.13)], the presence of erosive disease [HR 2.03 (95% CI 1.22, 3.37)], a higher CRP 
level [HR 1.09 (95% CI 1.01, 1.18)], smoking status [HR 2.39 (95% CI 1.31, 4.38)] as well 
as a higher HAQ-score [HR 1.53 (95% CI 1.06, 2.20)] at baseline were all independently 
associated with increased mortality. In the multivariate analysis, the inclusion period 
remained independently associated with mortality risk [HR 0.84 (95% CI 0.77, 0.92)] over 
time. As a sensitivity analysis, the multivariate analysis was performed with and without 
imputed data, revealing no differences (data not shown).
Table 3. Univariate and multivariate analysis of HRs for mortality in all RA patients.
Univariate model Multivariate model
Variables Hazard Ratio 
(95 % CI)
P-value Hazard ratio 
(95% CI)
P-value
Age, years 1.09 (1.07-1.11) <0.0001 1.10 (1.07-1.13) <0.0001
Gender (male) 1.54 (1.01-2.34) 0.045 0.85 (0.50-1.46) 0.554
BMI 1.00 (0.94-1.07) 0.906 0.96 (0.88-1.05) 0.363
RF (positive) 1.36 (0.89-2.10) 0.234 1.23 (0.65-2.35) 0.522
Anti-CCP (positive) 1.14 (0.75-1.76) 0.527 1.41 (0.75-2.68) 0.289
Erosive disease (positive) 3.41 (2.21-5.26) <0.0001 2.03 (1.22-3.37) 0.006
ESR, mm1sthr 1.011(1.006-1.016) <0.0001 0.990 (0.980-1.001) 0.065
CRP, 10mg/L 1.09 (1.05-1.14) 0.0001 1.09 (1.01-1.18) 0.030
Smoking status 1.50 (0.93-2.41) 0.095 2.39 (1.31-4.38) 0.006
HAQ (0-3) 2.08 (1.57-2.76) <0.0001 1.53 (1.06-2.20) 0.022
Inclusion year 0.91 (0.84-0.98) 0.015 0.84 (0.77-0.92) <0.0001
Age: age at inclusion in EAC cohort. Gender: female versus male, erosive disease:   ≥3 erosions 
scored on X-hands and feet (Sharp- van der Heijde score). smoking status: never smoked versus 
ever smoked (smoking in past and current).  
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Figure 1. (A) Inclusion Period 1: 1993–95; SMR 1.35 (95% CI 0.95, 1.93); P = 0.097; (B) inclusion 
Period 2: 1996–98; SMR 1.23 (95% CI 0.91, 1.67); P = 0.185; (C) inclusion Period 3: 1999–2006; 
SMR 0.49 (95% CI 0.31, 0.77); P = 0.001. 
The general Dutch population (- - -); the RA patients from the EAC cohort (—). x-axis, survival 
probability; y-axis, years.
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The outcome of RA patients has improved over the last decade. This improvement is 
generally expressed by lower rates of joint destruction and higher remission rates. The 
findings of this study suggest that current treatment strategies might have positive 
impact on the survival of RA patients as well. 
The relationship between therapies and mortality rates in patients with RA has been 
studied extensively; however, no consistent effects have been shown.2  Importantly, to 
our knowledge no previous studies have investigated the relationship between different 
treatment strategies and mortality in an early arthritis cohort. In the present study, three 
treatment strategies were applied that differed importantly with regard to readiness to 
initiate DMARD therapy, choice of DMARDs and frequency of combination therapy (Table 
1). The duration between first symptoms and first assessment by the rheumatologist was 
not different between the three periods, indicating that the observed findings were not 
thanks to early referral. 
The present study not only observed reduction in the increased mortality risk in RA but 
also revealed a tendency towards a reduced mortality risk for patients included in the third 
period. At first glance, this reduced mortality rate is surprising. Apart from a higher ESR 
(observed in inclusion Period 1), no other differences in baseline characteristics between 
patients included in the three inclusion periods were found. This makes it unlikely that less 
severe patients were included in the third inclusion period. Another possible explanation 
is the presence of secular trends in mortality by specific adoption of healthier life styles 
by RA patients compared with the general population. As far as physical activities are 
concerned, even now RA patients spend less time on physical activities than the general 
population.21 It is, however, plausible that increased knowledge of modifiable risk factors 
for mortality resulted in better treatment of such risk factor comorbidities and thus 
contributed to the observed improved mortality rate. Another possible hypothesis is 
that patients with a serious, potentially fatal illness who also develop joint complaints 
will not be referred to the rheumatologist and as such contribute to the mortality rate of 
the general population but not of the arthritis population. At present, insufficient data 
are available to explore these potential explanations.
As mentioned before, this study observed a lack of increased mortality in the most 
recent cohort. Unfortunately, this last cohort is too small to allow a subanalysis in 
responders to therapy vs non-responders. So in theory it may be possible that there still 
is an increased mortality in the subgroup of patients who did not respond well. However, 
we are underpowered to make this analysis. 
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In line with the previous studies it was observed that a higher age at disease onset, 
erosive disease, a higher CRP level, smoking status and a higher HAQ-score at baseline 
are risk factors for mortality. Of these, erosive disease and HAQ-score are the two 
significant predictors of mortality (HR 2.03 and 1.53, respectively) in the univariate as 
well as the multivariate analysis. Smoking status was not associated with increased risk 
in the univariate model, though an association was found in the multivariate model. 
Our male patients tend to smoke more often than females and we hypothesize that this 
seemingly unexpected finding is due to the fact that we present HRs after adjustment for 
sex. Increased CRP level has previously been shown to associate with an increased risk 
of cardiovascular disease and cardiovascular mortality in particular. This suggests a link 
between ongoing inflammation and increased risk of cardiovascular events.22,23 Some 
variables like anti-CCP, RF and BMI are considered to be of predictive value for mortality. 
Although the presence of anti-CCP antibodies is associated with a more destructive 
disease course in RA patients, and increased BMI (irrespective of RA) is associated with 
mortality, we did not observe an association between anti-CCP or BMI and mortality in 
this study.24,25
One might be reminded of another Dutch study that reported no increased mortality in 
RA patients.26 This was probably based on their relatively short follow-up time, making 
it an observation too early. This was confirmed by their second research, where they 
observed that excess mortality emerged after 10 years.27
However, a recent study from the states suggested that excess mortality is caused by 
accelerated ageing and that this phenomenon is responsible for the fact that RA patients 
at onset of disease are already effectively>2 years older than the general population,28 
so if this is true one would have expected to observe excess mortality in the last period 
as well.
In conclusion, clinical practice in rheumatology has shown impressive progress with 
regard to treatment of signs and symptoms of RA as well as slowing down the rate of 
joint damage and prevention of functional disability. These current treatment strategies 
are characterized by rapid institution of appropriate treatment schedules, tight control of 
disease activity and combination therapies.7 This study suggests an association between 
better care for patients with early RA and improved survival. As such it underlines 
the importance of early potent treatment strategies in comparison with wait-and-see 
policies.
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PART I:  EARLY RECOGNITION OF ARTHRITIS
In the first part of this thesis we focused on the early recognition of arthritis patients. 
Previous research in the Leiden early arthritis clinic revealed that the median duration 
between onset of symptoms and the first visit to a rheumatologists in early arthritis 
patients was almost 14 weeks and in early RA patients about 18 weeks.1 Keeping in mind 
that nowadays the challenge is to start therapy in RA patients as soon as possible, a 
change in diminishing this delay was preferable. The  ‘local’ cause of this delay could 
mainly be attributed to delay on part of the general practitioner. 
Therefore, a new initiative to tackle this problem was set up as described in chapter 2. 
As it can be difficult for GPs to recognize arthritis of the small hand and feet joints, it is 
understandable that GPs apply a wait-and-see approach.2 In Leiden and Groningen a 
new initiative was launched to offer GPs help with this problem. GPs were encouraged to 
send patients in which they were unsure on the presence of arthritis to the early arthritis 
recognition clinics (EARCs). After 1 year, the results of these clinics were evaluated. We 
observed that in Leiden 42% (168/400) and in Groningen 49% (104/212) of the patients 
were diagnosed with arthritis. The major aim of these clinics was to reduce the so-
called GP delay; this was successful in both EARCs and the observed  median delays 
in the early arthritis patients were  2.0 (0.4–8.4) weeks in Leiden and 2.3 (0.6–9.1) in 
Groningen. More interestingly, the patients with undifferentiated arthritis (UA) or RA 
had a median GP-delay of approximately 2 weeks compared to 9 weeks of UA and RA 
patients that arrived at the outpatient clinic in the same timeframe via regular referrals. 
The aforementioned duration of GP-delay in the EARC and regular referrals was lower 
than the historical GP-delay on RA patients (median 11.8 weeks).1
Even though the duration of the GP-delay was stable over time, between 1993-2006 the 
reduction in GP-delay is potentially not solely a consequence of the initiated EARCs. It 
has to be noted that before these EARCs were initiated, GPs in the surrounding area were 
educated on rheumatic diseases in general and they were introduced to the concept of 
the upcoming EARCs. Thereby, in 2009 renewed guidelines on arthritis was provided 
for Dutch general practitioners.3 Under these new guidelines, GPs are advised to refer 
patients of whom they suspect presence of RA within 4 weeks instead of after 6 weeks 
which was advised in the previous guidelines. Together, these factors may have played 
a role in raising the awareness and knowledge of (rheumatoid) arthritis and the need 
for prompt referral. For this reason, the presence of the EARC itself may not be the only 
cause of the substantial decrease in GP-delay in arthritis patients. Therefore, it would be 
interesting to get to know the motivations of GPs on their referral of patients via regular 





be developed that specifically target referral tactics of GPs. It should be stressed that a 
long GP delay is mainly a problem in the Netherlands. For example, in the UK, studies 
revealed that patient delay was the most important contributor to delayed assessment 
by a rheumatologist.4,5 A recent study across ten centres in Europe revealed that the 
median delay caused by RA patients ranged from 2 till 8 weeks.(6) Although this was 
relatively low in our cohort (median 2 weeks in early arthritis patients) it is fascinating 
to learn the motivations of patients to seek medical help. Motivations of arthralgia 
patients that visited the EARC are described in chapter 3.  In all arthralgia patients the 
median symptom duration before they first visited a GP was 4 weeks. Patients that had 
arthritis sought medical help faster than arthralgia patients without arthritis (2.6 versus 
5.9 weeks). In general, the motivations did not differ between arthritis and non-arthritis 
patients. Though, arthritis patients sought medical help because their symptoms 
occurred suddenly and because they were advised to do so by their friends and family. 
Besides comparing arthritis and non-arthritis patients we made comparisons between 
arthralgia patients that had a short patient delay (<4weeks) and a prolonged patient 
delay (>4 weeks). This revealed that impairments either work-related or in physical 
functioning were major motivations to seek medical help promptly. One of the main 
questions was whether certain symptom characteristics, motivations or variables related 
to the ability to carry out work frequently occurred together. In other words, whether 
there was a clustering of variables in the same arthralgia patients. This was assessed by a 
data reduction method called a partial least square regression analysis (PLS). This indeed 
revealed two clusters. A group of patients was found that was characterised by a short 
patient delay, a sudden onset of symptoms, functional impairment and absenteeism. 
The other group of patients consisted of patients with a prolonged patient delay, a 
gradual onset of symptoms and no absenteeism. It has to be mentioned that these 
arthralgia patients are a selection of patients in which a GP was doubtful on the presence 
of arthritis so they do not represent all arthralgia patients that visit a GP. Besides that, 
musculoskeletal problems are very common in the general population, and a large 
survey (population-based with 3664 respondents) showed that just about half of these 
persons consulted their health professional.7,8 This is consistent with the findings of an 
Austrian initiative called the ‘rheuma-bus’, here as well they discovered that 40% of the 
persons with musculoskeletal problems never contacted a physician. Importantly, only 
14% of all arthralgia patients that visited the EARC were aware that in case an arthritis is 
present it is relevant to act quickly (as in seeking medical help). Even knowing someone 
with RA was not necessarily a trigger for seeking medical advice or for recognition of 
symptoms.9 In combination with the previously observed findings and in combination 
with reports on the lack of knowledge on arthritis and RA in the UK and Canada,10-12 
this calls for a need to raise public awareness. However, in which way this can best be 
achieved remains open for debate. For instance, one might start to investigate if persons 
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are able to self-diagnose an arthritis, future research within the EARC could focus on the 
ability of patients to recognise a true arthritis by comparing the arthritis-manikins filled 
out by the patients as well as the physician on their concordance. Finally, the long-term 
effectiveness of the EARC has to be assessed. 
 
PART II:  A THERAPEUTIC WINDOW OF OPPORTUNITY IN RA
After early recognition by GPs and identification of RA by a rheumatologists the next 
concern is to start promptly with anti-rheumatic treatment. It has been established that 
delay in initiation of treatment after the diagnosis RA has been made has been associated 
with progression of joint damage.13 It has even been suggested that a certain window of 
opportunity for treatment exists in RA. It is thought that in this certain period the disease 
is not fully matured yet and that therapeutic intervention (DMARD-therapy) can alter the 
disease course in such a way that chronicity is prevented. In chapter 4 we investigated 
whether such a period truly exists by performing a systematic literature research. Since 
many studies included symptom duration in their analysis we systematically reviewed 
all such studies to assess whether short symptom duration at treatment initiation was 
associated with less progression of disease. The quality of the studies was assessed by a 
predefined scoring system and best evidence synthesis was applied to determine the level 
of evidence per category. We observed that there was strong evidence for an association 
between short symptom duration and less radiographic damage and moderate evidence 
for an association between symptom duration and other outcomes in RA such as the 
achievement of certain disease states (remission under therapy defined as e.g. DAS-
28<2.6 DAS-28<1.6, ACR remission et cetera). Another important outcome was DMARD-
free sustained remission, which was defined as the sustained absence of synovitis after 
discontinuation of DMARD-therapy for at least one year. Via the qualitative approach we 
observed there was moderate evidence for an association between symptom duration 
and DMARD-free sustained remission. However, we had access to the raw data of these 
three cohorts and were able to perform a meta-analysis. This revealed that symptom 
duration was independently associated with DMARD-free sustained remission also 
when adjusted for age, gender and the more disease specific markers such as RF and 
ESR. One might argue that via this method we could not identify publication bias, since it 
is not possible to draw a funnel plot for a qualitative review. However, symptom duration 
was not the main subject of interest in these studies.  Altogether, even taking patient 
heterogeneity into account, these data convinced us there might be a therapeutic 
window present and that indeed early treatment after diagnosis of RA is justified but, 
we were not able to point out when this window ‘opens’ of ‘closes’. 
In chapter 4, it was investigated whether an association existed between symptom 





association existed between shorter symptom duration and the chance of DMARD-free 
sustained remission. It has to be mentioned that this was achieved by comparing hazard 
ratios from cox-proportional hazard regression models. The applied model assumed a 
linear association between every week increase in symptom duration and the chance of 
DMARD-free sustained remission. This led us to the question regarding the shape of the 
association between symptom duration and DMARD-free sustained remission. 
In chapter 5 we explored the shape of the association of symptom duration with the 
persistence of RA. Until now it is unknown whether this relation is linear, referring to ‘the-
earlier-the-better principle’ or whether a certain time-frame exists in which the disease 
is more susceptible to therapeutic interventions, referring to a ‘window of opportunity’. 
In a linear association it is presumed that the total inflammatory load (product of the 
severity and duration of inflammation) at the time of treatment onset is related to the 
disease outcome. On the other hand, in the literature a ‘window of opportunity’ in RA 
is often mentioned, it has been said to enclose the first twelve weeks after symptom 
onset. In this confined period the disease is presumably more susceptible to therapeutic 
interventions. This cut-off of 12 weeks seems to be based on expert opinion, though 
later on there are data available that support this window of 12 weeks, showing that 
patients with less than 12 weeks of symptom duration have a more beneficial outcome. 
However, it has not been shown that after a certain period of symptom duration the 
effect of treatment diminishes. We took advantage of two large early RA cohorts and 
the main outcome was DMARD-free sustained remission. We observed that over a 
5-year period of follow-up the curves of the log-hazard ratios (chance on DMARD-free 
sustained remission) against symptom duration was non-linear. The log-hazard ratios 
were calculated by using cox-proportional hazards regression models with natural cubic 
splines. The advantage of this approach is that it does not assume linear associations. 
In addition, discrimination was measured by using time-dependent ROC-curves. The 
symptom duration with optimal discriminative ability was 14.9 weeks in the EAC and 19.1 
weeks in ESPOIR. Since the course of disease in ACPA positive and ACPA negative patients 
differs, we hypothesized that processes that underlie the disease might be influenced 
differently. Although achieving DMARD-free sustained remission in ACPA positive 
patients is less frequent than in ACPA negative patients, we observed that the optimal 
discriminative ability in ACPA positive RA was 11.4 weeks and for ACPA-negative RA 15.0 
weeks. The endpoint of DMARD-free sustained remission is not often achieved (5-11%) 
and relies on the opinion of the treating rheumatologist and willingness of the patient in 
question regarding the (dis)continuation of DMARD-therapy. Two additional endpoints 
namely a certain level of radiographic progression and sustained remission irrespective 
of treatment, though less fitting the hypothesis, were investigated. For these outcomes 
the shape of the log-hazard ratios curves wasn’t linear either. This suggests that there 
is a confined period present in RA patients in which it is more beneficial to start with 
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DMARD-therapy.  Summarizing the data, the proposed 12-week window in the literature 
doesn’t seem misplaced. Though based on current data one might say the window is 
confined to the first 5 or 6 months after symptom onset, taking the time until DMARD-
treatment into account. Clearly, it is not possible to draw definitive conclusions on when 
this window ‘opens’ and ‘closes’. For this project we relied on the patient’s memory of 
when the ‘symptoms’ started and the willingness of both patients and rheumatologists 
to discontinue DMARD-therapy. With respect to the start of symptoms; although being 
assessed similarly there is no uniform definition of a ‘symptom’. Despite the fact that 
criteria are proposed for standardised duration,14 the applicability remains to be seen 
since experiencing symptoms will always be an individual matter. With respect to the 
clinical practice the most important message is that indeed a ‘therapeutic window of 
opportunity’ exists in RA. Thus, it is better to start DMARD-treatment immediately in RA 
patients than waiting for example 6 months, even if the disease course appears to be 
mild. For basic translational research the existence of a window strongly suggests that 
there is a change in underlying processes. The questions remains open which processes 
change, when they originate and how these processes can be altered by specific targeted 
therapies. Currently, patients with arthralgia that are susceptible to develop RA are being 
followed longitudinally in the clinically suspected arthralgia cohort (CSA). This cohort can 
give insight in not only the phenotype of arthralgia patients that convert to RA but might 
also focus on changes in specific disease processes which in the long haul can be related 
to reversibility in RA patients. 
PART III: DIAGNOSTIC AND PROGNOSTIC VALUE OF DISEASE  
  SYMPTOMS, CHARACTERISTICS  AND CLASSIFICATION  
  CRITERIA IN ARTHRALGIA, EARLY ARTHRITIS AND RA  
  PATIENTS
The presence of morning stiffness is easily assessed by taking a patient’s history, and it 
is often mentioned to be one of the first symptoms of RA besides fatigue.15 Also, until 
recently it has been an item in the classification criteria for RA, though it was omitted 
from the 2010 ACR-EULAR criteria for RA.16 Data on the discriminative ability of morning 
stiffness between RA and various rheumatologic diseases, however, is scarce and 
information on the diagnostic ability in arthralgia patients and prognostic value in RA 
patients is absent. Therefore, in chapter 6 we evaluated the diagnostic value of morning 
stiffness in arthralgia and early arthritis patients and the prognostic value in early RA 
patients. To this end, we used 1641 arthralgia patients from three cohorts. Two of these, 
the EARCs from Leiden and Groningen were described above.17 The third cohort was the 
Rotterdam Early Arthritis Cohort (REACH).18 Approximately 50% of the arthralgia patients 
that were referred to these cohorts were diagnosed with arthritis at their first visit with 





morning stiffness with a duration of ≥60 minutes in arthralgia patients was associated 
with the presence of arthritis (Leiden EARC OR1.49(95%CI1.001-2.20), Groningen EARC 
OR2.21 (1.33-3.69) and REACH OR1.55(0.97-2.47)). Overall, the sensitivities were low 
(21-38%) and the specificities ranged between 73-85%. Hereafter, we investigated the 
discriminative ability of morning stiffness among early arthritis patients in two cohorts, 
the Leiden EAC and the French ESPOIR cohort.19;20 First, the duration of morning stiffness 
was depicted against the diagnosis of the early arthritis patients after 1 year of follow-up. 
This demonstrated that the median duration in RA patients (classified according to the 
2010 ACR/EULAR criteria) was 60 minutes and longer than that of other early arthritis 
patients (except SLE-patients, n=22). This was an interesting observation because only 
two studies in the literature describe that the discriminative ability of morning stiffness is 
poor, those studies had relatively small sample sizes (93 RA versus 46 non-inflammatory 
joint diseases and 31 RA versus 23 SLE and 34 osteoarthritis patients).21,22 The diagnostic 
ability of morning stiffness  ≥60 minutes in early arthritis was significantly associated 
with the diagnosis of 2010-RA after 1 year, also independent of other predictors (SJC, 
ACPA, RF, symptom duration and ESR). Several factors may play a role in the omission of 
morning stiffness form the newly formed 2010 ACR/EULAR criteria. For instance, patients 
with a diagnosis other than RA or UA were excluded (which makes it more difficult to find 
a difference in patients that are quite alike). Secondly, the endpoint in the criteria was 
methotrexate use after 1 year. Furthermore, in 760 out of 3115 patients information on 
morning stiffness was missing and in the remaining patients, which did have information 
on morning stiffness, it was assessed differently in the various cohorts (present/absent, 
</≥1 hour, or categories on duration). We also looked at the optimal discriminative 
duration of morning stiffness in early arthritis patients for RA. Here we observed that 
in both cohorts the optimal discriminative duration was around 30 minutes of morning 
stiffness. Finally, we investigated whether certain duration of morning stiffness at 
baseline (≥30, ≥60 and ≥90 minutes) had a prognostic value on long-term outcomes in 
RA, such as joint-destruction and DMARD-free sustained remission. We did not observe 
an association between these durations and a worse outcome. This was in contrast with 
a previous result from the QUEST-RA study where an association was observed between 
morning stiffness and a lower chance of remission. However it should be noted that the 
definitions of remission were different and that in patients from the Leiden EAC also a 
discontinuation of DMARD-therapy was achieved.23 Though morning stiffness alone is 
not enough to use as a diagnostic, it should be used in clinical practice in the decision-
making of the diagnostic process. Especially since it is easy to assemble. 
In the past decades many genetic studies focused on susceptibility genes for RA.  In 
chapter 7 we studied whether PTPN22,24 a strong susceptibility gene for RA, was 
also associated with joint destruction in RA patients. This gene was already tested in 
a different dataset and an association with joint destruction was found.25 Though, no 
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adjustments were made for ACPA. Since replication is one of the keystones in science 
to prevent false positive findings current research was conducted in two ACPA-positive 
datasets. We observed that PTPN22, although it predisposes to ACPA positive RA, is not 
associated with increased radiological joint destruction. 
 To elaborate  on radiological joint destruction in RA, in chapter 8 we investigated the 
role of baseline erosions and its association with future joint damage in more detail. 
As established, joint erosions are a typical manifestation in RA and have been part of 
several classification criteria for RA for decades.26;27 On the other hand, one of the key 
goals  in treatment of RA is to prevent joint damage. In this research it was further 
explored whether baseline erosions themselves were independently associated with 
future joint damage or whether this process was mediated via other mechanisms. To this 
end, RA patients were studied which had 7 years of follow-up; X-rays on hand and feet 
were scored via the Sharp-van der Heijde method. Several hypothesis were proposed 
and subsequently tested for mediation (by the mediation model proposed by Baron and 
Kenny).28 In short the proposed ‘variables’ that were tested in mediation analyses were; 
symptom duration, auto-antibodies (RF and ACPA), systemic inflammation (ESR) and 
local clinical inflammation (SJC). These variables were chosen for the following reason. 
Symptom duration was chosen because we hypothesized that if patients presented later 
in time to a rheumatologists the would have a more advanced disease. Furthermore 
we hypothesized  that since autoantibodies are associated with severe radiological joint 
damage they could also be associated with baseline erosions and finally that a more 
severe disease at presentation (reflected by systemic and local clinical inflammation) 
could be associated with baseline erosions. To summarize, baseline erosions were not 
located in the causal path of any of the above variables and thus had an independent 
effect on future joint damage. It is interesting to note that patients with baseline 
erosions at any point in time had 3.45 times more joint damage than patients without 
erosions at baseline. However, the exact mechanism for the development of baseline 
erosions was not explained yet. To this end, we investigated a subgroup of RA patients in 
which MRI data was present at baseline. These data led to the suggestion that subclinical 
inflammation (observed by MRI) is relevant for the development of baseline erosions 
but this study only provided an indication for causality and further research to the exact 
mechanism may be obtained from animal models in the near future. 
The last years a collaborated initiative by the American College of Rheumatology and the 
European league against rheumatic diseases presented new classification criteria for RA 
(also referred to as the 2010 ACR-EULAR criteria for RA). One of the aims was to classify 
patients in an earlier phase of the disease.  Many studies were conducted to evaluate 
the diagnostic testing properties of the 2010 criteria for RA. A recent meta-analysis on 





the intended population.29 However, it was insufficiently clear whether the phenotype 
between the two criteria is different. Several studies observed that some disease 
characteristics of ‘2010 RA’ were milder than in ‘1987 RA’ patients. Yet, no studies were 
performed comparing long-term outcomes in RA patients. Therefore, in  chapter 9 we 
compared two long-term outcomes (radiological joint damage and disease persistence) 
in relation to the classification criteria of RA. At baseline, no large differences were 
observed, except that 1987 RA patients more often experienced morning stiffness than 
2010 RA patients, which can be attributed to the fact that morning stiffness is a part 
of the 1987 criteria for RA. Less severe radiological joint damage and more frequent 
DMARD-free sustained remission was achieved in favour of the 2010 RA patients. Sub-
analyses demonstrated that patients that were positive for both criteria sets had the 
worst prospects. in addition, analyses were repeated by adding the erosion-criterion 
for RA (≥3 erosive joints) in addition to the 2010-criteria point system and this didn’t 
influenced the results. In conclusion, current study demonstrated that patient classified 
according to the 2010 criteria for RA have a milder disease course than patients classified 
according to the 1987 criteria for RA. 
PART IV: MORTALITY IN RA
In chapter 10 we set out to replicate whether a genetic variation in TRAF1/C5 was associated 
with mortality in RA. In the original investigation by Panoulas et al. an association was 
found between the susceptible genotype GG (of rs3761847) with increased mortality 
from sepsis or cancer, though not by cardiovascular death.30 Cardiovascular death is 
the most common cause of death in the general population as well as in RA patients. 
The idea was that this might have been missed because patients were enrolled at an 
advanced disease stage. Therefore, we studied 615 RA patients that were prospectively 
followed in the Leiden EAC and were genotyped for rs10818488. In our cohort the main 
cause of death was cardiovascular disease (37.7%) followed by cancer ( 28.6%) and 
infections (9.1%). Contrary to Panoulas et al, we did not find an association between 
the susceptibility allele and overall mortality, nor with cardiovascular mortality, cancer-
related mortality or mortality due to infections. In addition, analyses were repeated in a 
large (n=5634) non-RA cohort of elderly persons and here no associations were observed 
between rs2416808 (R2 >0.99 with rs10818488) and mortality or cardiovascular, 
cancer of infection related death either. This strengthened our observation of a lacking 
association between TRAF1/C5 and mortality. 
Autoantibodies in RA (RF and ACPA) have been associated with poor outcomes, like 
radiological joint damage and disease persistence.31,32 In the 2010 criteria for RA a 
distinction has been made in assigning points, taking into account the titre of RF and 
ACPA. Assuming that a higher titre will lead to a poor outcome and therefore those 
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patients require therapeutic intervention.  Though, no consistent findings are present 
with respect to altitude of the titre and subsequently a poor outcome. With respect 
to mortality in RA patients, presence of RF is well recognised to be associated with 
increased mortality risks. On the other hand, data on the presence of ACPA and mortality 
is still scarce. Therefore, in chapter 11 we investigated, in 4962 early arthritis patients, 
whether there was an association between mortality and RF/ACPA positivity and their 
titre. Early arthritis patients from the Norfolk  Arthritis Register (NOAR) and Leiden EAC 
were studied.19;33 Antibody status was stratified into negative, low or high positive (as 
proposed by the 2010 ACR/EULAR criteria for RA) and subsequently into negative and 
positive. When antibody status was stratified as such, no consistent findings between 
the cohorts were observed. More interestingly, when counting the number of antibodies 
in a patients (zero, one antibody and two antibodies) we observed that the presence of 
two antibodies (thus double positive) was associated with increased mortality adjusted 
HRs (95% CI) NOAR: 1.35 (1.09 to 1.68), EAC: 1.57 (1.15 to 2.14) compared to patients 
who had either one antibody or none antibodies.
Throughout this thesis various themes are presented, mainly focussing on early detection 
of those persons which are at risk for developing RA or those who have RA and are at 
risk of having a poor outcome. This all leads in one direction, namely to start treatment 
as early as possible! In the last decades treatment options as well as their approach in 
RA patients have changed dramatically. Nowadays, DMARD-therapy is started with such 
promptness that joint damage is prevented, low disease activity scores are achieved 
and even drug free remission is a real goal. Observing these beneficial outcomes in 
RA patients one final questions remains: do these improved treatment strategies also 
benefit the survival of RA patients? In chapter 12 we investigated, in the Leiden EAC, 
the survival of 684 RA patients that were exposed to different treatment strategies 
compared to the general Dutch population. The applied treatment strategies were as 
follows; From 1993 to 1995 patients were treated with NSAIDs and only late in the 
course of their disease with DMARDs. From 1996 to 1998 patients were promptly treated 
with either HCQ or SSZ. From 1999 to 2008 patients were immediately treated with 
MTX monotherapy or a  combination with other disease-modifying drugs. In the first 2 
periods increased standardized mortality rates (SMRs) were observed 1.35 (95% CI 0.94, 
1.93) and 1.23 (95% CI 0.91, 1.67), this means that patients that were diagnosed with 
RA between 1993 and 1998 had a higher mortality risk than their matched peers from 
the general Dutch population. Interestingly, RA patients included in the latest period 
had a decreased mortality ratio 0.49 (95% CI 0.31-0.77). To actually find a reduced SMR 
is surprising, but several explanation can be given for this. It might be explained by the 
presence of secular trends in mortality by specific adaptation of healthier lifestyles by 
RA patients versus the general population. On the other hand we know that RA patients 





likely there is increased awareness of risk factors for comorbidities which may result 
in better treatment and therefore lower mortality risks. Another plausible explanation 
is that patients with a potential fatal illness who also develop joint symptoms are not 
referred to the rheumatologists and therefore not included in our cohort and as such will 
contribute to the mortality rate of the general population instead of the RA-patients. It 
should be noted that mortality data are difficult to interpret. It is not possible to compare 
SMRs between countries, this is due to the differences in survival between general 
populations. Furthermore, one should also take into account the design of the cohort 
and the duration of follow-up. Since the analyses always take places over a certain time 
period that ran its course, it is important to keep in mind that the findings are outdated. 
This means that as a clinician you would like to know the mortality risk over e.g. 20 years 
period of a newly diagnosed RA patient in 2015 (so at this moment), you will need to 
wait another 20 years before you can answer this question.  Nonetheless, current study 
suggests an association between better treatment of RA patients and improved survival. 
CONCLUSIONS AND FUTURE PERSPECTIVES
To summarize, the current thesis presents a range of subjects starting with the success 
of the early recognition clinics in two University hospitals in the Netherlands (Leiden and 
Groningen). By this initiative the GP delay was diminished incredibly, which resulted in 
presentation of arthritis patients at the rheumatologists at an earlier stage. Important 
questions that are not addressed in the current thesis and deserve more attention are 
the: did the (rheumatoid) arthritis patients truly benefit from this early recognition in 
terms of prompt initiation of treatment and improved overall quality of life and are 
the EARCs cost-infective? With respect to these questions it remains difficult to find 
adequate parameters to study this. Possibly a combination by objective measures (joint 
damage either by MRI or X-rays) and patient reported outcomes (VAS-morning stiffness, 
-fatigue, work-participation) can be used to this end.  Despite that it is good that because 
of the EARCs the GP-delay diminished, a next challenge is to understand the motives and 
doubts of GPs to refer or not to refer patients to a rheumatologist. When this has been 
ascertained, targeted interventions specifically for GPs can be developed.
In this thesis we strongly support the notion that there is a therapeutic window of 
opportunity in RA. Current observations are of course based on assumptions regarding 
the actual onset of the disease as reported by the patients themselves (so when they, 
for example, experience swelling or pain in their joints). It is, in that sense, extremely 
difficult to catch the ‘true’ moment of disease onset. Since we do not yet have a golden 
standard by specific cellular-, cytokine-, bone- alterations that are pathognomic for RA 
and especially this is one of the objectives in research in the earliest phases of RA. An 
attempt to better understand the development of RA in a phase in which patients have 
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symptoms but not yet arthritis commenced with the establishment of the clinically 
suspect arthralgia (CSA) cohort. This cohort is still ongoing and more follow-up will show 
which symptoms and characteristics are important in the development of RA. If in the 
future a biological explanation for the ‘start’ of RA is found, the next step is to discover 
to ‘off-switch’ since this might give possibilities for targeted therapeutic intervention. 
On the other hand, it can also be assumed that mechanism that facilitate treatment-
response are different from mechanisms that promote disease persistence or disease 
extinguishment. In this thesis we only studied the window of opportunity in RA patients 
that received therapeutic intervention (DMARDS/glucocorticoids). However, there 
remained a small portion of RA patients that achieved spontaneous remission without 
intervention.  Another interesting question, and for a subject prone to future research, 
is to better understand the biological mechanism and alterations in these RA patients.  
With respect to mortality data, I do think there are many stones that have been left 
unturned in this area. For example,  the results from the joined research with the NOAR 
that revealed having 2 antibodies predisposes for early mortality. It would be interesting 
to extend this research to include the latest discovery of anti-carbamylated proteins to 
the number of antibodies, as well as to study different causes of death in addition to 
overall mortality. 
In conclusion, the current thesis showed that lots of progress was made in the attempt 
to recognize rheumatoid arthritis earlier, that a therapeutic window of opportunity exits 
and that with prompt initiation of adequate DMARD-treatment RA should no longer be 
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Reumatoïde artritis (RA) is een systemische auto-immuunziekte die zich voornamelijk 
kenmerkt door symmetrische synovitis (ontsteking) van de kleine hand- en 
voetgewrichten. Bij RA kan elk gewricht met synoviale bekleding aangedaan zijn. Deze 
ontsteking van het synovium aan de binnenzijde van de gewrichten uit zich aan de 
buitenzijde van het lichaam door een typische zwelling van gewrichten (artritis).
Naast synovitis, kunnen zich na langdurige ontstekingsactiviteit ook extra-articulaire 
manifestaties  voordoen zoals diverse longaandoeningen, oogziekten, huidafwijkingen 
zoals reumanoduli (knobbels op bijvoorbeeld de ellenbogen) en hart- en vaatziekten 
(HVZ). HVZ komen tegenwoordig in beperktere mate voor vanwege de betere kennis 
en behandeling van mogelijke risicofactoren. De prevalentie van RA in de Europese en 
Noord-Amerikaanse landen is ongeveer 0,5-1,0 procent met een incidentie van 20-50 
nieuwe gevallen per 100.000 personen per jaar. Vrouwen krijgen twee tot drie keer 
vaker te maken met RA dan mannen. Hoewel RA bij volwassenen op iedere leeftijd kan 
voorkomen, zijn de meeste patiënten van middelbare leeftijd bij het begin  van de ziekte.
RA-patiënten kunnen naast gezwollen gewrichten ook last hebben van pijnlijke 
gewrichten, of ochtendstijfheid ervaren in en rondom de gewrichten ; daarnaast kunnen 
ze bewegingsbeperkingen hebben en last hebben van vermoeidheid.
De exacte pathogenese van RA is nog niet bekend. Genetische en omgevingsfactoren 
(bijvoorbeeld roken) spelen beide een rol bij het ontstaan  en het verloop van RA. In de 
jaren zeventig en tachtig van de twintigste eeuw, werden de belangrijkste genetische 
risicofactoren (HLA-DRB1 allelen) voor de ontwikkeling van RA geïdentificeerd. Later 
zijn via kandidaat-gen-benaderingen en genoom-brede associatiestudies (genome-wide 
associations studies, hierna: GWAS), meer single nucleotide polymorphisms (SNPs) in 
de Kaukasische RA-patiënten  geïdentificeerd die de gevoeligheid op het ontwikkelen 
van RA vergroten. In dit proefschrift komen twee van deze SNPs, te weten PTPN22  en 
TRAF1-C5 aan bod.
Als RA onbehandeld blijft, kan dit leiden tot aanzienlijke gewrichtsdestructie, die  zelfs 
kan resulteren in invaliditeit van de patiënten. Echter, het ziekteverloop bij patiënten kan 
individueel verschillend zijn, variërend van  mild en niet-destructief tot snel en destructief.
Auto-antilichamen
In RA zijn verschillende antilichamen zijn gevonden; de bekendste zijn de reumafactor en 
de anti-citrullinated peptide antilichamen (ACPA). Reumafactor is het meest ‘klassieke’ 





ook bij patiënten met andere auto-immuunziekten, infectieziekten en zelfs bij gezonde 
individuen. Niet alle patiënten die positief zijn bevonden voor reumafactor zullen RA 
ontwikkelen. Bij vroege RA-patiënten is de prevalentie van reumafactor ongeveer 60 
procent. ACPA, daarentegen, is meer specifiek voor RA en de gedachte is dat het een 
belangrijke rol speelt in de pathogenese van de ziekte. De prevalentie van ACPA in vroege 
RA-patiënten is ongeveer 50%. Er is een overlap in de aanwezigheid van antistoffen bij RA-
patiënten. Dit betekent dat de meeste patiënten die positief zijn getest op de aanwezigheid 
van ACPA ook positief zijn voor de aanwezigheid van reumafactor. Daar komt nog bij dat 
reumafactor en ACPA al aanwezig kunnen zijn nog voordat de diagnose RA is gesteld en nog 
voordat patiënten klachten ervaren. Dit is bekend geworden uit bloeddonor-onderzoek.
Classificatie van RA
In 1859 gebruikte Alfred Garrod de term “reumatoïde artritis” voor het eerst. Een arts 
stelt de diagnose RA  op basis van een combinatie van bepaalde eigenschappen (zoals 
de aanwezigheid van auto-antilichamen) en symptomen (bijvoorbeeld ochtendstijfheid, 
symmetrische gewrichtszwelling, pijnlijkheid van gewrichten) die een patiënt heeft. 
Omdat het een klinische diagnose is kan dit leiden tot een heterogene groep patiënten. 
Bij onderzoek is het doel om de bevindingen te kunnen toepassen op groepsniveau. Om 
dat te bereiken, is een homogene groep patiënten nodig. Daarom zijn er door de jaren 
heen diverse classificatiecriteria opgesteld.  In dit proefschrift zullen patiënten worden 
geclassificeerd volgens de ACR 1987 of 2010 ACR-EULAR criteria voor RA.
Behandeling en behandelstrategieën
De afgelopen vijftig jaar zijn de behandelkeuzen en de behandelstrategieën voor RA 
drastisch veranderd. In 1970 was het gebruikelijk om te beginnen met niet-steroïdale 
anti-inflammatoire geneesmiddelen (NSAIDs  zoals diclofenac). Opvallend was dat pas 
met een ziekte-modificerende anti-reumatische-geneesmiddel (disease modifying anti-
reumatische drug (DMARD)- therapie werd gestart nadat er zichtbare radiografische 
schade aan gewrichten was aangetoond. Verschillende conventionele DMARDs waren 
beschikbaar, zoals anti-malariamiddelen (hydroxychloroquine), sulfasalazine, orale 
goudverbindingen, intramusculair goud, azathioprine en methotrexaat. Wanneer 
NSAID’s hadden gefaald, werd gestart met een DMARD-therapie en bij voorkeur één 
die het minst giftig was. Destijds werd een zogeheten piramide-model toegepast; dit 
betekent dat wanneer de ziekteactiviteit onvoldoende werd onderdrukt een andere 
DMARD werd toegevoegd aan de behandeling. Aan het eind van de twintigste eeuw is 
deze vorm van behandelingsstrategie veranderd. Een DMARD-therapie werd namelijk 
veel eerder in het ziekteverloop gestart en ook werd vaker gestart met een zogeheten 
combinatietherapie. Verschillende klinische onderzoeken hebben laten zien dat gebruik 
van een combinatietherapie met corticosteroïden (zoals prednison) in een vroeg stadium 
van RA, heeft geleid tot minder gewrichtsschade. Naast de conventionele DMARDs is 
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een ander type DMARD op de markt gebracht, namelijk de ‘biologicals’. Deze biologicals 
zijn geneesmiddelen die genetisch zijn gemanipuleerd, door gebruik te maken van 
menselijke genen in niet-humane celculturen om op die manier een biologische stof 
te produceren. Patiënten die biologicals gebruiken zijn vatbaarder voor infecties 
(bijvoorbeeld tuberculose). Daarnaast gaat  het gebruik van biologicals gepaard met 
hoge kosten. Daarom wordt behandeling met biologicals beperkt tot RA-patiënten bij 
wie de behandeling van twee of meer conventionele DMARDS niet heeft aangeslagen. 
 
Vroege herkenning en ‘the window of opportunity’
Uit onderzoek is gebleken  dat een vroege start van een agressieve behandeling bij RA-
patiënten  minder gewrichtsschade over de lange termijn oplevert. Het doel is daarom 
zo snel mogelijk te beginnen met de behandeling van RA-patiënten. Om een vroege start 
van DMARD-therapie mogelijk te maken is het noodzakelijk dat patiënten snel nadat hun 
klachten zijn begonnen door een reumatoloog worden gezien. 
Hoe snel een reumatoloog patiënten ziet  verschilt van  land tot land. Dat heeft onder 
meer te maken met de beschikbaarheid van een reumatologisch centrum (bijvoorbeeld 
dicht in de buurt van de patiënten of op grote afstand) en met de manier waarop de 
gezondheidszorg is georganiseerd. In Nederland is de gezondheidszorg op zodanige wijze 
georganiseerd dat huisartsen controle hebben over de toegang tot medische specialisten 
zoals reumatologen (zij vervullen een poortwachtersfunctie). 
Daarnaast moet de patiënt de drang hebben om medische hulp te zoeken vanwege zijn 
ontstane klachten. In het  Nederlandse gezondheidszorgsysteem, zal een huisarts wel de 
combinatie van klachten en lichamelijk onderzoek als een potentieel reumatologische 
aandoening moeten herkennen en zo snel mogelijk moeten verwijzen naar een reumatoloog. 
In 2011 bezochten in Nederland in totaal, 295 per 1.000 mannelijke personen en 325 per 
1.000 vrouwelijke personen hun huisarts vanwege klachten aan het bewegingsapparaat. 
Van deze bezoekers bleken 5 per 1.000 mannelijke personen en 6 per 1.000 vrouwelijke 
personen onder de diagnose ‘reumatoïde artritis’ te zijn geregistreerd. Hierbij dient wel 
opgemerkt te worden dat deze getallen zijn gebaseerd op zowel nieuwe patiënten als op 
reeds met  RA gediagnosticeerde patiënten. 
Naast het feit dat  bij  RA een vroege behandeling moet worden gestart, is zelfs de 
suggestie gedaan dat de behandeling in het zogenaamde therapeutische “window of 
opportunity” moet worden gestart. Hoewel dit concept nog niet volledig is uitgewerkt, 
is de gedachte dat dit een periode vertegenwoordigt in een zeer vroege fase van de 
ziekte waarbij therapeutische modificatie succesvoller is, wat waarschijnlijk te maken 
heeft met nog niet volledige volgroeide ziekteprocessen. Het idee is dat deze periode de 





In een recent onderzoek in Nederland  is geconstateerd dat de totale vertraging tussen 
het  ontstaan van de klachten en het bezoek aan de reumatoloog bij RA-patiënten 18,4 
weken was (mediaan) en dat de huisarts-vertraging de grootste bijdrage had aan dit 
geheel (twee-derde deel). Bovendien bleek dat slechts 31% van de RA-patiënten werd 
gezien binnen de periode van twaalf weken na het begin van de symptomen.
Ernst van de ziekte: gewrichtsschade en persisterende ziekte 
Er zijn verschillende manieren om de ernst van RA bestuderen. De vraag rijst wat wordt 
bedoeld met de term “ernst”, omdat artsen en patiënten deze term waarschijnlijk 
verschillend zullen  interpreteren. Voor een patiënt kan het belangrijk zijn dat zijn of 
haar dagelijkse activiteiten niet zijn aangetast , dat hij/zij minder pijn, vermoeidheid 
en stijfheid heeft en dat hij/zij liever minder medicijnen gebruikt. Dat laatste kan ook 
andersom zijn. Sommige patiënten zijn juist bang om hun medicijnengebruik af te 
bouwen omdat ze vrezen voor een terugval. 
Reumatologen geven deels de voorkeur aan ‘objectieve’ parameters om de ernst van 
de ziekte te meten, bijvoorbeeld door het volgen van inflammatoire markers zoals de 
bezinking en het CRP, en de aanwezigheid van erosieve gewrichten op röntgenfoto’s. 
Reumatologen zullen ook rekening houden met het aantal gezwollen en pijnlijke 
gewrichten dat ze vinden bij het lichamelijk onderzoek. Tegenwoordig worden ook 
nieuwe technieken toegepast om de ernst van de ziekte te bepalen -hetzij in de klinische 
praktijk of voor onderzoeksdoeleinden - zoals echografie en magnetische resonantie 
imaging (MRI) van handen en voeten.
Het hoofddoel van de behandeling bij RA is te streven naar ziekteremissie: dit is niet alleen 
een haalbaar doel in klinische studies en trials , maar ook in de klinische praktijk. Door de 
jaren heen is remissie als uitkomstmaat uitgebreid bestudeerd. Er bestaat heterogeniteit 
in de definitie van remissie, zo hoort bijvoorbeeld een bepaalde mate van ziekteactiviteit 
bij een bepaalde score (DAS-28 <2.6 of DAS-28> 1.6 ) die wordt bereikt.  Het ultieme 
doel is de DMARD-vrije remissie. De DMARD-vrije en aanhoudende remissie is in het 
onderhavige proefschrift gedefinieerd als de aanhoudende afwezigheid van artritis na 
het staken van  een DMARD-therapie, waaronder biologicals en corticosteroïden voor 
de gehele follow-up en gedurende ten minste één jaar. Deze vorm van remissie valt te 
beschouwen als het tegenovergestelde van een persisterende ziekte en komt het meest 
in de buurt als surrogaat voor ‘genezing’ van RA.
Mortaliteit in RA
Sterfte is de meest onwenselijke uitkomst van een ziekte en voor RA  is dit in de afgelopen 
jaren uitgebreid onderzocht. Hoewel dit resultaat onomkeerbaar is, kunnen voorspellers 
van mortaliteit aanwijzingen geven voor therapeutische interventies omdat die ook vaak 
andere uitkomsten op lange termijn voorspellen. 
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In eerdere onderzoeken is RA  in verband gebracht met een verhoogd sterftecijfer in 
vergelijking met de algemene populatie (1,2-1,3 in inceptie-cohorten en 1,6-1,7 in niet-
inceptie-cohorten). Verder is waargenomen dat de incidentie mortaliteit (IMR ) in RA in 
de tijd afnam , met een geschatte gepoolde IMR van 4,7 / 100 persoons-jaren voor studies 
vóór 1970 tot 2,0 / 100 persoonsjaren voor studies gestart na 1985. Dit resulteerde 
in een relatieve daling van 2,6% per jaar tussen 1955 en 1995. Deze observaties zijn 
gebaseerd op de vroege RA-cohorten die zijn gestart tussen 1955-1995, dus voordat 
vroege en agressieve behandelingen werden geïntroduceerd. 
De belangrijkste doodsoorzaken bij RA zijn HVZ, kanker en infecties;  de percentages 
daarvan zijn  vergelijkbaar met die van de algemene populatie. Hoewel de verhouding 
van cardiovasculaire sterfte  niet hoger is dan die bij de algemene populatie, overlijden 
RA-patiënten wel op jongere leeftijd. RA is geassocieerd met HVZ, en het risico op HVZ 
is ongeveer  twee tot drie maal hoger dan bij de algemene populatie. Vooral versnelde 
atherosclerose (aderverkalking) wordt waargenomen bij RA-patiënten, en die kan 
voorafgaan aan grote cardiovasculaire gebeurtenissen. Deze versnelde atherosclerose 
valt echter niet alleen te verklaren door de traditionele HVZ-risicofactoren die vaker 
voorkomen bij RA-patiënten, zoals hypertensie, hyperlipidemie, diabetes en roken, maar 
wordt waarschijnlijk ook veroorzaakt door een aanhoudende ontsteking.
Het doel van het onderhavige proefschrift:
De vier hoofddoelen van dit proefschrift zijn:
 
1. Het verbeteren van vroegtijdige herkenning van artritis. 
2. Het onderzoeken van de aanwezigheid van een ‘therapeutic window of opportunity’ 
in RA.
3. Het onderzoeken van diagnostische en prognostische markers in artralgie, artritis en 
vroege RA-patiënten. 
4. Het identificeren van voorspellers voor sterfte en het vergelijken van overleving van 
RA-patiënten met de algemene Nederlandse bevolking. 
Het proefschrift is opgedeeld in vier delen.
De belangrijkste resultaten van het  proefschrift
In deel I zijn de werkzaamheid van twee early arthritis recognition clinics (vroege artritis 
herkenning klinieken) geëvalueerd en de redenen voor artralgie-patiënten om medische 
hulp te zoeken. Zoals hiervoor beschreven is in Nederland de gemiddelde vertraging 
waarmee RA-patiënten worden gezien door een reumatoloog na het ontstaan  van de 





toe te schrijven aan de vertraging bij/door de huisarts. Dit bevestigt, in combinatie met 
eerdere gegevens over de ‘wait-and-see approach’, dat het voor huisartsen lastig kan 
zijn om artritis van de kleine gewrichten van de handen en voeten te herkennen. Om 
deze huisartsen-vertraging te verminderen is een nieuw inloopspreekuur gecreëerd in 
twee academische ziekenhuizen in Leiden en Groningen (Nederland): de early arthritis 
recognition clinic (EARC). In plaats van het toepassen van de wait-and-see aanpak, 
konden huisartsen wanneer ze onzeker waren over de aanwezigheid van artritis hun 
patiënten doorsturen naar de  EARC. Dit inloopspreekuur werd twee keer per week 
gehouden; patiënten hoefden geen  afspraak te maken.  Nadat patiënten een kleine 
vragenlijst (over hun klachten en redenen om medisch hulp te zoeken) hadden ingevuld, 
werden zij gezien door een ervaren reumatoloog. Deze reumatoloog voerde vervolgens 
een volledig gewrichtsonderzoek uit. Wanneer tijdens het gewrichtsonderzoek artritis 
werd vastgesteld, kwam de patiënt binnen één week terug op de polikliniek voor een 
volledige anamnese en lichamelijk onderzoek inclusief extra laboratoriumonderzoek, 
röntgenfoto’s van handen en voeten en de start van een passende behandeling. 
In hoofdstuk 2 zijn de eerstejaars resultaten van deze inloopspreekuren geëvalueerd. De 
huisartsen-vertraging was de belangrijkste uitkomst, gevolgd door de totale vertraging. 
In Leiden werd 42% (168/400) en in Groningen 49% (104/212) van de patiënten 
gediagnosticeerd met artritis. De doelstelling van deze klinieken was om de huisartsen-
vertraging te verminderen.  Dit was succesvol in beide EARCs en de waargenomen 
vertraging bij de vroege artritis-patiënten was 2,0 (0,4-8,4) weken in Leiden en 2,3 
(0,6-9,1) weken in Groningen. Een interessante bevinding was dat patiënten met 
ongedifferentieerde artritis (UA) of RA via de EARC een mediane huisartsen-vertraging 
hadden van ongeveer twee weken in vergelijking met negen weken van UA en RA-
patiënten die op de polikliniek reumatologie in dezelfde periode werden gezien en  via 
normale verwijzing van de huisarts waren binnengekomen. Ook was de duur van de 
huisartsen-vertraging  lager dan de historische huisartsen-vertraging bij RA-patiënten 
(mediaan 11,8 weken).
Hoofdstuk 3 bevat de bestudering van de beweegredenen van artralgie (gewrichtspijn)-
patiënten om medische hulp te zoeken. De gemiddelde klachtenduur in alle artralgie-
patiënten was vier weken voordat zij voor het eerst een huisarts bezochten. Het bleek 
dat patiënten die artritis hadden sneller de huisarts bezochten dan patiënten die geen 
artritis hadden (2,6 versus 5,9 weken).  In het algemeen verschilden de redenen voor het 
zoeken van medische hulp niet tussen patiënten met en zonder artritis. Artritis-patiënten 
zochten vooral  medische hulp omdat hun klachten plotseling waren ontstaan en omdat 
hun familie en vrienden dit adviseerden. Naast het vergelijken van artritis-patiënten met 
niet-artritis-patiënten is ook gekeken naar de vertraging bij de patiënten zelf; dus patiënten 
die kort (<4 weken) en lang (>4 weken) na het ontstaan van hun klachten naar de huisarts 
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zijn gegaan. Hieruit bleek dat  zowel de werk-gerelateerde beperkingen als beperkingen 
met betrekking tot hun  fysieke functioneren belangrijke redenen waren om snel naar 
de huisarts te gaan. Een belangrijke vraag in het onderzoek was of bepaalde klachten, 
bepaalde beweegredenen voor het bezoeken van de huisarts of bepaalde opvattingen 
over het functioneren op het werk vaker gezamenlijk voorkwamen. Met andere woorden 
of  een clustering van deze variabelen vaak voorkwam bij  eenzelfde soort artralgie-patiënt. 
Hiervoor is  een data-reductie methode gebruikt: een partial least square regression 
analyse (PLS). Dit leverde twee groepen patiënten op. De eerste groep patiënten had 
als kenmerken een korte patiëntenvertraging (<4 weken na het ontstaan van klachten 
bij de huisarts), een plotseling ontstaan van de klachten, functionele beperkingen en 
ziekteverzuim. De tweede groep patiënten had als kenmerken een lange patiënten-
vertraging, een geleidelijk ontstaan van de klachten, en geen werkverzuim. Het is 
belangrijk om te vermelden dat  het hiervoor genoemde onderzoek is uitgevoerd bij 
patiënten met gewrichtspijn bij wie de huisarts twijfelde over de aanwezigheid van 
artritis. Het onderzoek omvat dus geen vertegenwoordiging van alle patiënten met 
gewrichtspijn die de huisarts bezoeken, maar betreft slechts een selectie.
In deel II van dit proefschrift is gekeken of een therapeutische ‘window of opportunity’ 
aanwezig was  in RA. Eerdere studies hebben aangetoond dat een vroege start van de 
behandeling in RA leidt tot een gunstiger resultaat. Een ‘vroege start’ is door de jaren 
heen op verschillende manieren geïnterpreteerd;  bijvoorbeeld binnen twee jaar na de 
diagnose RA tot starten met behandeling versus binnen een paar weken na de diagnose 
starten met behandeling. Daarom is de volgende onderzoeksvraag geformuleerd: 
Hebben RA-patiënten waarbij de behandeling is gestart snel nadat hun klachten zijn 
begonnen (korte klachtenduur) een gunstiger resultaat dan patiënten met een lange 
klachtenduur? Omdat in veel studies ‘klachtenduur’ als co-variabele is opgenomen in 
de analyse is in hoofdstuk 4 een systematisch literatuuronderzoek uitgevoerd en zijn 
al deze studies systematisch beoordeeld om te onderzoeken of een korte klachtenduur 
bij aanvang van de behandeling in verband valt te brengen met minder progressie van 
de ziekte. De kwaliteit van een onderzoek is  beoordeeld met behulp van een vooraf 
gedefinieerd scoresysteem en er is een ‘best evidence synthesis’ toegepast om de 
bewijskracht per categorie te bepalen. Sterk bewijs is gevonden voor een verband 
tussen een korte klachtenduur en minder radiografische schade, en matig bewijs voor 
een verband tussen klachtenduur en andere uitkomsten bij RA, zoals het verkrijgen van 
een bepaalde ziektestatus (remissie onder therapie is gedefinieerd door het behalen van 
bepaalde ziekteactiviteit scores; DAS-28 <2.6 DAS-28 <1,6, ACR remissie etcetera). 
Een ander belangrijk resultaat was de DMARD-vrij aanhoudende remissie, die 
werd gedefinieerd als aanhoudende afwezigheid van artritis na het staken van een 





Via de kwalitatieve benadering is matig bewijs gevonden voor een verband tussen de 
klachtenduur en een DMARD-vrije aanhoudende remissie.  Omdat er toegang bestond 
tot de ruwe data van deze drie cohorten was een meta-analyse uitvoerbaar. Hieruit bleek 
dat de kortere klachtenduur onafhankelijk van andere variabele verband hield  met een 
grotere kans op een DMARD-vrije aanhoudende remissie ook na correcties voor leeftijd, 
geslacht en de meer specifieke ziektemarkers zoals de reumafactor en bezinking. 
Deze resultaten leidden tot de volgende vraag: is deze associatie lineair volgens ‘the-
earlier-the-better- principle?’ of ‘is er een bepaalde tijdsperiode waarin behandeling 
van de ziekte beter aanslaat onder verwijzing  naar een ‘window of opportunity’. Deze 
vraag  is in hoofdstuk 5 opgepakt door onderzoek te doen naar de vorm van het verband 
tussen de klachtenduur en een DMARD-vrije remissie ( het tegenovergestelde van 
persisterende ziekte) in twee grote vroege RA-cohorten. 
Wanneer enerzijds een lineair verband het uitgangspunt vormt, dan wordt aangenomen 
dat de totale inflammatoire belasting (product van de ernst en de duur van de ontsteking) 
op het moment van de start van de behandeling samenhangt met de uitkomst van de ziekte. 
Anderzijds, wordt in de literatuur vaak een ‘window of opportunity’ in RA  aangehaald 
dat zou bestaan uit de eerste 12 weken na het ontstaan van klachten. In deze periode zou 
de ziekte vermoedelijk gevoeliger zijn voor therapeutische interventies. Dit afkappunt 
van 12 weken lijkt te zijn gebaseerd op adviezen van experts. Deze adviezen zijn later wel 
ondersteund door onderzoeken waaruit bleek dat patiënten met minder dan 12 weken 
klachtenduur een gunstigere uitkomst hadden. Er is echter niet aangetoond dat na een 
bepaalde periode van symptoomduur het effect van de behandeling vermindert. Twee 
grote vroege RA cohorten zijn gebruikt en de belangrijkste uitkomst was: een DMARD-
vrije aanhoudende remissie.  Geobserveerd is dat, over een periode van 5 jaar follow-up, 
de curve van de log-hazard ratio (de kans op een DMARD-vrije aanhoudende remissie) 
afgezet tegen de klachtenduur, niet-lineair was. De log-hazard ratio’s zijn berekend 
met behulp van cox-proportional hazards regression models met natural cubic splines. 
Het voordeel van deze benadering is dat het geen lineaire associaties veronderstelt. 
Bovendien is het discriminerend vermogen gemeten met time-dependent ROC-curves. 
De klachtenduur met het optimale onderscheidend vermogen was 14,9 weken in de 
EAC en 19,1 weken in ESPOIR. Het eindpunt van de DMARD-vrije aanhoudende remissie 
wordt niet vaak bereikt (5-11%) en is afhankelijk van het advies van de behandelend 
reumatoloog en de wil van patiënten om de DMARD-therapie te staken. Daarom zijn 
nog twee extra eindpunten, onderzocht: namelijk een zekere radiografische progressie 
én aanhoudende remissie ongeacht de voortzetting van de behandeling. Ook voor deze 
eindpunten was de vorm van het log-hazard ratio curves niet-lineair. Dit voert tot de 
conclusie, dat de hiervoor genoemde resultaten wel degelijk suggereren dat er een 
specifieke periode bestaat voor RA-patiënten waarin het voor hen voordelig is om te 
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starten met een DMARD-therapie. De voorgestelde 12-weekse periode in de literatuur 
lijkt dus niet misplaatst. Hoewel, op basis van de huidige gegevens zou  kunnen worden 
gesteld  dat deze periode de eerste vijf of zes maanden na het optreden van de eerste 
klachten bestrijkt.
In deel III van dit proefschrift is gekeken naar ziektekenmerken die een voorspellende 
of diagnostische waarde hebben in artralgie, vroege artritis en reumatoïde artritis 
patiënten.
In hoofdstuk 6 is  een bekend ziektekenmerk voor RA, namelijk ochtendstijfheid, die vaak 
wordt beoordeeld in de klinische praktijk, onderzocht op het diagnostisch vermogen 
in drie artralgie-cohorten en twee vroege-artritis cohorten en op het prognostisch 
vermogen in twee vroege RA-cohorten. Recent onderzoek naar ochtendstijfheid toonde 
verbanden aan met een verminderde functionele capaciteiten in de ochtend, de 
effecten op de kwaliteit van leven en verlies van werk. Daarnaast zou ochtendstijfheid 
een slechte discriminator zijn tussen RA en andere reumatologische aandoeningen. 
Deze waarnemingen zijn echter gebaseerd op studies met zeer lage patiëntenaantallen. 
Hiervoor zijn 1641 artralgie-patiënten uit drie cohorten gebruikt. Twee van deze cohorten, 
de EARCs uit Leiden en Groningen zijn hiervoor beschreven; het derde cohort was het 
Rotterdamse Early Arthritis Cohort (REACH). Ongeveer 50% van de artralgie-patiënten 
die werden verwezen naar deze cohorten, werden gediagnosticeerd met artritis bij 
hun eerste bezoek aan de reumatoloog.  Geobserveerd is dat ochtendstijfheid met een 
duur van ≥60 minuten in artralgie-patiënten werd geassocieerd met de aanwezigheid 
van artritis (Leiden EARC OR1.49, Groningen EARC OR2.21 en REACH OR1.55). Hierna 
is het onderscheidend vermogen van ochtendstijfheid bij patiënten met vroege artritis 
in twee cohorten onderzocht, de Leiden EAC en het Franse ESPOIR cohort. De duur van 
ochtendstijfheid werd afgebeeld met de diagnose van de patiënten met vroege artritis 
na 1 jaar follow-up. Dit toonde aan dat de mediane duur 60 minuten was in RA-patiënten 
en langer dan de duur van alle andere reumatologische aandoeningen. Het diagnostisch 
vermogen van ochtendstijfheid ≥60 minuten in vroege artritis-patiënten liet een 
significant  verband zien met de diagnose van de 2010-RA na één  jaar,  onafhankelijk 
van andere voorspellers voor RA (zoals gezwollen gewrichten, ACPA, reumafactor, 
klachtenduur en bezinking).  Ook is gekeken naar de optimale discriminerende duur van 
ochtendstijfheid voor RA in vroege artritis-patiënten. Dat liet zien  dat in beide cohort de 
optimale discriminerende duur van ochtendstijfheid ongeveer 30 minuten bedroeg. Ten 
slotte is onderzocht of een bepaalde duur van ochtendstijfheid bij aanvang (≥30, ≥60 en 
≥90 minuten) een voorspellende waarde zou hebben op de lange termijn resultaten in 
RA, zoals gewrichtsschade en een DMARD-vrije aanhoudende remissie. Hierbij is géén 
verband gevonden tussen ochtendstijfheid en een slechtere lange termijn uitkomst. 





kan ochtendstijfheid in de klinische praktijk wel bruikbaar zijn in de besluitvorming van 
het diagnostisch proces. 
In hoofdstuk 7 is onderzocht of een SNP in het gebied van het protein tyrosine 
phosphatase non-receptor 22  (PTPN22) verband houdt met radiologische schade bij 
RA-patiënten in een selectie van ACPA-positieve RA-patiënten afkomstig van twee 
cohorten. Dit gebied codeert voor een negatieve regulatie van T-cel activatie en is een 
belangrijke risicofactor voor het ontwikkelen van RA in ACPA-positieve-patiënten. Dit 
gen werd al getest in een andere dataset en daar is een verband met gewrichtsschade 
gevonden. In dat desbetreffende onderzoek is geen correctie uitgevoerd voor ACPA. 
Omdat replicatie een van de hoekstenen in wetenschappelijk onderzoek vormt om zo de 
kans op vals-positieve bevindingen te verkleinen, is het onderzoek uitgevoerd in 2 ACPA-
positieve datasets. Hierbij is géén verband gevonden tussen PTPN22 met radiologische 
gewrichtsschade in RA-patiënten. 
In hoofdstuk 8 is meer in detail de rol van baseline erosies (d.w.z. erosies die reeds 
aanwezig zijn op het moment dat de diagnose wordt gesteld) onderzocht en het 
verband met progressie van gewrichtsschade. Zoals bekend zijn gewrichtserosies 
een typische uiting in RA en maken ze al decennia lang deel uit van de verschillende 
classificatiecriteria voor RA. Eén van de belangrijkste doelen in de behandeling van RA 
is om gewrichtsbeschadiging te voorkomen. In dit onderzoek is verder onderzocht of 
de baseline erosies onafhankelijk in verband konden worden gebracht met toekomstige 
gewrichtsschade of dat zij in dit proces als mediator optraden via andere mechanismen. 
Hiervoor zijn RA-patiënten onderzocht die zeven jaar follow-up hadden en van wie 
röntgenfoto’s van handen en voeten waren gescoord volgens de Sharp-Van der Heijde 
methode. Verschillende hypotheses zijn opgesteld en vervolgens getest voor mediatie. 
De volgende voorgestelde ‘variabelen’ die zijn getest in mediatie analysen: klachtenduur, 
auto-antilichamen (reumafactor en ACPA), systemische ontsteking (bezinking) en de 
lokale klinische ontsteking (aantal gezwollen gewrichten). Voor deze variabelen is gekozen 
omdat de gedachte was dat  patiënten die zich later presenteerden bij een reumatoloog, 
mogelijk al een verder gevorderd stadium van de ziekte hadden (en dus daarom al 
baseline erosies hadden); aangezien auto-antilichamen verband houden met ernstige 
radiologische gewrichtsschade zouden deze ook in verband te brengen zijn met baseline 
erosies en tenslotte werd gedacht dat een ernstigere ziekte bij presentatie (gereflecteerd 
door systemische en lokale klinische ontsteking) ook verband zou kunnen houden met 
baseline erosies. Samenvattend, baseline erosies bevonden zich niet in het causale pad 
van een van de hiervoor staande variabelen en hadden dus een onafhankelijk effect op 
toekomstige gewrichtsschade. Verder is het belangrijk om op te merken dat patiënten 
met baseline erosies op elk tijdsmoment  3,45 keer meer gewrichtsschade hadden dan 
patiënten zonder baseline erosies. De precieze mechanismes voor de ontwikkeling van 
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baseline erosies zijn nog niet bekend. Om hierachter te komen is  een kleine subgroep 
van RA patiënten, die ook MRI-data op baseline hadden, verder onderzocht.  Deze data 
suggereerden dat subklinische ontstekingen (waargenomen met MRI) relevant zijn voor 
de ontwikkeling van baseline erosies. Hoewel dit onderzoek uitsluitend een indicatie 
geeft voor causaliteit is verder onderzoek nodig naar het exacte mechanisme van 
baseline erosies en dit valt mogelijk te doen met behulp van diermodellen.
 
De laatste criteria-set om RA mee te classificeren, de 2010 ACR-EULAR-criteria , wordt 
beschouwd als sensitief maar is minder specifiek voor RA. Bovendien is het doel van 
deze criteria-set om patiënten eerder in het ziekteverloop te identificeren, waardoor 
het mogelijk is om klinische trials uit te voeren met patiënten in een vroeger stadium, 
het liefst nog voordat ze structurele gewrichtsschade hebben ontwikkeld. Gebleken 
is dat het fenotype van ‘2010 RA-patiënten’ milder is dan het fenotype van patiënten 
geclassificeerd volgens de 1987-criteria voor RA;  de lange termijn uitkomsten voor deze 
twee criteria ontbraken echter. Daarom is  in hoofdstuk 9  gekeken naar de progressie 
van gewrichtsschade over zeven jaar follow-up en naar de DMARD-vrije remissie over 
tien jaar follow-up in RA-patiënten die zijn geclassificeerd  volgens de 1987- en de 2010- 
criteria voor RA. Patiënten die geclassificeerd waren volgens de 2010-criteria als RA-
patiënten ontwikkelden minder radiologische gewrichtsschade en  behaalden vaker 
de DMARD-vrije remissie ten opzichte van patiënten die geclassificeerd waren volgens 
de 1987-criteria. Sub-analyses zijn verricht waarbij het nieuw ontwikkelde erosie-
criterium voor RA is toegepast (≥3 erosieve gewrichten) naast het puntensysteem van 
de 2010-classificatie criteria. Hierbij werd een kleine groep patiënten op basis van het 
erosie-criterium alsnog als patiënten met ‘RA’ geclassificeerd. Dit was echter niet van 
invloed op de eerder geobserveerde resultaten. Dit leidt tot de conclusie dat de huidige 
studie heeft aangetoond dat patiënten die geclassificeerd zijn volgende de 2010-criteria 
voor RA een milder verloop hebben dan patiënten die volgens de 1987-criteria voor RA 
zijn geclassificeerd.  
In deel IV van het proefschrift ligt de focus op de mortaliteit in RA-patiënten. Sterfte is de 
meest onwenselijke uitkomst van een ziekte en is door de jaren heen uitgebreid onderzocht. 
Hoewel dit resultaat onomkeerbaar is, kunnen risicofactoren/voorspellers voor sterfte 
wel aanwijzingen geven voor therapeutische interventies omdat deze zelfde voorspellers 
ook vaak verband houden met andere lange termijn uitkomsten (zoals gewrichtsschade). 
Uit eerdere onderzoeken is gebleken dat RA-patiënten een hoger sterftecijfer hadden, 
dus een kortere levensduur,  dan de algemene populatie.  Deze bevindingen waren 
afkomstig uit studies in een tijdperk waarin een afwachtend behandelingsbeleid werd 
gehanteerd; dus nog voordat de vroege en agressieve behandeling was geïntroduceerd. 
De belangrijkste doodoorzaken voor RA-patiënten zijn HVZ, kanker en infecties, en de 





In hoofdstuk 10  is onderzocht of een genetische variatie in TRAF1 / C5 verband houdt 
met sterfte in RA-patiënten. In het oorspronkelijke onderzoek door Panoulas et al. 
werd een verband gevonden tussen de gevoelige genotype GG (van rs3761847) en een 
verhoogd sterfterisico door  sepsis en kanker, maar is geen verband aangetoond met 
de cardiovasculaire dood.  Het idee was dat dit verband niet werd gevonden  omdat 
patiënten werden bestudeerd in een ver gevorderd stadium van hun ziekte (dat zou 
kunnen betekenen dat patiënten die in een eerdere ziektefase waren overleden aan hart 
en vaatziekten niet geïncludeerd waren). Daarom zijn 615 patiënten met RA onderzocht 
die prospectief werden gevolgd in de Leidse EAC met genotypering voor rs10818488. In 
dit cohort waren de belangrijkste doodsoorzaken hart- en vaatziekten (37,7%), gevolgd 
door kanker (28,6%) en infecties (9,1%). In tegenstelling tot Panoulas et al, werd géén 
verband gevonden tussen het  gevoeligheidsallel en sterfte in het algemeen, en evenmin 
met cardiovasculaire mortaliteit, kanker-gerelateerde sterfte of sterfte door infecties. 
Daarnaast zijn dezelfde analyses herhaald in een groot niet-RA cohort(n = 5634) van 
ouderen en ook daar zijn geen verbanden gevonden tussen rs2416808 (R2> 0,99 met 
rs10818488) met sterfte in het algemeen, noch met cardiovasculaire mortaliteit, noch 
met kanker-gerelateerde sterfte of sterfte door infecties.
In hoofdstuk 11 is onderzocht of er een verband bestaat tussen sterfte en de aanwezigheid 
van reumafactor of ACPA  alsook hun titer in vroege artritispatiënten. Uit eerder 
onderzoek is bekend dat auto-antilichamen (zoals reumafactor en ACPA) verband houden 
met een ongunstige uitkomst zoals radiologsiche schade en het voortbestaan van de 
ziekte. Wat betreft sterfte onder RA-patiënten, is enerzijds bekend dat de aanwezigheid 
van reumafactor verband houdt met verhoogd sterfterisico. Anderzijds zijn de gegevens 
over de aanwezigheid van ACPA en sterfte nog schaars. Vroege artritispatiënten uit de 
Norfolk Arthritis Register (NOAR) en de Leiden EAC zijn bestudeerd. De aanwezigheid 
van antilichamen werd gestratificeerd in een negatieve, een lage of hoge positieve titer 
(zoals voorgesteld door de 2010 ACR / EULAR-criteria voor RA) en vervolgens is gekeken 
naar de hoeveelheid aanwezige antilichamen. Wanneer de status van het antilichaam 
werd gestratificeerd op basis van de titer werden geen consistente bevindingen tussen 
de cohorten waargenomen. Wanneer echter het aantal antilichamen in een patiënt (nul, 
één antilichaam en twee antilichamen) werd geteld, leverde de aanwezigheid van twee 
antilichamen (dus dubbel positief) een relatie op met een verhoogde sterfterisico, dit 
in vergelijking met patiënten die ofwel één antilichaam of geen antilichamen hadden.
Zoals eerder beschreven, zijn in de laatste decennia de toegepaste behandelingsopties 
in RA-patiënten drastisch veranderd. Tegenwoordig wordt de DMARD-therapie gestart 
met een zodanige  voortvarendheid dat gewrichtsschade wordt voorkomen, lage 
ziekteactiviteitscores worden behaald en zelfs medicatie-vrije remissie een streven is. Bij 
de observatie van deze gunstige uitkomsten in RA-patiënten resteert de  vraag of met deze 
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verbeterde behandelingsstrategieën ook de overleving van RA-patiënten is toegenomen? 
In hoofdstuk 12 is de overleving van 684 RA-patiënten (afkomstig uit de Leiden EAC) 
die volgens verschillende strategieën zijn behandeld, vergeleken met de algemene 
Nederlandse bevolking.  De toegepaste behandelingsstrategieën waren als volgt: 
-  van 1993-1995 werden patiënten behandeld met NSAID’s en pas later in de loop van 
hun ziekte met DMARDs;
-  van 1996 tot 1998 werden patiënten direct behandeld met ofwel hydroxychloroquine 
of sulfasalazine; 
-  van 1999-2008 werden patiënten direct behandeld met methotrexaat monotherapie. 
 
In de eerste twee perioden zijn de sterftecijfers van de RA-patiënten toegenomen. Dit 
betekent dat patiënten die werden gediagnosticeerd met RA tussen 1993 en 1998 een 
hoger sterfterisico hadden dan hun leeftijdsgenoten uit de algemene Nederlandse 
bevolking. Interessant is dat RA-patiënten die in de laatste periode (1999 -2008) werden 
gediagnosticeerd een lager sterfterisico hadden dan de algemene populatie. Deze laatste 
bevinding is verassend en hiervoor vallen verschillende verklaringen te geven. Een 
verklaring zou kunnen zijn  de specifieke aanpassing van het volgen van een gezondere 
levensstijl door RA-patiënten in vergelijking met die  van de algemene bevolking. Hoewel 
wel bekend is dat RA-patiënten nu minder tijd besteden aan lichamelijke inspanning dan 
de algemene bevolking. Verder zou het zo kunnen zijn dat er een toegenomen alertheid 
bestaat op risicofactoren die voor comorbiditeiten kunnen zorgen. Deze krijgen daarom een 
betere behandeling,  wat leidt tot een lager sterfterisico. Een andere mogelijke verklaring 
is dat patiënten met een potentieel dodelijke ziekte die ook gewrichtssymptomen 
ontwikkelen niet worden verwezen naar de polikliniek reumatologie en dus niet in ons 
cohort worden geïncludeerd, waardoor zij bijdragen aan het sterftecijfer van de algemene 
bevolking in plaats van aan het sterftecijfer van de RA-patiënten.  Omdat de analyses 
altijd gedurende een bepaalde periode hebben plaats gevonden waarin het onderzoek 
liep, is het belangrijk om in gedachten te houden dat de bevindingen zijn verouderd. 
Niettemin suggereert de huidige studie dat er een positief verband bestaat tussen een 
betere behandeling van RA-patiënten en toegenomen overleving.
CONCLUSIES EN TOEKOMSTPERSPECTIEVEN
Dit proefschrift presenteert een scala van onderwerpen te beginnen met de 
inloopspreekuren voor vroeg-herkenning van artritis in twee academische ziekenhuizen 
in Nederland (Leiden en Groningen). Door dit initiatief is de huisartsenvertraging 






Vragen die dit proefschrift niet beantwoord maar die zeker aandacht verdienen zijn: 
Hebben de (reumatoïde) artritis-patiënten daadwerkelijk profijt van deze vroegtijdige 
herkenning in de vorm van een snellere behandelingsstart, en een betere kwaliteit van leven? 
Zijn de EARC’s kosten-effectief? 
 
Het blijft een uitdaging om deze vragen te beantwoorden en lastig om adequate 
parameters hiervoor  te vinden. Mogelijk kan een combinatie van objectieve uitkomsten 
(gewrichtsschade op röntgenfoto’s of MRIs) en subjectieve uitkomsten (VAS-
ochtendstijfheid, - moeheid, en arbeidsparticipatie) voor dit doel worden gebruikt. Een 
daarop volgende uitdaging is het, om nog beter de motieven en twijfels van de huisarts 
om patiënten te verwijzen of juist niet te verwijzen naar een reumatoloog  in kaart te 
brengen. 
Dit proefschrift onderschrijft  het idee dat er een therapeutisch window of opportunity 
voor RA bestaat. Natuurlijk zijn deze waarnemingen gebaseerd op de veronderstelling 
dat de patiënt zelf de daadwerkelijke aanvang van de ziekte (het ervaren van pijn en 
zwelling in de gewrichten) waarneemt. Het is bijzonder moeilijk om het werkelijke 
moment waarop de ziekte begint vast te stellen. Er bestaat geen gouden standaard door 
specifiek cellulair-, cytokine- of bot-veranderingen die pathognomisch zijn voor RA. Dit 
is een van de doelstellingen in het onderzoek naar de vroegste fase van RA. Om beter 
inzicht te krijgen in de ontwikkeling van RA is een cohort opgericht waarin patiënten 
worden gevolgd in een fase waarin ze symptomen (klinisch verdachte gewrichtspijn) 
hebben maar nog géén artritis: het clinically suspect arthralgia (CSA) cohort. Dit cohort is 
nog gaande en follow-up  zal uiteindelijke tonen welke verschijnselen en eigenschappen 
belangrijk zijn in de ontwikkeling van RA.
In dit proefschrift is alleen de window of opportunity in RA-patiënten die therapeutische 
interventie (DMARDS / glucocorticoïden) ontvingen, bestudeerd. Toch is er een klein 
deel van de RA-patiënten dat spontane remissie heeft bereikt zonder medicamenteuze 
interventie. Deze groep patiënten is niet bestudeerd, maar het zou zeer interessant zijn 
om de mechanismen die deze spontane remissie van artritis bewerkstelligen verder te 
ontrafelen. Met betrekking tot de sterftedata zou met het oog op de toekomst diepgaander 
gekeken kunnen worden naar de rol van antilichamen. De resultaten van het onderzoek in 
de Leiden EAC en het NOAR-cohort hebben onthuld  dat patiënten met twee antilichamen 
een toegenomen sterfterisico hadden. Het zou interessant zijn om dat onderzoek uit te 
breiden en hierbij het recent gevonden anti-gecarbamyleerd- antilichaam toe te voegen 
en dan tevens te kijken naar mogelijke verbanden met de verschillende doodsoorzaken. 
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De conclusie is dat dit proefschrift aan toont dat veel vooruitgang is geboekt in het 
bevorderen van de vroege herkenning van reumatoïde artritis, dat een therapeutisch 
window of opportunity bestaat én dat RA niet langer moeten worden gezien als een 
chronische aandoening , maar dat medicatievrije remissie en een verbeterde overleving 
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Alves voor de REACH-data. And thanks to our international colleagues from the ESPOIR 
and NOAR cohorts; professor B. Fautrel, dr C. Gaujoux-Viala, dr. S. Verstappen and dr. J 
Humphreys for all their efforts.
Het secretariaat bestaande uit Nancy, Hughine en Joyce, wil ik bedanken waar ik te 
allen tijde terecht kon met vragen. Evenals de datamanagers Cedric en Jozé voor het 
bijhouden van de EAC-database en het scanwerk van de EARC. 
Alle reumatologen, arts-assistenten en researchverpleegkundigen bedankt voor het 
includeren van patiënten in de EAC en het screenen van de EARC-patiënten. 
Alle collega-promovendi die door de jaren heen op kamers C1-45, C1-46 en op de 5e hebben 
gewerkt. Natuurlijk wil ik mijn ‘eiland-genoten’ niet vergeten te noemen en bedanken. 
Annemarie, voor het meedenken met vraagstukken, onze vele congresbezoeken en je 
humor binnen en buiten werktijd. Diederik, voor het herhaaldelijk uitleggen van het 
verschil tussen fixed en random effect… Hanna, wat fijn dat ik eindelijk weer een ‘maatje’ 
had in de vroege ochtenduren, ik kijk ernaar uit straks weer collega’s te zijn in het LUMC! 
Wouter en Lukas, jullie waren goede gesprekspartners in de scorekamer. Leonie,  mijn 





Dr. Tsonaka, beste Roula, ik heb goede herinneringen aan onze vele gesprekken over het 
window of opportunity project.  Dr. Le Cessie, beste Saskia, bedankt voor alle hulp bij het 
mortality artikel en het wekken van mijn interesse voor onderzoek en statistiek. 
Mijn opleiders in het MCH, Dr. Bootsma en Drs. De Vreede, Beste Aart en Mariëlle, 
het starten in de kliniek en het afmaken van een proefschrift is wellicht niet de ideale 
combinatie. Jullie gaven mij vertrouwen, een leuke groep collega’s en jullie boden ruimte 
om de laatste dingen af te ronden. 
Mijn lieve vrienden, bedankt voor jullie steun, tips, geduld en gezellige momenten de 
afgelopen jaren. 
Annemiek en Nina, bedankt voor jullie opbeurende woorden en onze gezamenlijke 
dinertjes. Rachel, m’n paranimf-op-afstand, onze eerste publicatie hebben we samen 
geschreven, je enthousiasme, je scherpe observaties, onze gesprekken over de toekomst 
en onze vriendschap zijn erg waardevol voor me. 
Mijn twee paranimfen; Danielle en Willemien. Daan, als verzopen katjes stonden we 12 
jaar geleden op de grote markt tijdens de EL-CID week. In de jaren erna is een hechte 
vriendschap gegroeid, waarin we veel mooie momenten samen hebben beleefd. Ik vind 
het heel fijn dat je op deze bijzondere dag naast me wil staan.  Willemien, wie had anders 
mijn paranimf kunnen zijn dan jij? We hebben de afgelopen jaren alle ups en downs van 
onze onderzoeken gedeeld, elkaar geholpen, gestimuleerd en met name veel gelachen. 
Ook nu tijdens onze MCH tijd weet je nuchterheid me met beide benen op de grond te 
houden. Bedankt dat je me wilt bijstaan vandaag en voor je vriendschap buiten werktijd. 
Natuurlijk wil ik mijn schoonouders, Wim en Josephine, bedanken voor hun steun, 
oprechte interesse en de afleiding die ze gegeven hebben tijdens de vele vakanties in 
Houston. Dat was precies wat we nodig hadden! Mijn schoonbroers/zussen, Stefanie, 
Jessy, Tim en Stefan, voor de gezellige momenten en vaak onaangekondigde momenten. 
Jessy in het bijzonder voor het ontwerpen van de kaft.
Mijn zusje, Pauline, bedankt voor je oneindige interesse en optimisme maar ook voor 
onze serieuze gesprekken. Lieve pappa en mamma, het is moeilijk te verwoorden 
wat jullie voor me betekenen. Bedankt voor jullie vertrouwen en het zoeken van een 
positieve kant wanneer ik het allemaal even niet meer zie zitten.  
Lieve Bart, ik zal niet ontkennen dat afgelopen jaren moeilijk waren en ik veel van je 
gevraagd hebt. Af en toe had je het helemaal gehad met mijn ‘stukjes’… Ik heb grote 
bewondering voor de manier waarop  je ons gezin draaiende weet te houden! Mijn 
allerliefste Thalia, niemand is zo vrolijk en lacht zoveel als jij, ik ben zo benieuwd naar 
wat jij de toekomst zal brengen – en vice versa. 
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